0001558370-23-009521.txt : 20230512 0001558370-23-009521.hdr.sgml : 20230512 20230512090049 ACCESSION NUMBER: 0001558370-23-009521 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230512 DATE AS OF CHANGE: 20230512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CAPRICOR THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001133869 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34058 FILM NUMBER: 23913460 BUSINESS ADDRESS: STREET 1: 8840 WILSHIRE BLVD STREET 2: 2ND FLOOR CITY: BEVERLY HILLS STATE: CA ZIP: 90211 BUSINESS PHONE: (310) 358-3200 MAIL ADDRESS: STREET 1: 8840 WILSHIRE BLVD STREET 2: 2ND FLOOR CITY: BEVERLY HILLS STATE: CA ZIP: 90211 FORMER COMPANY: FORMER CONFORMED NAME: Nile Therapeutics, Inc. DATE OF NAME CHANGE: 20070920 FORMER COMPANY: FORMER CONFORMED NAME: SMI PRODUCTS INC DATE OF NAME CHANGE: 20010206 10-Q 1 capr-20230331x10q.htm 10-Q
0.310.3225247354242827432019-12-192024-12-192020-03-272025-03-270001133869--12-312023Q1falseP5Y25255154002524140225255154P60DP1YP1YP1YP60DP5YP24M0.78P9M0001133869us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001133869us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001133869us-gaap:CommonStockMember2023-01-012023-03-310001133869us-gaap:CommonStockMember2022-01-012022-03-310001133869us-gaap:RetainedEarningsMember2023-03-310001133869us-gaap:ComprehensiveIncomeMember2023-03-310001133869us-gaap:AdditionalPaidInCapitalMember2023-03-310001133869us-gaap:RetainedEarningsMember2022-12-310001133869us-gaap:ComprehensiveIncomeMember2022-12-310001133869us-gaap:AdditionalPaidInCapitalMember2022-12-310001133869us-gaap:RetainedEarningsMember2022-03-310001133869us-gaap:AdditionalPaidInCapitalMember2022-03-310001133869us-gaap:RetainedEarningsMember2021-12-310001133869us-gaap:AdditionalPaidInCapitalMember2021-12-310001133869us-gaap:CommonStockMember2023-03-310001133869us-gaap:CommonStockMember2022-12-310001133869us-gaap:CommonStockMember2022-03-310001133869us-gaap:CommonStockMember2021-12-310001133869capr:June2021AtMarketProgramMember2022-12-310001133869us-gaap:EmployeeStockOptionMember2022-12-310001133869capr:ConsultingAgreementMembercapr:DrEduardoMarbanMember2022-01-012022-01-310001133869capr:ConsultingAgreementMembercapr:DrEduardoMarbanMember2020-07-012020-07-310001133869us-gaap:EmployeeStockOptionMember2023-03-310001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2021Member2021-06-300001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2020Member2020-06-300001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2021Member2023-01-012023-01-010001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2021Member2022-01-012022-01-010001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2020Member2021-06-112021-06-110001133869us-gaap:EmployeeStockOptionMembercapr:StockOptionPlan2020Member2021-01-012021-01-0100011338692024-04-01capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2023-03-3100011338692023-04-01capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2023-01-012023-03-310001133869capr:CsmcMember2023-01-012023-03-310001133869capr:CsmcMember2022-01-012022-03-310001133869srt:MinimumMember2023-01-012023-03-310001133869srt:MaximumMember2023-01-012023-03-310001133869us-gaap:LeaseholdImprovementsMember2023-03-310001133869us-gaap:FurnitureAndFixturesMember2023-03-310001133869us-gaap:EquipmentMember2023-03-310001133869us-gaap:LeaseholdImprovementsMember2022-12-310001133869us-gaap:FurnitureAndFixturesMember2022-12-310001133869us-gaap:EquipmentMember2022-12-310001133869capr:June2021AtMarketProgramMember2021-06-212022-12-310001133869us-gaap:ComprehensiveIncomeMember2023-01-012023-03-310001133869capr:UnrelatedPartyMember2023-01-012023-03-310001133869capr:RelatedPartyMember2023-01-012023-03-310001133869capr:UnrelatedPartyMember2022-01-012022-03-310001133869capr:CorporateOfficesLeaseMember2022-01-012022-03-310001133869us-gaap:RetainedEarningsMember2023-01-012023-03-310001133869us-gaap:RetainedEarningsMember2022-01-012022-03-310001133869srt:MinimumMembercapr:VivariumSpaceLeaseMember2021-11-010001133869srt:MaximumMembercapr:VivariumSpaceLeaseMember2021-11-010001133869capr:FacilitiesLeaseMember2022-07-310001133869capr:VivariumSpaceLeaseMember2021-11-010001133869capr:PropertyLocatedAt10865RoadToCureInDiegoMember2021-10-010001133869capr:CsmcMember2023-03-310001133869capr:CsmcMember2022-12-310001133869capr:CaliforniaInstituteForRegenerativeMedicineMemberus-gaap:LondonInterbankOfferedRateLIBORMember2023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2022-03-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember2022-12-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember2022-12-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember2023-03-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember2023-03-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember2023-01-012023-03-310001133869capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember2023-01-012023-03-3100011338692022-03-310001133869us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001133869us-gaap:FairValueMeasurementsRecurringMember2023-03-310001133869us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001133869us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001133869us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001133869us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-3100011338692023-05-100001133869capr:RomeLicenseAgreementMember2023-01-012023-03-310001133869capr:ExosomesLicenseAgreementMember2023-01-012023-03-310001133869capr:CsmcLicenseAgreementMember2023-01-012023-03-310001133869capr:CorporateOfficesLeaseMember2023-01-012023-03-310001133869capr:ParticularPatentOrApplicationOrAnyParticularLicensedProductMembercapr:ExosomesLicenseAgreementMember2021-04-282021-04-280001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember2023-01-012023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2022-01-012022-03-310001133869capr:ExosomesLicenseAgreementMember2021-04-282021-04-280001133869capr:NonPaymentOfRoyaltiesMembercapr:ExosomesLicenseAgreementMember2023-01-012023-03-310001133869capr:MaterialBreachHasNotBeenCuredMembercapr:ExosomesLicenseAgreementMember2023-01-012023-03-310001133869capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMembercapr:ExosomesLicenseAgreementMember2023-01-012023-03-310001133869capr:FailsToCureBreachAfterNoticeFromCsmcMembercapr:ExosomesLicenseAgreementMember2023-01-012023-03-310001133869capr:JhuLicenseAgreementMember2023-01-012023-03-310001133869capr:FailsToCureBreachAfterNoticeFromCsmcMembercapr:ExosomesLicenseAgreementMember2021-04-282021-04-280001133869capr:CaliforniaInstituteForRegenerativeMedicineMember2023-01-012023-03-3100011338692021-06-012021-06-300001133869us-gaap:WarrantMember2023-01-012023-03-310001133869us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001133869srt:MaximumMembercapr:JhuLicenseAgreementMember2023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember2023-03-310001133869capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember2022-01-240001133869capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMembercapr:JhuLicenseAgreementMember2023-01-012023-03-310001133869capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMembercapr:ExosomesLicenseAgreementMember2021-04-282021-04-280001133869capr:PropertyLocatedAt10865RoadToCureInDiegoMember2021-10-012021-10-010001133869capr:ConsultingAgreementMembersrt:BoardOfDirectorsChairmanMember2023-01-012023-03-310001133869capr:CaliforniaInstituteForRegenerativeMedicineMember2016-06-162016-06-160001133869capr:JhuLicenseAgreementMember2022-03-310001133869capr:CompletionOfPhaseTwoDueMembercapr:JhuLicenseAgreementMember2022-03-012022-03-310001133869capr:PropertyLocatedAt10865RoadToCureInDiegoMember2022-07-012022-07-010001133869capr:VivariumSpaceLeaseMember2022-12-012022-12-310001133869capr:PropertyLocatedAt10865RoadToCureInDiegoMember2022-12-012022-12-010001133869capr:FacilitiesLeaseMember2022-07-012022-07-310001133869capr:CorporateOfficesLeaseMember2022-07-012022-07-310001133869capr:VivariumSpaceLeaseMember2021-11-012021-11-0100011338692022-01-012022-03-310001133869capr:CaliforniaInstituteForRegenerativeMedicineMember2023-03-310001133869capr:CaliforniaInstituteForRegenerativeMedicineMember2016-06-1600011338692021-01-012021-12-3100011338692021-12-3100011338692020-12-310001133869capr:June2021AtMarketProgramMember2021-06-222021-06-2200011338692023-01-012023-03-3100011338692022-12-310001133869srt:MinimumMembercapr:RomeLicenseAgreementMember2023-01-012023-03-3100011338692023-03-310001133869capr:NonPaymentOfRoyaltiesMembercapr:CsmcLicenseAgreementMember2023-01-012023-03-310001133869capr:MaterialBreachHasNotBeenCuredMembercapr:CsmcLicenseAgreementMember2023-01-012023-03-310001133869capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMembercapr:CsmcLicenseAgreementMember2023-01-012023-03-310001133869capr:FailsToCureBreachAfterNoticeFromCsmcMembercapr:CsmcLicenseAgreementMember2023-01-012023-03-31iso4217:USDiso4217:EURiso4217:USDxbrli:sharesxbrli:purecapr:itemxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the quarterly period ended March 31, 2023

or

Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

for the transition period from       to         

Commission File Number: 001-34058

CAPRICOR THERAPEUTICS, INC.

(Exact Name Of Registrant As Specified In Its Charter)

Delaware

88-0363465

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification No.)

10865 Road to the Cure, Suite 150, San Diego, California 92121

(Address of principal executive offices including zip code)

(858) 727-1755

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes   No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes   No

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

CAPR

The Nasdaq Capital Market

As of May 10, 2023, there were 25,269,926 shares of the registrant’s common stock, par value $0.001 per share, issued and outstanding.

INDEX TO QUARTERLY REPORT ON FORM 10-Q

    

PAGES

 

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

5

Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022

5

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2023 and 2022

6

Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2023 and 2022

7

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2022

8

Notes to Unaudited Condensed Consolidated Financial Statements

9

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

Item 3. Quantitative and Qualitative Disclosures about Market Risk

40

Item 4. Controls and Procedures

40

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

40

Item 1A. Risk Factors

40

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

41

Item 3. Defaults Upon Senior Securities

41

Item 4. Mine Safety Disclosures

41

Item 5. Other Information

41

Item 6. Exhibits

42

Signatures

43

2

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, but are not limited to, statements about:

how long we expect to maintain liquidity to fund our planned level of operations and our ability to obtain additional funds for our operations;
the development of our drug and vaccine candidates, including when we expect to undertake, initiate and complete clinical trials of our drug and vaccine candidates;
the expectation, plans, projections, initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials, compassionate uses, Investigational New Drug (“IND”) filings, Clinical Trial Application (“CTA”) filings, New Drug Application (“NDA”) filings, Biologics License Application (“BLA”), and other regulatory submissions;
regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market;
the regulatory status of our drug and vaccine candidates, including our ability to obtain and maintain orphan drug, rare pediatric and Regenerative Medicine Advanced Therapy (“RMAT”) designations for our lead product candidate, CAP-1002;
our use of clinical research centers, third party manufacturers and other contractors;
our ability to find collaborative partners for research, development and commercialization of potential products and retain commercial rights for our product candidates in the collaborations;
our ability to manufacture products for clinical and commercial use;
our ability to procure materials necessary for the manufacture of our product candidates;
our ability to protect our patents and other intellectual property;
the potential impact of COVID-19 on our business, including our ability to conduct clinical trials and further product candidate development;
our ability to raise additional financing and the terms of any additional financing;
our ability to market any of our products;
the implementation of our business model and strategic plans for our business, technologies and product candidates;
our estimates of our expenses, ongoing losses, future revenue and capital requirements;
the impact of taxes on our business;
our ability to compete against other companies and research institutions;
our ability to expand our operations internationally;
the effect of potential strategic transactions on our business;
acceptance of our products by doctors, patients or payors and the availability of reimbursement for our product candidates;
our ability to attract and retain key personnel; and
the volatility of our stock price.

We caution you that the forward-looking statements highlighted above do not encompass all of the forward-looking statements made in this Quarterly Report on Form 10 - Q.

You should not rely upon forward-looking statements as predictions of future events. We have based the forward-looking statements contained in this Quarterly Report on Form 10-Q primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations and prospects. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and

3

other factors. Moreover, we operate in a very competitive and challenging environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Quarterly Report on Form 10-Q. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Additionally, final data may differ significantly from preliminary data reported in this document.

The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make, if any.

This Quarterly Report on Form 10-Q also contains data, estimates and forecasts that are based on independent industry publications or other publicly available information, as well as other information based on our internal sources. Although we believe that the third-party sources referred to in this Quarterly Report on Form 10-Q are reliable, we have not independently verified the information provided by these third parties. While we are not aware of any misstatements regarding any third-party information presented in this report, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors.

4

PART I — FINANCIAL INFORMATION

Item 1.   Financial Statements.

CAPRICOR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS

    

March 31, 2023

    

(unaudited)

December 31, 2022

CURRENT ASSETS

Cash and cash equivalents

$

10,605,528

$

9,603,242

Marketable securities

 

34,566,342

 

31,818,020

Receivables

 

547,580

 

547,580

Prepaid expenses and other current assets

 

875,092

 

919,892

TOTAL CURRENT ASSETS

 

46,594,542

 

42,888,734

PROPERTY AND EQUIPMENT, net

 

4,811,044

 

4,588,030

OTHER ASSETS

 

  

 

  

Lease right-of-use assets, net

2,189,651

2,349,974

Other assets

 

268,172

 

268,172

TOTAL ASSETS

$

53,863,409

$

50,094,910

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

 

  

 

  

Accounts payable and accrued expenses

$

5,407,016

$

4,834,683

Accounts payable and accrued expenses, related party

18,716

89,234

Lease liabilities, current

693,652

682,039

Deferred revenue, current

31,012,773

17,980,599

TOTAL CURRENT LIABILITIES

 

37,132,157

 

23,586,555

LONG-TERM LIABILITIES

 

  

 

  

CIRM liability

3,376,259

3,376,259

Lease liabilities, net of current

1,699,682

1,878,070

Deferred revenue, net of current

 

5,449,062

 

9,467,932

TOTAL LONG-TERM LIABILITIES

 

10,525,003

 

14,722,261

TOTAL LIABILITIES

 

47,657,160

 

38,308,816

COMMITMENTS AND CONTINGENCIES (NOTE 6)

 

  

 

  

STOCKHOLDERS’ EQUITY

 

  

 

  

Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding

 

 

Common stock, $0.001 par value, 50,000,000 shares authorized, 25,255,154 and 25,241,402 shares issued and outstanding, respectively

 

25,255

 

25,241

Additional paid-in capital

 

150,934,085

 

148,735,420

Accumulated other comprehensive income

 

94,986

 

105,244

Accumulated deficit

 

(144,848,077)

 

(137,079,811)

TOTAL STOCKHOLDERS’ EQUITY

 

6,206,249

 

11,786,094

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

53,863,409

$

50,094,910

See accompanying notes to the unaudited condensed consolidated financial statements.

5

CAPRICOR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

Three months ended March 31, 

    

2023

    

2022

REVENUE

Revenue

$

2,986,696

$

TOTAL REVENUE

 

2,986,696

 

OPERATING EXPENSES

 

  

 

  

Research and development

 

7,661,519

 

5,115,699

General and administrative

 

3,509,885

 

2,715,835

TOTAL OPERATING EXPENSES

 

11,171,404

 

7,831,534

LOSS FROM OPERATIONS

 

(8,184,708)

 

(7,831,534)

OTHER INCOME (EXPENSE)

 

  

 

  

Investment income

416,442

13,440

TOTAL OTHER INCOME (EXPENSE)

 

416,442

 

13,440

NET LOSS

(7,768,266)

(7,818,094)

OTHER COMPREHENSIVE INCOME (LOSS)

 

  

 

  

Net unrealized loss on marketable securities

 

(10,258)

 

COMPREHENSIVE INCOME (LOSS)

$

(7,778,524)

$

(7,818,094)

Net loss per share, basic and diluted

$

(0.31)

$

(0.32)

Weighted average number of shares, basic and diluted

 

25,247,354

 

24,282,743

See accompanying notes to the unaudited condensed consolidated financial statements.

6

CAPRICOR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

For the Three Months Ended March 31, 2023

OTHER

TOTAL

COMMON STOCK

ADDITIONAL PAID-

COMPREHENSIVE

ACCUMULATED

STOCKHOLDERS'

    

SHARES

    

AMOUNT

    

IN CAPITAL

    

INCOME

    

DEFICIT

    

EQUITY 

Balance at December 31, 2022

 

25,241,402

$

25,241

$

148,735,420

$

105,244

$

(137,079,811)

$

11,786,094

Stock-based compensation

 

 

 

2,194,784

 

 

 

2,194,784

Stock options exercised

 

13,752

14

 

3,881

 

 

 

3,895

Unrealized loss on marketable securities

 

 

 

 

(10,258)

 

 

(10,258)

Net loss

 

 

 

 

 

(7,768,266)

 

(7,768,266)

Balance at March 31, 2023

 

25,255,154

$

25,255

$

150,934,085

$

94,986

$

(144,848,077)

$

6,206,249

For the Three Months Ended March 31, 2022

OTHER

TOTAL

COMMON STOCK

ADDITIONAL PAID-

COMPREHENSIVE

ACCUMULATED

STOCKHOLDERS'

    

SHARES

    

AMOUNT

    

IN CAPITAL

    

INCOME (LOSS)

    

DEFICIT

    

EQUITY 

Balance at December 31, 2021

 

24,185,001

$

24,185

$

139,404,060

$

$

(108,060,279)

$

31,367,966

Stock-based compensation

1,065,329

1,065,329

Stock options exercised

139,155

139

27,326

27,465

Net loss

 

 

 

 

 

(7,818,094)

 

(7,818,094)

Balance at March 31, 2022

 

24,324,156

$

24,324

$

140,496,715

$

$

(115,878,373)

$

24,642,666

See accompanying notes to the unaudited condensed consolidated financial statements.

7

CAPRICOR THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three months ended March 31, 

    

2023

    

2022

Cash flows from operating activities:

Net loss

$

(7,768,266)

$

(7,818,094)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

  

 

  

Depreciation and amortization

 

230,101

 

92,490

Stock-based compensation

 

2,194,784

 

1,065,329

Changes in lease liabilities

(6,452)

72,734

Changes in operating assets and liabilities:

 

  

 

  

Receivables

 

 

34,753

Prepaid expenses and other current assets

 

44,800

 

216,691

Accounts payable and accrued expenses

572,333

407,203

Accounts payable and accrued expenses, related party

(70,518)

(24,540)

Deferred revenue

 

9,013,304

 

30,000,000

Net cash provided by operating activities

 

4,210,086

 

24,046,566

Cash flows from investing activities:

 

  

 

  

Purchase of marketable securities

 

(34,803,580)

 

Proceeds from sales and maturities of marketable securities

 

32,045,000

 

Purchases of property and equipment

(347,690)

(567,616)

Payments for leasehold improvements

 

(105,425)

 

(57,744)

Net cash used in investing activities

 

(3,211,695)

 

(625,360)

Cash flows from financing activities:

 

  

 

  

Proceeds from exercise of stock awards

 

3,895

 

27,465

Net cash provided by financing activities

 

3,895

 

27,465

Net increase in cash and cash equivalents

 

1,002,286

 

23,448,671

Cash and cash equivalents balance at beginning of period

 

9,603,242

 

34,885,274

Cash and cash equivalents balance at end of period

$

10,605,528

$

58,333,945

Supplemental disclosures of cash flow information:

 

  

 

  

Interest paid in cash

$

$

Income taxes paid in cash

$

$

See accompanying notes to the unaudited condensed consolidated financial statements.

8

CAPRICOR THERAPEUTICS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1.            ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple drug and vaccine candidates in various stages of development.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023, from which the December 31, 2022 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

Basis of Consolidation

Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.

Liquidity

The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.

Cash, cash equivalents, and marketable securities as of March 31, 2023 were approximately $45.2 million, compared to approximately $41.4 million as of December 31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a Japanese corporation, in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 – “License and Distribution Agreements”). Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright & Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").

The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.

9

The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:

the timing and costs associated with its research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase III clinical study of CAP-1002 in DMD;
the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;
the timing and costs associated with potential commercialization of its product candidates;
the number and scope of its research programs, including the expansion of our exosomes program; and
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.

The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants.

The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.

Business Uncertainty Related to the Coronavirus

The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees, and the impact may continue in future periods.

In light of past uncertainties due to COVID-19 and its economic and other impacts, the Company submitted for the Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021. As of March 31, 2023, the Company has recorded a receivable for $547,580 for the remainder of funds expected to be received.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.

Marketable Securities

The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and are carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities

10

are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are presented as other comprehensive income (loss) as a separate component of stockholders’ equity. As of March 31, 2023, marketable securities consist primarily of short-term United States treasuries.

Property and Equipment

Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $230,101 and $92,490 for the three months ended March 31, 2023 and 2022, respectively.

Property and equipment, net consisted of the following:

    

March 31, 

    

December 31, 

    

2023

    

2022

Furniture and fixtures

$

143,573

$

139,336

Laboratory equipment

 

4,566,146

 

4,237,089

Leasehold improvements

 

1,498,655

 

1,393,230

 

6,208,374

 

5,769,655

Less accumulated depreciation

 

(1,397,330)

 

(1,181,625)

Property and equipment, net

$

4,811,044

$

4,588,030

Leases

ASC Topic 842, Leases (“ASC 842”), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance.

Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them.

The Company leases office and laboratory space, all of which are operating leases (see Note 6 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.

The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.

11

Revenue Recognition

The Company adopted ASU 606, Revenue for Contracts from Customers, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 – “License and Distribution Agreements).

The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.

The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and sharing of revenues are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or royalties achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.

The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.

Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to

12

complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.

Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.

Under the Exclusive Commercialization and Distribution Agreement for the U.S. (the “U.S. Distribution Agreement”) with Nippon Shinyaku the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the duration of the HOPE-3 clinical trial. Therefore, upon receipt of the upfront payment, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.

Grant Income

Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the “CIRM Award”) from the California Institute for Regenerative Medicine (“CIRM”) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized for the three months ended March 31, 2023 and 2022.

Research and Development

Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development. Research and development (“R&D”) costs amounted to approximately $7.7 million and $5.1 million for the three months ended March 31, 2023 and 2022, respectively.

Comprehensive Income (Loss)

Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $7.8 million for the three months ended March 31, 2023 and 2022. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.

Clinical Trial Expense

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense

13

recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.

Stock-Based Compensation

The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.

The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260-10, Earnings per Share. Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive.

As of March 31, 2023 and 2022, warrants and options to purchase 7,971,557 and 5,674,191 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three months ended March 31, 2023 and 2022.

14

Fair Value Measurements

Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:

Level Input:

    

Input Definition:

Level I

Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Level II

Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.

Level III

Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2023 for assets and liabilities measured at fair value on a recurring basis:

March 31, 2023

    

Level I

    

Level II

    

Level III

    

Total

Marketable Securities

$

34,566,342

$

$

$

34,566,342

Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. The amortized cost for these marketable securities as of March 31, 2023 was $34,471,356.

Recent Accounting Pronouncements

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

2.            STOCKHOLDER’S EQUITY

ATM Program

The Company established an “at-the-market” program (the “ATM Program”) on June 21, 2021, with an aggregate offering price of up to $75.0 million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses.

From June 21, 2021 through December 31, 2022, the Company sold an aggregate of 2,098,333 shares of common stock under the ATM Program at an average price of approximately $5.93 per share for gross proceeds of approximately $12.4 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.4 million. Subsequent to December 31, 2022 and through May 11, 2023, no shares were sold under the ATM Program.

15

Outstanding Shares

At March 31, 2023, the Company had 25,255,154 shares of common stock issued and outstanding.

3.            STOCK AWARDS, WARRANTS AND OPTIONS

Warrants

The following table summarizes all warrant activity for the three months ended March 31, 2023:

Weighted Average

    

Warrants

    

Exercise Price

Outstanding at December 31, 2022

 

105,782

$

1.37

Granted

Exercised

Outstanding at March 31, 2023

 

105,782

$

1.37

The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock:

Warrants Outstanding

March 31, 

December 31, 

Exercise Price

Expiration

Type

    

Grant Date

    

2023

    

2022

    

per Share

    

Date

Common Warrants

12/19/2019

40,782

 

40,782

$

1.10

12/19/2024

Common Warrants

3/27/2020

65,000

 

65,000

$

1.5313

3/27/2025

105,782

105,782

Stock Options

The Company’s Board of Directors (the “Board”) has approved five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the “2012 Plan”), (iii) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”), (iv) the 2020 Equity Incentive Plan (the “2020 Plan”), and (v) the 2021 Equity Incentive Plan (the “2021 Plan”). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan.

In June 2020, the Company’s stockholders approved the 2020 Equity Incentive Plan (the “2020 Plan”), which authorized 2,500,000 shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.  Pursuant to the “evergreen” provision, on January 1, 2021, 823,084 shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, no new shares were added to the share reserve under the 2020 Plan pursuant to its “evergreen” provisions.

In June 2021, the Company’s stockholders approved the 2021 Plan, which authorized 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards.  The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2023 and 2022, 1,262,070 and 1,209,250 shares were added under the 2021 Plan, respectively.

As of March 31, 2023, 1,756,664 options remain available for issuance under the respective stock option plans.

The Company’s stock option plans are administered by the Board, or the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the

16

aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one to four years. The term of stock options granted under each of the plans cannot exceed ten years.

The estimated weighted average fair value of the options granted during the three months ended March 31, 2023 and 2022 were approximately $3.47 and $2.87 per share, respectively.

The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the three months ended March 31, 2023 and 2022:

    

Three months ended March 31, 

 

2023

2022

Expected volatility

 

115 - 121

%  

123

%

Expected term

 

5 - 7 years

 

6 years

Dividend yield

 

0

%  

0

%

Risk-free interest rates

 

3.6 - 3.9

%  

1.5 - 1.7

%

Employee and non-employee stock-based compensation expense was as follows:

Three months ended March 31, 

    

2023

    

2022

General and administrative

$

1,754,223

$

857,583

Research and development

 

440,561

 

207,746

Total

$

2,194,784

$

1,065,329

The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.

Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.

As of March 31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $15.2 million, which is expected to be recognized over a weighted average period of approximately 1.5 years.

17

The following is a schedule summarizing employee and non-employee stock option activity for the three months ended March 31, 2023:

Number of

Weighted Average

Aggregate

    

Options

    

Exercise Price

    

Intrinsic Value

Outstanding at December 31, 2022

 

5,776,839

$

2.97

 

Granted

 

2,220,979

 

3.91

 

  

Exercised

 

(19,688)

 

1.52

 

$

54,741

Expired/Cancelled

 

(112,355)

 

4.66

 

  

Outstanding at March 31, 2023

 

7,865,775

$

3.22

$

8,303,587

Exercisable at March 31, 2023

 

3,091,952

$

2.69

$

4,890,171

The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock for each of the respective periods.

4.            CONCENTRATIONS

Concentration of Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company has historically maintained accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation (the “FDIC”) for up to $250,000. The Company’s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of March 31, 2023, were approximately $45.3 million. Historically, the Company has not experienced any significant losses in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held.

5.            GOVERNMENT GRANT AWARDS

CIRM Grant Award (HOPE)

On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.

After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term

18

of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. If we elect to do so, Capricor would be required to repay some or all of the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.

In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of March 31, 2023, Capricor’s liability balance for the CIRM Award was approximately $3.4 million.

6.            COMMITMENTS AND CONTINGENCIES

Short-Term Operating Leases

Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon 90 days’ written notice to the other party. Commencing in July 2022, the monthly lease payment was $7,869 per month.

Expenses incurred under short-term operating leases for the three months ended March 31, 2023 and 2022 were $23,607 and $17,394, respectively.

Long-Term Operating Leases

Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (“CSMC”), a related party (see Note 8 – “Related Party Transactions”), pursuant to a lease (the “Facilities Lease”) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional 24-month period extending the term through July 31, 2024 with a monthly lease payment of $10,707.

The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (“Altman”) for office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the “San Diego Lease”). The rent is subject to a 3.0% annual rent increase during the initial lease term of five years, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of five years.  The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022 the monthly lease payment was increased to $49,322 per month. Effective December 1, 2022, the monthly lease payment was increased to $51,444 per month.

Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (“Explora”), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $4,021 per month for an exclusive large vivarium room located in San Diego, California. The lease term is for one-year and will automatically renew for additional successive one-year renewal terms unless either party provides the other party with 60-day written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of 4.5% bringing the base rent to approximately $4,202 per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of five years.

19

The long-term real estate operating leases are included in “lease right-of-use assets, net” on the Company’s condensed consolidated balance sheet and represent the Company’s right-to-use the underlying assets for the lease term. The Company’s obligation to make lease payments are included in “lease liabilities, current” and “lease liabilities, net of current” on the Company’s condensed consolidated balance sheet.

The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of March 31, 2023:

2023 (remainder)

$

601,801

2024

765,986

2025

710,259

2026

547,948

Total minimum lease payments

2,625,994

Less: imputed interest

(232,660)

Total operating lease liabilities

$

2,393,334

Included in the condensed consolidated balance sheet:

Current portion of lease liabilities

$

693,652

Lease liabilities, net of current

1,699,682

Total operating lease liabilities

$

2,393,334

Other Information:

Weighted average remaining lease term

3.36 years

Weighted average discount rate

5.36%

As of March 31, 2023, ROU assets for operating leases were approximately $2.2 million and operating lease liabilities were approximately $2.4 million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company’s operating leases under ASC 842 for the period indicated:

Three months ended March 31, 

2023

    

2022

Lease costs, unrelated parties

$

160,486

$

158,084

Lease costs, related parties

32,120

Lease payments, unrelated parties

166,938

85,352

Lease payments, related parties

32,120

Legal Contingencies

The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise.

Accounts Payable

During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.

Other Funding Commitments

The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 – “License and Distribution Agreements”).

20

Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement.

Employee Severances

The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability under these severance packages has been recorded as of March 31, 2023.

7.            LICENSE AND DISTRIBUTION AGREEMENTS

Intellectual Property Rights for Capricor’s Technology - CAP 1002 and Exosomes

Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Università Degli Studi Di Roma La Sapienza (the “University of Rome”), Johns Hopkins University (“JHU”) and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.

University of Rome License Agreement

Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields.

Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments.

The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party’s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days’ written notice to the University of Rome.

The Johns Hopkins University License Agreements

License Agreement for CDCs

Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.

21

Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase III study for which a payment of $500,000 will be due.

The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice.

License Agreement for Exosome-based Vaccines and Therapeutics

Capricor and JHU entered into an Exclusive License Agreement (the “JHU Exosome License Agreement”) effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license of JHU’s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how.

Pursuant to the JHU Exosome License Agreement, JHU was paid an upfront license fee of $10,000 and Capricor has agreed to reimburse JHU for certain fees and costs incurred in connection with the prosecution of certain patent rights.

Additionally, Capricor is required to meet certain development milestones for which a milestone payment fee shall be due and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a double-digit percentage of any non-royalty consideration received from any sublicenses, subject to certain exclusions. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to pay royalties on one or more third party patents as a requirement to make or sell a licensed product. In addition, Capricor will, beginning with the third year of the JHU Exosome License Agreement, be obligated to pay JHU a minimum annual royalty which is non-refundable but will be credited against royalties incurred by Capricor for the year in which the minimum annual royalty becomes due.

The JHU Exosome License Agreement will, unless sooner terminated, continue in each country until the date of expiration of the last to expire patent included within the patent rights in that country, or if no patents issue, then for 20 years. The JHU Exosome License Agreement may be terminated by Capricor upon 90 days’ written notice in its discretion and with 60 days’ notice with respect to any particular patent or application or as to any particular licensed product. The JHU Exosome License Agreement may also be terminated by either party if the other party fails to perform or otherwise breaches any of its obligations and fails to cure such breach within a 60-day cure period commencing upon notice. A material breach by Capricor may include (a) a delinquency with respect to payment or reporting; (b) the failure by Capricor to timely achieve a specified milestone or otherwise failing to diligently develop, commercialize, and sell licensed products throughout the term of the JHU Exosome License Agreement; (c) non-compliance with record keeping or audit obligations; (d) voluntary bankruptcy or insolvency of Capricor; and (e) non-compliance with Capricor’s insurance obligations.

22

Cedars-Sinai Medical Center License Agreements

License Agreement for CDCs

On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “Original CSMC License Agreement”), for certain intellectual property related to its cardiosphere-derived cell (“CDC”) technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.

The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.

Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.

Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty-bearing product.

The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days’ notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.

On March 20, 2015, August 5, 2016, December 26, 2017, June 20, 2018, and July 27, 2021, Capricor and CSMC entered into a number of amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents, among other things. Capricor reimbursed CSMC for certain attorneys’ fees and filing fees incurred in connection with the additional patent applications.

23

License Agreement for Exosomes

On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.

Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty bearing product.

The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.

On February 27, 2015, June 10, 2015, August 5, 2016, December 26, 2017, June 20, 2018, September 25, 2018, August 19, 2020, August 28, 2020, and March 19, 2021, Capricor and CSMC entered into a number of amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, and added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights; failure to meet those milestones would cause CSMC to have the right to convert the license from exclusive to non-exclusive or co-exclusive, or to terminate the license, subject to Capricor’s right to license such patent rights for internal research purposes on a non-exclusive basis.  These amendments also obligated Capricor to reimburse CSMC for certain attorneys’ fees and filing fees in connection with the additional patent applications and patent families.

Cell Line License Agreement with Life Technologies

On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in the first quarter of 2022 and additional milestone fees may become due on the progress of our development program.

24

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)

On January 24, 2022, Capricor entered into the U.S. Distribution Agreement with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002, for the treatment of DMD.

Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and in addition Capricor will have the right to receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments, if achieved. In the first quarter of 2022, Capricor received an upfront payment of $30.0 million. Pursuant to the terms of the U.S. Distribution Agreement, there are potential additional sales and development milestone payments of up to $705.0 million.

The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, Revenue for Contracts from Customers. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase III clinical study.

The Company determined the initial transaction price totaled $30.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the total $30.0 million initial transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract’s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits. For the three months ended March 31, 2023, the Company recognized approximately $3.0 million as revenue. In relation to the U.S. Distribution Agreement, as of March 31, 2023, the Company recorded approximately $19.0 million as current deferred revenue and approximately $5.4 million as deferred revenue, net of current portion, on the Company’s condensed consolidated balance sheets.

The Company had no opening or closing contract asset balances recognized.  The difference between the opening and closing balances of the Company’s contract liability results from the Company performance of services in connection to its performance obligation.

The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of March 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $24.5 million. 78% of the remaining performance obligations are expected to be recognized over the next 12 months, with the remainder recognized thereafter. Remaining performance obligations estimates are subject to change.  

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)

On February 10, 2023, Capricor entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Distribution Agreement”) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.

Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023, and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.

25

The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, Revenue for Contracts from Customers. The Company determined the initial transaction price totaled $12.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $12.0 million as current deferred revenue on the Company’s condensed consolidated balance sheets as of March 31, 2023.

8.            RELATED PARTY TRANSACTIONS

Lease and Sub-Lease Agreement

As noted above, Capricor is a party to lease agreements with CSMC (see Note 6 – “Commitments and Contingencies”), and CSMC has served as an investigative site in Capricor’s clinical trials. Additionally, Dr. Eduardo Marbán, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company’s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.

Consulting Agreements

In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company’s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days’ notice.

In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marbán whereby he was granted an option to purchase 50,000 shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marbán was granted an additional option grant to purchase 50,000 shares of the Company’s common stock.

Payables to Related Party

As of March 31, 2023 and December 31, 2022, the Company had accounts payable and accrued expenses to related parties totaling $18,716 and $89,234, respectively. CSMC accounts for $8,716 and $79,234 of the total accounts payable and accrued expense to related parties as of March 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the three months ended March 31, 2023 and 2022, the Company paid CSMC approximately $111,400 and $66,600, respectively, for such costs.

26

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and the condensed consolidated notes to those statements included elsewhere in this Quarterly Report on Form 10-Q. This discussion includes forward-looking statements that involve risks and uncertainties. As a result of many factors, our actual results may differ materially from those anticipated in these forward-looking statements.

As used in this Quarterly Report on Form 10-Q, references to “Capricor Therapeutics,” the “Company,” “we,” “us,” “our” or similar terms include Capricor Therapeutics, Inc. and its wholly-owned subsidiary. References to “Capricor” are with respect to Capricor, Inc., our wholly-owned subsidiary.

Company Overview

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.

Since our inception, we have devoted substantial resources to developing CAP-1002 and our other product candidates including our exosomes platform, developing our manufacturing processes, staffing our company and providing general and administrative support for these operations. We do not have any products approved for sale. Our ability to eventually generate any product revenue sufficient to achieve profitability will depend on the successful development, approval and eventual commercialization of CAP-1002 for the treatment of DMD and our other product candidates. If successfully developed and approved, we intend to commercialize CAP-1002 in the United States and Japan with our partner, Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), and may enter into additional licensing agreements or strategic collaborations in other markets. If we generate product sales or enter into licensing agreements or strategic collaborations, or further distribution relationships, we expect that any revenue we generate will fluctuate from quarter-to-quarter and year-to-year as a result of the timing and amount of any product sales, license fees, milestone payments and other payments. If we fail to complete the development of our product candidates in a timely manner, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.

A summary description of our key product candidates, is as follows:

CAP-1002 for the treatment of DMD (Phase III): Our core program is focused on the development and commercialization of a cell therapy technology, (referred herein as CAP-1002) comprised CDCs, which are an endogenous population of stromal cells isolated from donated cells of healthy human hearts, for the treatment of DMD. CAP-1002 is designed to slow disease progression in DMD through the immunomodulatory, anti-inflammatory, and anti-fibrotic actions of CDCs, which are mediated by secreted exosomes laden with bioactive cargo. Among the cargo elements known to be bioactive in CDC exosomes are microRNAs. Collectively, these non-coding RNA species alter gene expression in macrophages and other target cells, dialing down generalized inflammation and stimulating tissue regeneration in DMD (and in a variety of other inflammatory diseases). This mechanism of action, which is consistent with the changes observed in clinical studies to date in circulating inflammatory biomarkers, contrasts with that of exon-skipping oligonucleotides and gene therapy approaches, which aim to restore dystrophin expression. DMD is a rare form of muscular dystrophy which results in muscle degeneration and premature death. Additionally, the absence of dystrophin in muscle cells leads to significant cell damage and ultimately causes muscle cell death and fibrotic replacement. The annual cost of care for patients with DMD is very high and increases with disease progression. We therefore believe that DMD represents a significant market opportunity for our product candidate, CAP-1002.

To date, we have completed two promising clinical trials investigating CAP-1002 for DMD. Data from the first trial, a Phase I/II trial named HOPE-Duchenne, suggested improvements in skeletal and cardiac endpoints. In HOPE-2, a Phase II clinical trial conducted in the United States, CAP-1002 was used to treat patients with late-stage DMD. In March 2022, we announced that the final one-year results from HOPE-2

27

were published in The Lancet showing that the trial met its primary efficacy endpoint of the mid-level dimension of the Performance of the Upper Limb (“PUL”) v1.2 (p=0.01) and additional positive endpoints of full PUL v2.0 (p=0.04) and a cardiac endpoint of left ventricular ejection fraction (p=0.002). CAP-1002 was generally safe and well-tolerated throughout the studies. Additionally, we are conducting an open label extension (“OLE”) study of the HOPE-2 trial in which 12 patients have elected to continue treatment of CAP-1002. We have announced positive one-year and 18-month results from this ongoing OLE study. Data from the OLE study suggests disease modification with statistically significant differences in the PUL v2.0 scale in the CAP-1002 original treatment group when compared to the original placebo group from HOPE-2. In addition, disease progression was attenuated equally in both groups once patients began treatment in the OLE. CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study.

We are currently enrolling the HOPE-3, Phase III clinical study investigating CAP-1002 for the treatment of late-stage DMD patients for the potential approval of CAP-1002 in the United States. HOPE-3 is a multi-center, randomized, double-blind, placebo-controlled study currently designed to treat up to 68 patients at approximately 15-20 investigative sites in the United States. The primary outcome measure will be the full  PUL v2.0 at one-year. HOPE-3 will also measure various secondary endpoints including cardiac function assessments. At this time, we have 13 active sites and are on track to fully enroll the currently designed study by the second half of 2023. At this time, our plans to conduct an interim analysis for sample size re-estimation and analysis of conditional power remain unchanged and we anticipate that these results will be available in the fourth quarter of this year.

Under our RMAT designation, we recently met with the FDA in a Type-B CMC meeting where we discussed our manufacturing plans in anticipation of a potential BLA application. In the meeting, we discussed our plans with respect to commercial manufacturing activities, including our potency assay and other product release criteria to support commercialization. In the meeting, we also discussed the potential need to add some number of patients to HOPE-3 who will be treated with commercial-scale Good Manufacturing Practice (“GMP”) CAP-1002 product manufactured at our new San Diego facility, in order to support a potential BLA application. Our San Diego facility is designed to produce commercial-scale GMP CAP-1002 product and we believe that it will be available to manufacture CAP-1002 doses by the third quarter of 2023. At this time, we have requested a follow-on Type B clinical meeting with FDA and expect to have further clarity following the FDA’s response on this topic. Furthermore, at the request of the FDA, we have submitted the 12-month results from our HOPE-2 OLE for their review and we continue to discuss our pathway towards potential registration.

The regulatory pathway for CAP-1002 is supported by RMAT designation as well as orphan drug designation. If Capricor were to receive market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher based on its designation as a rare pediatric disease. Capricor has entered into two Commercialization and Distribution Agreements with Nippon Shinyaku appointing Nippon Shinyaku as its exclusive distributor of CAP-1002 in the United States and Japan.

Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precision-engineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently published preclinical data on our StealthXTM platform showing the rapid development of a recombinant protein-based vaccine for immunization and prevention against SARS-CoV-2, the virus causing COVID-19. At this time, we are developing vaccines and therapeutics for infectious diseases, monogenic diseases and other potential indications. Our platform builds on advances in fundamental RNA and protein science, targeting technology and manufacturing, providing us the opportunity to potentially build a broad pipeline of new therapeutic candidates. Our current strategy is focused on securing partners who will provide capital and additional resources to bring this program into the clinic, should we decide to do so.

As of March 31, 2023, we had cash, cash equivalents, and marketable securities totaling approximately $45.2 million. We estimate this will fund our operating expenses and capital expenditure requirements into the fourth quarter of 2024. This expectation excludes any potential additional milestone payments under our commercialization and distribution

28

agreements with Nippon Shinyaku. We have not generated any revenues from the commercial sale of products. We will not be able to generate any product revenues until, and only if, we receive approval to sell our drug candidates from the FDA or other regulatory authorities.

Due to our significant research and development expenditures, and general administrative costs associated with our operations, we have generated substantial operating losses in each period since our inception. Our net losses were approximately $7.8 million for each of the three month periods ended March 31, 2023 and 2022. As of March 31, 2023, we had an accumulated deficit of approximately $144.8 million. We expect to incur significant expenses and operating losses for the foreseeable future.

Recent Operational Developments

Continued discussions with FDA following our Type-B CMC meeting regarding commercial plans in anticipation of a potential BLA submission and we have now submitted a request for a Type-B clinical meeting.
We completed construction in our San Diego Research and Development Facility of a new GMP pilot manufacturing facility as we prepare for potential commercial launch. This facility is being designed to be compliant with U.S., European Medicines Agency (“EMA”), and other international standards. This facility is designed to produce commercial-scale GMP CAP-1002 product for further clinical and potential commercial use.
In February 2023 we entered into a Commercialization and Distribution Agreement (the “Japan Distribution Agreement”) with Nippon Shinyaku for the exclusive commercialization and distribution of CAP-1002 for DMD in Japan. Under the terms of the Japan Distribution Agreement, we will be responsible for the development of the clinical program in Japan required to obtain manufacturing and marketing approval for CAP-1002 as well as for the manufacturing of CAP-1002.  Pursuant to the Japan Distribution Agreement, we have the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and in addition, Capricor will have the right to receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments, if achieved. We received an upfront payment of $12.0 million in the first quarter of 2023 and have the potential to receive additional milestone payments of up to approximately $89 million, subject to foreign currency exchange rates.  
We are conducting an OLE study of the HOPE-2 trial in which 12 patients have elected to continue treatment of CAP-1002. In February 2023, we announced positive 18-month results from this ongoing OLE Study.  The one year and 18-month data from this OLE study showed statistically significant improvements on the PUL v2.0 for patients on CAP-1002 testing three different hypotheses of treatment benefit during the open label extension. We plan to report the 24-month OLE data in the second quarter of this year.
Published preclinical data in the peer-reviewed journal, Microbiology Spectrum highlighting the therapeutic potential of our proprietary StealthXTM exosome platform. These results established the prospect of combining multiple targets in one vaccine and support exosomes as a potential suitable delivery vehicle for a variety of therapeutics cargo.

As we seek to develop and commercialize CAP-1002 or any other product candidates including those related to our exosomes program, we anticipate that our expenses will increase significantly and that we will need substantial additional funding to support our continuing operations. Until such time when we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of public or private equity financings, debt financings or other sources, which may include licensing agreements or strategic collaborations or other distribution agreements. We may be unable to raise additional funds or enter into such agreements or arrangements when needed on favorable terms, if at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development or commercialization of CAP-1002 or our other product candidates.

The COVID-19 pandemic has presented a substantial public health and economic challenge around the world. Our business operations and financial condition and results have been impacted to varying degrees, and we expect the impact will continue in future quarters particularly in connection with supply chain constraints.

29

Financial Operations Overview

We have no commercial product sales to date and will not have the ability to generate any commercial product revenue until after we have received approval from the FDA or equivalent foreign regulatory bodies to begin selling our pharmaceutical product candidates. Developing pharmaceutical products is a lengthy and very expensive process. Even if we obtain the capital necessary to continue the development of our product candidates, whether through a strategic transaction or otherwise, we do not expect to complete the development of a product candidate for several years, if ever. To date, most of our development expenses have related to our product candidates, consisting of CAP-1002 and our exosome technologies. As we proceed with the clinical development of CAP-1002, and as we further develop our exosome technologies, our expenses will further increase. Accordingly, our success depends not only on the safety and efficacy of our product candidates, but also on our ability to finance the development of our products and our clinical programs. Our recent major sources of working capital have been primarily proceeds from public equity sales of securities and upfront payments pursuant to our U.S. and Japan Distribution Agreements with Nippon Shinyaku. While we pursue our preclinical and clinical programs, we continue to explore potential partnerships for the development of one or more of our product candidates in the US and in other territories across the world.

Our results have included non-cash compensation expense due to the issuance of stock options and warrants, as applicable. We expense the fair value of stock options and warrants over their vesting period as applicable. When more precise pricing data is unavailable, we determine the fair value of stock options using the Black-Scholes option-pricing model. The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. Generally, the awards vest based upon time-based conditions. Stock-based compensation expense is included in the condensed consolidated statements of operations under general and administrative (“G&A”) or research and development (“R&D”) expenses, as applicable. We expect to record additional non-cash compensation expense in the future, which may be significant.

Results of Operations

Revenue

Clinical Development Income. Clinical development income for the three months ended March 31, 2023 and 2022 was approximately $3.0 million and zero, respectively. The Company started recognizing the $30.0 million upfront payment received from Nippon Shinyaku related to an Exclusive Commercialization and Distribution Agreement (the “U.S. Distribution Agreement”) with Nippon Shinyaku in the third quarter of 2022. Revenue is ratably recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study.

Operating Expenses

Research and Development Expenses. R&D expenses consist primarily of compensation and other related personnel costs, supplies, clinical trial costs, patient treatment costs, rent for laboratories and manufacturing facilities, consulting fees, costs of personnel and supplies for manufacturing, costs of service providers for preclinical, clinical and manufacturing, certain legal expenses resulting from intellectual property prosecution, stock-based compensation expense and other expenses relating to the design, development, testing and enhancement of our product candidates.

30

The following table summarizes our R&D expenses by category for each of the periods indicated:

Three months ended March 31, 

    

2023

    

2022

    

Change ($)

    

Change (%)

    

Compensation and other personnel expenses

$

2,250,753

$

1,338,710

$

912,043

68

%

Duchenne muscular dystrophy (CAP-1002)

 

3,838,811

 

1,308,499

 

2,530,312

 

193

%

Exosomes platform research

581,986

 

1,257,423

 

(675,437)

 

(54)

%

Facility expenses

305,866

251,194

54,672

22

%

Stock-based compensation

440,560

207,746

232,814

112

%

Depreciation

137,750

89,990

47,760

53

%

Research and other projects

105,793

662,137

(556,344)

(84)

%

Total research and development expenses

$

7,661,519

$

5,115,699

$

2,545,820

50

%

R&D expenses for the three months ended March 31, 2023 increased by approximately $2.5 million, or 50%, compared to the three months ended March 31, 2022. The increase was primarily driven by the following:

$0.9 million increase in compensation and other personnel expenses primarily due to increases in headcount;
$2.5 million increase in our CAP-1002 DMD program primarily due to the ongoing HOPE-3 clinical trial, our HOPE-2 OLE clinical trial and our expanded manufacturing production efforts for CAP-1002;
$0.7 million decrease in exosomes platform research primarily due to reduced expenses related to certain research projects;
$0.1 million increase in facility expenses primarily due to expansion efforts;
$0.2 million increase in stock-based compensation expense primarily due to increases in headcount, risk-free rate and stock price, which resulted in an increase in fair value of options issued; and
$0.6 million decrease in research and other projects primarily due to the close-out of our INSPIRE program.

General and Administrative Expenses. G&A expenses consist primarily of compensation and other related personnel expenses for executive, finance and other administrative personnel, stock-based compensation expense, accounting, legal and other professional fees, consulting expenses, rent for corporate offices, business insurance and other corporate expenses.

The following table summarizes our G&A expenses by category for each of the periods indicated:

Three months ended March 31, 

    

2023

    

2022

    

Change ($)

    

Change (%)

Stock-based compensation

$

1,754,223

$

857,583

$

896,640

105

%

Compensation and other personnel expenses

 

873,385

 

847,879

 

25,506

 

3

%

Professional services

464,977

 

738,693

 

(273,716)

 

(37)

%

Facility expenses

155,713

61,517

94,196

153

%

Other corporate expenses

261,587

210,163

51,424

24

%

Total general and administrative expenses

$

3,509,885

$

2,715,835

$

794,050

29

%

G&A expenses for the three months ended March 31, 2023 increased by approximately $0.8 million, or 29%, compared to the three months ended March 31, 2022. The increase was primarily driven by the following:

$0.9 million increase in stock-based compensation expense primarily due to an increase in our risk-free rate and stock price, which resulted in an increase in fair value of options issued;
$0.3 million decrease in professional service expenses primarily due to a decrease in business development related expenses;
$0.1 million increase in facility expenses primarily due to expansion efforts; and
$0.1 million increase in other corporate expenses primarily related to travel and other general corporate expenses.

31

Investment Income. Investment income for the three months ended March 31, 2023 and 2022 was approximately $0.4 million and $13,440, respectively. The increase in investment income for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 is due to increased interest rates and the higher principal balance in our marketable securities, savings and money market fund accounts.

Products Under Active Development

CAP-1002 for the treatment of DMD – We are currently conducting our HOPE-3, Phase III study for DMD and our ongoing OLE study of HOPE-2 for which we expect to spend approximately $15.0 million to $20.0 million in 2023. The expenses for our DMD program will include costs for personnel, clinical, regulatory and manufacturing-related expenses, including expenses related to the scale-up for potential commercial scale manufacturing.

Exosome-Based Therapeutics and Vaccines – Our exosome platform is in early-stage preclinical development. We expect to spend approximately $4.0 million to $6.0 million during 2023 on development expenses related to our exosomes program, which includes personnel, preclinical studies and manufacturing related expenses for these technologies. Our expenses for this program are primarily focused on the expansion of our engineered exosomes platform including the conduct of IND-enabling studies.

Our expenditures on current and future clinical development programs, particularly our CAP-1002 and exosomes programs, cannot be predicted with any significant degree of certainty as they are dependent on the results of our current trials and our ability to secure additional funding and a strategic partner. Further, we cannot predict with any significant degree of certainty the amount of time which will be required to complete our clinical trials, the costs of completing research and development projects or whether, when and to what extent we will generate revenues from the commercialization and sale of any of our product candidates. The duration and cost of clinical trials may vary significantly over the life of a project as a result of unanticipated events arising during manufacturing and clinical development and as a result of a variety of other factors, including:

the number of trials and studies in a clinical program;
the number of patients who participate in the trials;
the number of sites included in the trials;
the rates of patient recruitment and enrollment;
the duration of patient treatment and follow-up;
the costs of manufacturing our product candidates;
the availability of necessary materials required to make our product candidates;
the costs, requirements and timing of, and the ability to secure, regulatory approvals; and
additional delays caused by the COVID-19 pandemic.

Liquidity and Capital Resources

The following table summarizes our liquidity and capital resources as of March 31, 2023 and December 31, 2022 and our net increase (decrease) in cash, cash equivalents, and marketable securities for the three months ended March 31, 2023 and 2022 and is intended to supplement the more detailed discussion that follows. The amounts stated in the tables below are expressed in thousands.

Liquidity and capital resources

    

March 31, 2023

    

December 31, 2022

 

Cash and cash equivalents

$

10,606

$

9,603

 

Marketable securities

$

34,566

$

31,818

Working capital

$

9,462

$

19,302

 

Stockholders’ equity

$

6,206

$

11,786

 

32

Three months ended March 31, 

Cash flow data

    

2023

    

2022

Cash provided by (used in):

Operating activities

$

4,210

$

24,047

Investing activities

(3,212)

(625)

Financing activities

4

27

Net increase in cash and cash equivalents

 

$

1,002

 

$

23,449

Our total cash, cash equivalents and marketable securities as of March 31, 2023 were approximately $45.2 million compared to approximately $41.4 million as of December 31, 2022. The increase in cash, cash equivalents and marketable securities from December 31, 2022 to March 31, 2023 is due to the upfront payment of $12.0 million from Nippon Shinyaku related to the Japan Distribution Agreement. As of March 31, 2023, we had approximately $47.7 million in total liabilities, of which $36.5 million relates to deferred revenue, and approximately $9.5 million in net working capital.

Cash provided by operating activities was approximately $4.2 million and approximately $24.0 million for the three months ended March 31, 2023 and 2022, respectively. The difference of approximately $19.8 million in cash from operating activities is due to the upfront payment of $12.0 million from Nippon Shinyaku. Furthermore, there was an increase of approximately $1.1 million in stock-based compensation and an increase of approximately $0.1 million in depreciation and amortization for the three months ended March 31, 2023 as compared to the same period in 2022. To the extent we obtain sufficient capital and/or long-term debt funding and are able to continue developing our product candidates, including if we expand our technology portfolio, engage in further research and development activities, and, in particular, conduct preclinical studies and clinical trials, we expect to continue incurring substantial losses.

We had cash flow used in investing activities of approximately $3.2 million and approximately $0.6 million for the three months ended March 31, 2023 and 2022, respectively. The net change in cash used in investing activities for the three months ended March 31, 2023 as compared to the same period of 2022 is due to the net effect from purchases, sales and maturities of marketable securities.

We had cash flow provided by financing activities of $3,895 and $27,465 for the three months ended March 31, 2023 and 2022, respectively. The decrease in cash provided by financing activities for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022 is primarily due to the decrease in the proceeds from issuance of stock in connection to the ATM Programs (as described below).

From inception through March 31, 2023, we financed our operations primarily through private and public sales of our equity securities, government grants and payments from distribution agreements and collaboration partners. As we have not generated any revenue from the commercial sale of our products to date, and we do not expect to generate revenue for several years, if ever, we will need to raise substantial additional capital to fund our research and development, including our long-term plans for clinical trials and new product development. We may seek to raise additional funds through various potential sources, such as equity and debt financings, government grants, or through strategic collaborations and license agreements or other distribution agreements. We can give no assurances that we will be able to secure such additional sources of funds to support our operations, complete our clinical trials or if such funds become available to us, that such additional financing will be sufficient to meet our needs. Moreover, to the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates or grant licenses on terms that may not be favorable to us.

33

Our estimates regarding the sufficiency of our financial resources are based on assumptions that may prove to be wrong. We may need to obtain additional funds sooner than planned or in greater amounts than we currently anticipate. At this time, we believe our cash resources are sufficient to fund our operations for at least the next twelve months. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:

the progress of our clinical and research activities;
the number and scope of our clinical and research programs;
the progress and success of our preclinical and clinical development activities;
the progress of the development efforts of parties with whom we have entered into research and development agreements;
our ability to successfully manufacture product for our clinical trials and potential commercial use;
the availability of materials necessary to manufacture our product candidates;
the costs of manufacturing our product candidates, and the progress of efforts with parties with whom we may enter into commercial manufacturing agreements, if necessary;
our ability to maintain current research and development programs and to establish new research and development and licensing arrangements;
additional costs associated with maintaining licenses and insurance;
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; and
the costs and timing of regulatory approvals.

As a result of the spread of the COVID-19 coronavirus, uncertainties have arisen that have impacted enrollment of clinical trials, deliverables related to contract performance, payments from trial sponsors, workforce stability, supply chain disruptions or delays, timing of grant disbursements as well as other potential business operations. While the disruption is currently expected to be temporary, there is considerable uncertainty around its expected duration. There could be other financial impacts on our business from the coronavirus, the specifics of which are unknown at this time.

Collaborations

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)

On January 24, 2022, Capricor entered into the U.S. Distribution Agreement with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002 for the treatment of DMD.

Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and in addition, Capricor will have the right to receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments, if achieved. In the first quarter of 2022, Capricor received an upfront payment of $30.0 million. Pursuant to the terms of the U.S. Distribution Agreement, there are potential additional sales and development milestone payments of up to $705.0 million.

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)

On February 10, 2023, Capricor entered into the Japan Distribution Agreement with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.

Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12 million in the first quarter of 2023 and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will

34

be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Upon approval, Capricor will sell commercial product to Nippon Shinyaku in Japan. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.

Financing Activities by the Company

ATM Program

On June 21, 2021, the Company initiated an at-the-market offering under a prospectus supplement for aggregate sales proceeds of up to $75.0 million (the “ATM Program”), with the common stock to be distributed at the market prices prevailing at the time of sale. The ATM Program was established under a Common Stock Sales Agreement (the “Sales Agreement,”), with H.C. Wainwright & Co. LLC (“Wainwright”), under which we may, from time to time, issue and sell shares of our common stock through Wainwright as sales agent. The Sales Agreement provides that Wainwright will be entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold. All shares issued pursuant to the ATM Program were issued pursuant to our shelf registration statement on Form S-3 (File No. 333-254363), which was initially filed with the Securities and Exchange Commission (the “SEC”), on March 16, 2021, amended on June 15, 2021 and declared effective by the SEC on June 16, 2021. From June 21, 2021 through December 31, 2022, the Company has sold an aggregate of 2,098,333 shares of common stock under the ATM Program at an average price of approximately $5.93 per share for gross proceeds of approximately $12.4 million. Approximately $62.6 million of common stock may still be sold pursuant to the ATM Program. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.4 million. Subsequent to December 31, 2022 and through May 11, 2023, no additional shares have been sold under the ATM Program.  

CIRM Grant Award

On June 16, 2016, Capricor entered into an award (the “CIRM Award”) with the California Institute for Regenerative Medicine (“CIRM”) in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of Duchenne muscular dystrophy-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.

After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award

35

into a loan. If we elect to do so, Capricor would be required to repay some or all of the amounts awarded by CIRM, therefore the Company accounts for this award as a liability rather than income.

In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of March 31, 2023, Capricor’s liability balance for the CIRM Award was approximately $3.4 million.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Estimates

Our financial statements are prepared in accordance with generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. We evaluate our estimates and assumptions on an ongoing basis, including research and development and clinical trial accruals, and stock-based compensation estimates. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates. We believe the following critical accounting policies reflect the more significant judgments and estimates used in the preparation of our financial statements and accompanying notes.

Leases

ASC 842, requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset, or ROU asset. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance.

Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them.

The Company leases office and laboratory space, all of which are operating leases. Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.

The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.

Revenue Recognition

The Company applies ASU 606, Revenue for Contracts from Customers, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to its distribution agreements.

36

The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.

The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or shares of product revenue. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or shared revenue payments will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and shared revenue payments, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and shared revenue payments are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or shared revenue payments achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or shared revenue payments was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.

The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.

Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.

Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.

37

Grant Income

The determination as to when income is earned is dependent on the language in each specific grant. Generally, we recognize grant income in the period in which the expense is incurred for those expenses that are deemed reimbursable under the terms of the grant. Grant income is due upon submission of reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards.

CIRM Grant Award

Capricor accounts for the disbursements under its CIRM Award as long-term liabilities. Capricor recognizes the CIRM grant disbursements as a liability as the principal is disbursed rather than recognizing the full amount of the grant award. After completing the CIRM funded research project and after the award period end date, Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and the stage of development at the time the election is made. In June 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Since Capricor may be required to repay some or all of the amounts awarded by CIRM, the Company accounts for this award as a liability rather than income.

Research and Development Expenses and Accruals

R&D expenses consist primarily of salaries and related personnel costs, supplies, clinical trial costs, patient treatment costs, rent for laboratories and manufacturing facilities, consulting fees, costs of personnel and supplies for manufacturing, costs of service providers for preclinical, clinical and manufacturing, and certain legal expenses resulting from intellectual property prosecution, stock compensation expense and other expenses relating to the design, development, testing and enhancement of our product candidates. Except for certain capitalized intangible assets, R&D costs are expensed as incurred.

Our cost accruals for clinical trials and other R&D activities are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical trial centers and contract research organizations (“CROs”), clinical study sites, laboratories, consultants or other clinical trial vendors that perform activities in connection with a trial. Related contracts vary significantly in length and may be for a fixed amount, a variable amount based on actual costs incurred, capped at a certain limit, or for a combination of fixed, variable and capped amounts. Activity levels are monitored through close communication with the CROs and other clinical trial vendors, including detailed invoice and task completion review, analysis of expenses against budgeted amounts, analysis of work performed against approved contract budgets and payment schedules, and recognition of any changes in scope of the services to be performed. Certain CRO and significant clinical trial vendors provide an estimate of costs incurred but not invoiced at the end of each quarter for each individual trial. These estimates are reviewed and discussed with the CRO or vendor as necessary, and are included in R&D expenses for the related period. For clinical study sites which are paid periodically on a per-subject basis to the institutions performing the clinical study, we accrue an estimated amount based on subject screening and enrollment in each quarter. All estimates may differ significantly from the actual amount subsequently invoiced, which may occur several months after the related services were performed.

In the normal course of business, we contract with third parties to perform various R&D activities in the on-going development of our product candidates. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients, and the completion of portions of the clinical trial or similar conditions. The objective of the accrual policy is to match the recording of expenses in the financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical trials and other R&D activities are recognized based on our estimates of the degree of completion of the event or events specified in the applicable contract.

No adjustments for material changes in estimates have been recognized in any period presented.

38

Stock-Based Compensation

Our results include non-cash compensation expense as a result of the issuance of stock, stock options and warrants, as applicable. We have issued stock options to employees, directors and consultants under our five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan), (iii) the 2012 Non-Employee Director Stock Option Plan, (iv) the 2020 Equity Incentive Plan, and (v) the 2021 Equity Incentive Plan. At this time, the Company only issues options under the 2020 Plan and the 2021 Plan.

We expense the fair value of stock-based compensation over the vesting period. When more precise pricing data is unavailable, we determine the fair value of stock options using the Black-Scholes option-pricing model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation. These variables and assumptions include the weighted-average period of time that the options granted are expected to be outstanding, the volatility of our common stock, and the risk-free interest rate. We account for forfeitures upon occurrence.

Stock options or other equity instruments to non-employees (including consultants) issued as consideration for goods or services received by us are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods.

The terms and vesting schedules for share-based awards vary by type of grant and the employment status of the grantee. Generally, the awards vest based upon time-based conditions. Stock-based compensation expense is included in general and administrative expense or research and development expense, as applicable, in the Statements of Operations and Comprehensive Income (Loss). We expect to record additional non-cash compensation expense in the future, which may be significant.

Clinical Trial Expense

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, CROs and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.

Recently Issued or Newly Adopted Accounting Pronouncements

Other recent accounting pronouncements issued by the Financial Accounting Standards Board, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

39

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

Interest Rate Sensitivity

Our exposure to market risk for changes in interest rates relates primarily to our marketable securities and cash and cash equivalents. As of March 31, 2023, the fair value of our cash, cash equivalents and marketable securities was approximately $45.2 million. Additionally, as of March 31, 2023, Capricor’s investment portfolio was classified as cash, cash equivalents and marketable securities, which consisted primarily of money market funds and bank money market, which included short-term U.S. treasuries, bank savings and checking accounts.

The goal of our investment policy is to place our investments with highly rated credit issuers and limit the amount of credit exposure. We seek to improve the safety and likelihood of preservation of our invested funds by limiting default risk and market risk. Our investments may be exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments, if any. We will manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying value has always approximated their fair value. Our policy is to mitigate default risk by investing in high credit quality securities, and we currently do not hedge interest rate exposure. Due to our policy of making investments in U.S. treasury securities with primarily short-term maturities, we believe that the fair value of our investment portfolio would not be significantly impacted by a hypothetical 100 basis point increase or decrease in interest rates.

Item 4.  Controls and Procedures.

We have adopted and maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that controls and procedures, no matter how well designed and operated, cannot provide absolute assurance of achieving the desired control objectives.

As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Controls over Financial Reporting

There has been no change in our internal control over financial reporting during the quarter ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.  Legal Proceedings.

We are not involved in any material pending legal proceedings.

Item 1A. Risk Factors.

Part 1, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023, describes important risk factors that could cause our business, financial condition, results of operations and prospects to differ significantly from those suggested by forward-looking statements made in this Quarterly Report on Form 10-Q or otherwise presented by us from time to time. There have been no material changes in

40

our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 17, 2023.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable.

Item 3.  Defaults Upon Senior Securities.

Not applicable.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

None.

41

Item 6.  Exhibits.

2.1

    

Agreement and Plan of Merger, dated as of August 15, 2007, by and among SMI Products, Inc., Nile Merger Sub, Inc. and Nile Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 17, 2007).

 

  

2.2

Agreement and Plan of Merger and Reorganization, dated as of July 7, 2013, by and among Nile Therapeutics, Inc., Bovet Merger Corp. and Capricor, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on July 9, 2013).

  

2.3

First Amendment to Agreement and Plan of Merger and Reorganization, dated as of September 27, 2013, by and between Nile Therapeutics, Inc., Bovet Merger Corp. and Capricor, Inc. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 3, 2013).

  

3.1

Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on February 9, 2007).

  

3.2

Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 26, 2013).

  

3.3

Certificate of Amendment of Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on June 4, 2019).

  

3.4

Amended and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on August 25, 2020).

10.1

Japan Commercialization and Distribution Agreement, dated as of February 10, 2023, by and among Capricor Therapeutics, Inc., Capricor, Inc., and Nippon Shinyaku Co. Ltd. (incorporated by reference to Exhibit 10.55 to the Company’s Annual Report on Form 10-K, filed with the SEC on March 17, 2023).

31.1

Certification of Principal Executive Officer.*

  

31.2

Certification of Principal Financial Officer.*

  

32.1

Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

  

32.2

Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

  

101

The following financial information from Capricor Therapeutics, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 formatted in Inline eXtensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statement of Changes in Stockholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.*

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

† Portions of the exhibit have been excluded because it is both not material and is the type of information that the registrant treats as private or confidential.  

42

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CAPRICOR THERAPEUTICS, INC.

 

 

 

Date: May 12, 2023

By:

/s/ Linda Marbán, Ph.D.

 

 

Linda Marbán, Ph.D.

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Date: May 12, 2023

By:

/s/ Anthony J. Bergmann

 

 

Anthony J. Bergmann

 

 

Chief Financial Officer

 

 

(Principal Financial and Accounting Officer)

43

EX-31.1 2 capr-20230331xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Linda Marbán, Ph.D., certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Capricor Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2023

/s/ Linda Marbán, Ph.D.

Name: Linda Marbán, Ph.D.

Title: Chief Executive Officer and Principal Executive Officer


EX-31.2 3 capr-20230331xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Anthony J. Bergmann, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Capricor Therapeutics, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2023

/s/ Anthony J. Bergmann

 

Name: Anthony J. Bergmann

 

Title: Chief Financial Officer and Principal Financial Officer

 


EX-32.1 4 capr-20230331xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Linda Marbán, Ph.D., the Principal Executive Officer of Capricor Therapeutics, Inc. (the “Company”), hereby certifies, to her knowledge, that:

(1) the Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.

Date: May 12, 2023

/s/ Linda Marbán, Ph.D.

 

Name: Linda Marbán, Ph.D.

 

Title: Chief Executive Officer and Principal Executive Officer

 


EX-32.2 5 capr-20230331xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Anthony J. Bergmann, the Principal Financial Officer of Capricor Therapeutics, Inc. (the “Company”), hereby certifies, to his knowledge, that:

(1) the Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Report.

Date: May 12, 2023

/s/ Anthony J. Bergmann

 

Name: Anthony J. Bergmann

 

Title: Chief Financial Officer and Principal Financial Officer

 


EX-101.SCH 6 capr-20230331.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payment (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc2) (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Calc3) (Details) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - STOCKHOLDER'S EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - LICENSE AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - LICENSE AGREEMENTS Default (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - STOCKHOLDER'S EQUITY link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - GOVERNMENT GRANT AWARDS link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 capr-20230331_cal.xml EX-101.CAL EX-101.DEF 8 capr-20230331_def.xml EX-101.DEF EX-101.LAB 9 capr-20230331_lab.xml EX-101.LAB EX-101.PRE 10 capr-20230331_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2023
May 10, 2023
Document and Entity Information    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-34058  
Entity Registrant Name CAPRICOR THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 88-0363465  
Entity Address, Address Line One 10865 Road to the Cure, Suite 150, San Diego  
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92121  
City Area Code 858  
Local Phone Number 727-1755  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol CAPR  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   25,269,926
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Entity Central Index Key 0001133869  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2023
Dec. 31, 2022
CURRENT ASSETS    
Cash and cash equivalents $ 10,605,528 $ 9,603,242
Marketable securities 34,566,342 31,818,020
Receivables 547,580 547,580
Prepaid expenses and other current assets 875,092 919,892
TOTAL CURRENT ASSETS 46,594,542 42,888,734
PROPERTY AND EQUIPMENT, net 4,811,044 4,588,030
OTHER ASSETS    
Lease right-of-use assets, net 2,189,651 2,349,974
Other assets 268,172 268,172
TOTAL ASSETS 53,863,409 50,094,910
CURRENT LIABILITIES    
Accounts payable and accrued expenses 5,407,016 4,834,683
Accounts payable and accrued expenses, related party 18,716 89,234
Lease liabilities, current 693,652 682,039
Deferred revenue, current 31,012,773 17,980,599
TOTAL CURRENT LIABILITIES 37,132,157 23,586,555
LONG-TERM LIABILITIES    
CIRM liability 3,376,259 3,376,259
Lease liabilities, net of current 1,699,682 1,878,070
Deferred revenue, net of current 5,449,062 9,467,932
TOTAL LONG-TERM LIABILITIES 10,525,003 14,722,261
TOTAL LIABILITIES 47,657,160 38,308,816
COMMITMENTS AND CONTINGENCIES (NOTE 6)
STOCKHOLDERS' EQUITY    
Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value, 50,000,000 shares authorized, 25,255,154 and 25,241,402 shares issued and outstanding, respectively 25,255 25,241
Additional paid-in capital 150,934,085 148,735,420
Accumulated other comprehensive income 94,986 105,244
Accumulated deficit (144,848,077) (137,079,811)
TOTAL STOCKHOLDERS' EQUITY 6,206,249 11,786,094
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 53,863,409 $ 50,094,910
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS    
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common Stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized 50,000,000 50,000,000
Common stock, shares issued 25,255,154 25,241,402
Common stock, shares outstanding 25,255,154 25,241,402
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
REVENUE    
Revenue $ 2,986,696  
TOTAL REVENUE 2,986,696  
OPERATING EXPENSES    
Research and development 7,661,519 $ 5,115,699
General and administrative 3,509,885 2,715,835
TOTAL OPERATING EXPENSES 11,171,404 7,831,534
LOSS FROM OPERATIONS (8,184,708) (7,831,534)
OTHER INCOME (EXPENSE)    
Investment income 416,442 13,440
TOTAL OTHER INCOME (EXPENSE) 416,442 13,440
NET LOSS (7,768,266) (7,818,094)
OTHER COMPREHENSIVE INCOME (LOSS)    
Net unrealized loss on marketable securities (10,258)  
COMPREHENSIVE INCOME (LOSS) $ (7,778,524) $ (7,818,094)
Net loss per share, basic $ (0.31) $ (0.32)
Net loss per share, diluted $ (0.31) $ (0.32)
Weighted-average number of shares of common stock outstanding basic 25,247,354 24,282,743
Weighted-average number of shares of common stock outstanding diluted 25,247,354 24,282,743
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
COMMON STOCK [Member]
ADDITIONAL PAID-IN CAPITAL [Member]
OTHER COMPREHENSIVE INCOME [Member]
ACCUMULATED DEFICIT [Member]
Total
Balance at Dec. 31, 2021 $ 24,185 $ 139,404,060   $ (108,060,279) $ 31,367,966
Balance (in shares) at Dec. 31, 2021 24,185,001        
Stock-based compensation   1,065,329     1,065,329
Stock options exercised $ 139 27,326     27,465
Stock options exercised (in shares) 139,155        
Net loss       (7,818,094) (7,818,094)
Balance at Mar. 31, 2022 $ 24,324 140,496,715   (115,878,373) 24,642,666
Balance (in shares) at Mar. 31, 2022 24,324,156        
Balance at Dec. 31, 2022 $ 25,241 148,735,420 $ 105,244 (137,079,811) 11,786,094
Balance (in shares) at Dec. 31, 2022 25,241,402        
Stock-based compensation   2,194,784     2,194,784
Stock options exercised $ 14 3,881     3,895
Stock options exercised (in shares) 13,752        
Unrealized gain on marketable securities     (10,258)   (10,258)
Net loss       (7,768,266) (7,768,266)
Balance at Mar. 31, 2023 $ 25,255 $ 150,934,085 $ 94,986 $ (144,848,077) $ 6,206,249
Balance (in shares) at Mar. 31, 2023 25,255,154        
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (7,768,266) $ (7,818,094)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 230,101 92,490
Stock-based compensation 2,194,784 1,065,329
Changes in lease liabilities (6,452) 72,734
Changes in operating assets and liabilities:    
Receivables   34,753
Prepaid expenses and other current assets 44,800 216,691
Accounts payable and accrued expenses 572,333 407,203
Accounts payable and accrued expenses, related party (70,518) (24,540)
Deferred revenue 9,013,304 30,000,000
Net cash provided by operating activities 4,210,086 24,046,566
Cash flows from investing activities:    
Purchase of marketable securities (34,803,580) 0
Proceeds from sales and maturities of marketable securities 32,045,000 0
Purchases of property and equipment (347,690) (567,616)
Payments for leasehold improvements (105,425) (57,744)
Net cash used in investing activities (3,211,695) (625,360)
Cash flows from financing activities:    
Proceeds from exercise of stock awards 3,895 27,465
Net cash provided by financing activities 3,895 27,465
Net increase in cash and cash equivalents 1,002,286 23,448,671
Cash and cash equivalents balance at beginning of period 9,603,242 34,885,274
Cash and cash equivalents balance at end of period $ 10,605,528 58,333,945
Supplemental disclosures of cash flow information:    
Interest paid in cash   0
Income taxes paid in cash   $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Mar. 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

1.            ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Description of Business

Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple drug and vaccine candidates in various stages of development.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023, from which the December 31, 2022 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

Basis of Consolidation

Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.

Liquidity

The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.

Cash, cash equivalents, and marketable securities as of March 31, 2023 were approximately $45.2 million, compared to approximately $41.4 million as of December 31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a Japanese corporation, in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 – “License and Distribution Agreements”). Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright & Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").

The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.

The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:

the timing and costs associated with its research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase III clinical study of CAP-1002 in DMD;
the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;
the timing and costs associated with potential commercialization of its product candidates;
the number and scope of its research programs, including the expansion of our exosomes program; and
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.

The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants.

The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.

Business Uncertainty Related to the Coronavirus

The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees, and the impact may continue in future periods.

In light of past uncertainties due to COVID-19 and its economic and other impacts, the Company submitted for the Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021. As of March 31, 2023, the Company has recorded a receivable for $547,580 for the remainder of funds expected to be received.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.

Marketable Securities

The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and are carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities

are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are presented as other comprehensive income (loss) as a separate component of stockholders’ equity. As of March 31, 2023, marketable securities consist primarily of short-term United States treasuries.

Property and Equipment

Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $230,101 and $92,490 for the three months ended March 31, 2023 and 2022, respectively.

Property and equipment, net consisted of the following:

    

March 31, 

    

December 31, 

    

2023

    

2022

Furniture and fixtures

$

143,573

$

139,336

Laboratory equipment

 

4,566,146

 

4,237,089

Leasehold improvements

 

1,498,655

 

1,393,230

 

6,208,374

 

5,769,655

Less accumulated depreciation

 

(1,397,330)

 

(1,181,625)

Property and equipment, net

$

4,811,044

$

4,588,030

Leases

ASC Topic 842, Leases (“ASC 842”), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance.

Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them.

The Company leases office and laboratory space, all of which are operating leases (see Note 6 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.

The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.

Revenue Recognition

The Company adopted ASU 606, Revenue for Contracts from Customers, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 – “License and Distribution Agreements).

The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.

The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and sharing of revenues are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or royalties achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.

The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.

Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to

complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.

Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.

Under the Exclusive Commercialization and Distribution Agreement for the U.S. (the “U.S. Distribution Agreement”) with Nippon Shinyaku the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the duration of the HOPE-3 clinical trial. Therefore, upon receipt of the upfront payment, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.

Grant Income

Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the “CIRM Award”) from the California Institute for Regenerative Medicine (“CIRM”) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized for the three months ended March 31, 2023 and 2022.

Research and Development

Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development. Research and development (“R&D”) costs amounted to approximately $7.7 million and $5.1 million for the three months ended March 31, 2023 and 2022, respectively.

Comprehensive Income (Loss)

Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $7.8 million for the three months ended March 31, 2023 and 2022. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.

Clinical Trial Expense

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense

recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.

Stock-Based Compensation

The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.

The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260-10, Earnings per Share. Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive.

As of March 31, 2023 and 2022, warrants and options to purchase 7,971,557 and 5,674,191 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three months ended March 31, 2023 and 2022.

Fair Value Measurements

Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:

Level Input:

    

Input Definition:

Level I

Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Level II

Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.

Level III

Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2023 for assets and liabilities measured at fair value on a recurring basis:

March 31, 2023

    

Level I

    

Level II

    

Level III

    

Total

Marketable Securities

$

34,566,342

$

$

$

34,566,342

Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. The amortized cost for these marketable securities as of March 31, 2023 was $34,471,356.

Recent Accounting Pronouncements

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDER'S EQUITY
3 Months Ended
Mar. 31, 2023
STOCKHOLDER'S EQUITY  
STOCKHOLDER'S EQUITY

2.            STOCKHOLDER’S EQUITY

ATM Program

The Company established an “at-the-market” program (the “ATM Program”) on June 21, 2021, with an aggregate offering price of up to $75.0 million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses.

From June 21, 2021 through December 31, 2022, the Company sold an aggregate of 2,098,333 shares of common stock under the ATM Program at an average price of approximately $5.93 per share for gross proceeds of approximately $12.4 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.4 million. Subsequent to December 31, 2022 and through May 11, 2023, no shares were sold under the ATM Program.

Outstanding Shares

At March 31, 2023, the Company had 25,255,154 shares of common stock issued and outstanding.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS
3 Months Ended
Mar. 31, 2023
STOCK AWARDS, WARRANTS AND OPTIONS  
STOCK AWARDS, WARRANTS AND OPTIONS

3.            STOCK AWARDS, WARRANTS AND OPTIONS

Warrants

The following table summarizes all warrant activity for the three months ended March 31, 2023:

Weighted Average

    

Warrants

    

Exercise Price

Outstanding at December 31, 2022

 

105,782

$

1.37

Granted

Exercised

Outstanding at March 31, 2023

 

105,782

$

1.37

The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock:

Warrants Outstanding

March 31, 

December 31, 

Exercise Price

Expiration

Type

    

Grant Date

    

2023

    

2022

    

per Share

    

Date

Common Warrants

12/19/2019

40,782

 

40,782

$

1.10

12/19/2024

Common Warrants

3/27/2020

65,000

 

65,000

$

1.5313

3/27/2025

105,782

105,782

Stock Options

The Company’s Board of Directors (the “Board”) has approved five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the “2012 Plan”), (iii) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”), (iv) the 2020 Equity Incentive Plan (the “2020 Plan”), and (v) the 2021 Equity Incentive Plan (the “2021 Plan”). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan.

In June 2020, the Company’s stockholders approved the 2020 Equity Incentive Plan (the “2020 Plan”), which authorized 2,500,000 shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.  Pursuant to the “evergreen” provision, on January 1, 2021, 823,084 shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, no new shares were added to the share reserve under the 2020 Plan pursuant to its “evergreen” provisions.

In June 2021, the Company’s stockholders approved the 2021 Plan, which authorized 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards.  The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2023 and 2022, 1,262,070 and 1,209,250 shares were added under the 2021 Plan, respectively.

As of March 31, 2023, 1,756,664 options remain available for issuance under the respective stock option plans.

The Company’s stock option plans are administered by the Board, or the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the

aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of one to four years. The term of stock options granted under each of the plans cannot exceed ten years.

The estimated weighted average fair value of the options granted during the three months ended March 31, 2023 and 2022 were approximately $3.47 and $2.87 per share, respectively.

The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the three months ended March 31, 2023 and 2022:

    

Three months ended March 31, 

 

2023

2022

Expected volatility

 

115 - 121

%  

123

%

Expected term

 

5 - 7 years

 

6 years

Dividend yield

 

0

%  

0

%

Risk-free interest rates

 

3.6 - 3.9

%  

1.5 - 1.7

%

Employee and non-employee stock-based compensation expense was as follows:

Three months ended March 31, 

    

2023

    

2022

General and administrative

$

1,754,223

$

857,583

Research and development

 

440,561

 

207,746

Total

$

2,194,784

$

1,065,329

The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.

Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.

As of March 31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $15.2 million, which is expected to be recognized over a weighted average period of approximately 1.5 years.

The following is a schedule summarizing employee and non-employee stock option activity for the three months ended March 31, 2023:

Number of

Weighted Average

Aggregate

    

Options

    

Exercise Price

    

Intrinsic Value

Outstanding at December 31, 2022

 

5,776,839

$

2.97

 

Granted

 

2,220,979

 

3.91

 

  

Exercised

 

(19,688)

 

1.52

 

$

54,741

Expired/Cancelled

 

(112,355)

 

4.66

 

  

Outstanding at March 31, 2023

 

7,865,775

$

3.22

$

8,303,587

Exercisable at March 31, 2023

 

3,091,952

$

2.69

$

4,890,171

The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock for each of the respective periods.

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.1
CONCENTRATIONS
3 Months Ended
Mar. 31, 2023
CONCENTRATIONS  
CONCENTRATIONS

4.            CONCENTRATIONS

Concentration of Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company has historically maintained accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation (the “FDIC”) for up to $250,000. The Company’s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of March 31, 2023, were approximately $45.3 million. Historically, the Company has not experienced any significant losses in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held.

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.1
GOVERNMENT GRANT AWARDS
3 Months Ended
Mar. 31, 2023
GOVERNMENT GRANT AWARDS  
GOVERNMENT GRANT AWARDS

5.            GOVERNMENT GRANT AWARDS

CIRM Grant Award (HOPE)

On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.

After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term

of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. If we elect to do so, Capricor would be required to repay some or all of the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.

In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of March 31, 2023, Capricor’s liability balance for the CIRM Award was approximately $3.4 million.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Mar. 31, 2023
COMMITMENTS AND CONTINGENCIES  
COMMITMENTS AND CONTINGENCIES

6.            COMMITMENTS AND CONTINGENCIES

Short-Term Operating Leases

Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon 90 days’ written notice to the other party. Commencing in July 2022, the monthly lease payment was $7,869 per month.

Expenses incurred under short-term operating leases for the three months ended March 31, 2023 and 2022 were $23,607 and $17,394, respectively.

Long-Term Operating Leases

Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (“CSMC”), a related party (see Note 8 – “Related Party Transactions”), pursuant to a lease (the “Facilities Lease”) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional 24-month period extending the term through July 31, 2024 with a monthly lease payment of $10,707.

The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (“Altman”) for office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the “San Diego Lease”). The rent is subject to a 3.0% annual rent increase during the initial lease term of five years, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of five years.  The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022 the monthly lease payment was increased to $49,322 per month. Effective December 1, 2022, the monthly lease payment was increased to $51,444 per month.

Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (“Explora”), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $4,021 per month for an exclusive large vivarium room located in San Diego, California. The lease term is for one-year and will automatically renew for additional successive one-year renewal terms unless either party provides the other party with 60-day written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of 4.5% bringing the base rent to approximately $4,202 per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of five years.

The long-term real estate operating leases are included in “lease right-of-use assets, net” on the Company’s condensed consolidated balance sheet and represent the Company’s right-to-use the underlying assets for the lease term. The Company’s obligation to make lease payments are included in “lease liabilities, current” and “lease liabilities, net of current” on the Company’s condensed consolidated balance sheet.

The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of March 31, 2023:

2023 (remainder)

$

601,801

2024

765,986

2025

710,259

2026

547,948

Total minimum lease payments

2,625,994

Less: imputed interest

(232,660)

Total operating lease liabilities

$

2,393,334

Included in the condensed consolidated balance sheet:

Current portion of lease liabilities

$

693,652

Lease liabilities, net of current

1,699,682

Total operating lease liabilities

$

2,393,334

Other Information:

Weighted average remaining lease term

3.36 years

Weighted average discount rate

5.36%

As of March 31, 2023, ROU assets for operating leases were approximately $2.2 million and operating lease liabilities were approximately $2.4 million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company’s operating leases under ASC 842 for the period indicated:

Three months ended March 31, 

2023

    

2022

Lease costs, unrelated parties

$

160,486

$

158,084

Lease costs, related parties

32,120

Lease payments, unrelated parties

166,938

85,352

Lease payments, related parties

32,120

Legal Contingencies

The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise.

Accounts Payable

During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.

Other Funding Commitments

The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 – “License and Distribution Agreements”).

Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement.

Employee Severances

The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability under these severance packages has been recorded as of March 31, 2023.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AND DISTRIBUTION AGREEMENTS
3 Months Ended
Mar. 31, 2023
LICENSE AND DISTRIBUTION AGREEMENTS  
LICENSE AND DISTRIBUTION AGREEMENTS

7.            LICENSE AND DISTRIBUTION AGREEMENTS

Intellectual Property Rights for Capricor’s Technology - CAP 1002 and Exosomes

Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Università Degli Studi Di Roma La Sapienza (the “University of Rome”), Johns Hopkins University (“JHU”) and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists.

University of Rome License Agreement

Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields.

Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments.

The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party’s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days’ written notice to the University of Rome.

The Johns Hopkins University License Agreements

License Agreement for CDCs

Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.

Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase III study for which a payment of $500,000 will be due.

The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice.

License Agreement for Exosome-based Vaccines and Therapeutics

Capricor and JHU entered into an Exclusive License Agreement (the “JHU Exosome License Agreement”) effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license of JHU’s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how.

Pursuant to the JHU Exosome License Agreement, JHU was paid an upfront license fee of $10,000 and Capricor has agreed to reimburse JHU for certain fees and costs incurred in connection with the prosecution of certain patent rights.

Additionally, Capricor is required to meet certain development milestones for which a milestone payment fee shall be due and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a double-digit percentage of any non-royalty consideration received from any sublicenses, subject to certain exclusions. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to pay royalties on one or more third party patents as a requirement to make or sell a licensed product. In addition, Capricor will, beginning with the third year of the JHU Exosome License Agreement, be obligated to pay JHU a minimum annual royalty which is non-refundable but will be credited against royalties incurred by Capricor for the year in which the minimum annual royalty becomes due.

The JHU Exosome License Agreement will, unless sooner terminated, continue in each country until the date of expiration of the last to expire patent included within the patent rights in that country, or if no patents issue, then for 20 years. The JHU Exosome License Agreement may be terminated by Capricor upon 90 days’ written notice in its discretion and with 60 days’ notice with respect to any particular patent or application or as to any particular licensed product. The JHU Exosome License Agreement may also be terminated by either party if the other party fails to perform or otherwise breaches any of its obligations and fails to cure such breach within a 60-day cure period commencing upon notice. A material breach by Capricor may include (a) a delinquency with respect to payment or reporting; (b) the failure by Capricor to timely achieve a specified milestone or otherwise failing to diligently develop, commercialize, and sell licensed products throughout the term of the JHU Exosome License Agreement; (c) non-compliance with record keeping or audit obligations; (d) voluntary bankruptcy or insolvency of Capricor; and (e) non-compliance with Capricor’s insurance obligations.

Cedars-Sinai Medical Center License Agreements

License Agreement for CDCs

On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “Original CSMC License Agreement”), for certain intellectual property related to its cardiosphere-derived cell (“CDC”) technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.

The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.

Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones.

Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty-bearing product.

The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days’ notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.

On March 20, 2015, August 5, 2016, December 26, 2017, June 20, 2018, and July 27, 2021, Capricor and CSMC entered into a number of amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents, among other things. Capricor reimbursed CSMC for certain attorneys’ fees and filing fees incurred in connection with the additional patent applications.

License Agreement for Exosomes

On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.

Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty bearing product.

The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.

On February 27, 2015, June 10, 2015, August 5, 2016, December 26, 2017, June 20, 2018, September 25, 2018, August 19, 2020, August 28, 2020, and March 19, 2021, Capricor and CSMC entered into a number of amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, and added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights; failure to meet those milestones would cause CSMC to have the right to convert the license from exclusive to non-exclusive or co-exclusive, or to terminate the license, subject to Capricor’s right to license such patent rights for internal research purposes on a non-exclusive basis.  These amendments also obligated Capricor to reimburse CSMC for certain attorneys’ fees and filing fees in connection with the additional patent applications and patent families.

Cell Line License Agreement with Life Technologies

On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in the first quarter of 2022 and additional milestone fees may become due on the progress of our development program.

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)

On January 24, 2022, Capricor entered into the U.S. Distribution Agreement with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002, for the treatment of DMD.

Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and in addition Capricor will have the right to receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments, if achieved. In the first quarter of 2022, Capricor received an upfront payment of $30.0 million. Pursuant to the terms of the U.S. Distribution Agreement, there are potential additional sales and development milestone payments of up to $705.0 million.

The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, Revenue for Contracts from Customers. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase III clinical study.

The Company determined the initial transaction price totaled $30.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the total $30.0 million initial transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract’s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits. For the three months ended March 31, 2023, the Company recognized approximately $3.0 million as revenue. In relation to the U.S. Distribution Agreement, as of March 31, 2023, the Company recorded approximately $19.0 million as current deferred revenue and approximately $5.4 million as deferred revenue, net of current portion, on the Company’s condensed consolidated balance sheets.

The Company had no opening or closing contract asset balances recognized.  The difference between the opening and closing balances of the Company’s contract liability results from the Company performance of services in connection to its performance obligation.

The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of March 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $24.5 million. 78% of the remaining performance obligations are expected to be recognized over the next 12 months, with the remainder recognized thereafter. Remaining performance obligations estimates are subject to change.  

Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)

On February 10, 2023, Capricor entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Distribution Agreement”) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.

Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023, and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.

The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, Revenue for Contracts from Customers. The Company determined the initial transaction price totaled $12.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $12.0 million as current deferred revenue on the Company’s condensed consolidated balance sheets as of March 31, 2023.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
3 Months Ended
Mar. 31, 2023
RELATED PARTY TRANSACTIONS  
RELATED PARTY TRANSACTIONS

8.            RELATED PARTY TRANSACTIONS

Lease and Sub-Lease Agreement

As noted above, Capricor is a party to lease agreements with CSMC (see Note 6 – “Commitments and Contingencies”), and CSMC has served as an investigative site in Capricor’s clinical trials. Additionally, Dr. Eduardo Marbán, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company’s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.

Consulting Agreements

In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company’s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days’ notice.

In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marbán whereby he was granted an option to purchase 50,000 shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marbán was granted an additional option grant to purchase 50,000 shares of the Company’s common stock.

Payables to Related Party

As of March 31, 2023 and December 31, 2022, the Company had accounts payable and accrued expenses to related parties totaling $18,716 and $89,234, respectively. CSMC accounts for $8,716 and $79,234 of the total accounts payable and accrued expense to related parties as of March 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the three months ended March 31, 2023 and 2022, the Company paid CSMC approximately $111,400 and $66,600, respectively, for such costs.

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Mar. 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Description of Business

Description of Business

Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple drug and vaccine candidates in various stages of development.

Basis of Presentation

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023, from which the December 31, 2022 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.

Basis of Consolidation

Basis of Consolidation

Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.

Liquidity

Liquidity

The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.

Cash, cash equivalents, and marketable securities as of March 31, 2023 were approximately $45.2 million, compared to approximately $41.4 million as of December 31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a Japanese corporation, in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 – “License and Distribution Agreements”). Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright & Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity").

The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.

The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:

the timing and costs associated with its research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase III clinical study of CAP-1002 in DMD;
the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;
the timing and costs associated with potential commercialization of its product candidates;
the number and scope of its research programs, including the expansion of our exosomes program; and
the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.

The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants.

The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.

Business Uncertainty Related to the Coronavirus

Business Uncertainty Related to the Coronavirus

The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees, and the impact may continue in future periods.

In light of past uncertainties due to COVID-19 and its economic and other impacts, the Company submitted for the Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021. As of March 31, 2023, the Company has recorded a receivable for $547,580 for the remainder of funds expected to be received.

Use of Estimates

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.

Marketable Securities

Marketable Securities

The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and are carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities

are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are presented as other comprehensive income (loss) as a separate component of stockholders’ equity. As of March 31, 2023, marketable securities consist primarily of short-term United States treasuries.

Property and Equipment

Property and Equipment

Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from five to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $230,101 and $92,490 for the three months ended March 31, 2023 and 2022, respectively.

Property and equipment, net consisted of the following:

    

March 31, 

    

December 31, 

    

2023

    

2022

Furniture and fixtures

$

143,573

$

139,336

Laboratory equipment

 

4,566,146

 

4,237,089

Leasehold improvements

 

1,498,655

 

1,393,230

 

6,208,374

 

5,769,655

Less accumulated depreciation

 

(1,397,330)

 

(1,181,625)

Property and equipment, net

$

4,811,044

$

4,588,030

Leases

Leases

ASC Topic 842, Leases (“ASC 842”), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance.

Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them.

The Company leases office and laboratory space, all of which are operating leases (see Note 6 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.

The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.

For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.

Revenue Recognition

Revenue Recognition

The Company adopted ASU 606, Revenue for Contracts from Customers, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 – “License and Distribution Agreements).

The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.

The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and sharing of revenues are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or royalties achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.

The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.

Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to

complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.

Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.

Under the Exclusive Commercialization and Distribution Agreement for the U.S. (the “U.S. Distribution Agreement”) with Nippon Shinyaku the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the duration of the HOPE-3 clinical trial. Therefore, upon receipt of the upfront payment, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.

Grant Income

Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the “CIRM Award”) from the California Institute for Regenerative Medicine (“CIRM”) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized for the three months ended March 31, 2023 and 2022.

Research and Development

Research and Development

Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, Research and Development. Research and development (“R&D”) costs amounted to approximately $7.7 million and $5.1 million for the three months ended March 31, 2023 and 2022, respectively.

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $7.8 million for the three months ended March 31, 2023 and 2022. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities.

Clinical Trial Expense

Clinical Trial Expense

As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense

recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.

Stock-Based Compensation

Stock-Based Compensation

The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.

The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.

Basic and Diluted Loss per Share

Basic and Diluted Loss per Share

The Company reports earnings per share in accordance with FASB ASC 260-10, Earnings per Share. Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive.

As of March 31, 2023 and 2022, warrants and options to purchase 7,971,557 and 5,674,191 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three months ended March 31, 2023 and 2022.

Fair Value Measurements

Fair Value Measurements

Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:

Level Input:

    

Input Definition:

Level I

Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.

Level II

Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.

Level III

Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2023 for assets and liabilities measured at fair value on a recurring basis:

March 31, 2023

    

Level I

    

Level II

    

Level III

    

Total

Marketable Securities

$

34,566,342

$

$

$

34,566,342

Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. The amortized cost for these marketable securities as of March 31, 2023 was $34,471,356.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
3 Months Ended
Mar. 31, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of property, plant and equipment

Property and equipment, net consisted of the following:

    

March 31, 

    

December 31, 

    

2023

    

2022

Furniture and fixtures

$

143,573

$

139,336

Laboratory equipment

 

4,566,146

 

4,237,089

Leasehold improvements

 

1,498,655

 

1,393,230

 

6,208,374

 

5,769,655

Less accumulated depreciation

 

(1,397,330)

 

(1,181,625)

Property and equipment, net

$

4,811,044

$

4,588,030

Schedule of fair value measurements

March 31, 2023

    

Level I

    

Level II

    

Level III

    

Total

Marketable Securities

$

34,566,342

$

$

$

34,566,342

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS (Tables)
3 Months Ended
Mar. 31, 2023
Warrant [Member]  
Summary of warrant activity

The following table summarizes all warrant activity for the three months ended March 31, 2023:

Weighted Average

    

Warrants

    

Exercise Price

Outstanding at December 31, 2022

 

105,782

$

1.37

Granted

Exercised

Outstanding at March 31, 2023

 

105,782

$

1.37

Schedule of outstanding warrants

The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock:

Warrants Outstanding

March 31, 

December 31, 

Exercise Price

Expiration

Type

    

Grant Date

    

2023

    

2022

    

per Share

    

Date

Common Warrants

12/19/2019

40,782

 

40,782

$

1.10

12/19/2024

Common Warrants

3/27/2020

65,000

 

65,000

$

1.5313

3/27/2025

105,782

105,782

Stock Option [Member]  
Schedule of fair value of option using Black-Scholes option

The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the three months ended March 31, 2023 and 2022:

    

Three months ended March 31, 

 

2023

2022

Expected volatility

 

115 - 121

%  

123

%

Expected term

 

5 - 7 years

 

6 years

Dividend yield

 

0

%  

0

%

Risk-free interest rates

 

3.6 - 3.9

%  

1.5 - 1.7

%

Schedule of employee and non-employee stock based compensation expense

Employee and non-employee stock-based compensation expense was as follows:

Three months ended March 31, 

    

2023

    

2022

General and administrative

$

1,754,223

$

857,583

Research and development

 

440,561

 

207,746

Total

$

2,194,784

$

1,065,329

Schedule of employee and non-employee stock option

The following is a schedule summarizing employee and non-employee stock option activity for the three months ended March 31, 2023:

Number of

Weighted Average

Aggregate

    

Options

    

Exercise Price

    

Intrinsic Value

Outstanding at December 31, 2022

 

5,776,839

$

2.97

 

Granted

 

2,220,979

 

3.91

 

  

Exercised

 

(19,688)

 

1.52

 

$

54,741

Expired/Cancelled

 

(112,355)

 

4.66

 

  

Outstanding at March 31, 2023

 

7,865,775

$

3.22

$

8,303,587

Exercisable at March 31, 2023

 

3,091,952

$

2.69

$

4,890,171

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Tables)
3 Months Ended
Mar. 31, 2023
COMMITMENTS AND CONTINGENCIES  
Schedule of Future Minimum Rental Payments

2023 (remainder)

$

601,801

2024

765,986

2025

710,259

2026

547,948

Total minimum lease payments

2,625,994

Less: imputed interest

(232,660)

Total operating lease liabilities

$

2,393,334

Included in the condensed consolidated balance sheet:

Current portion of lease liabilities

$

693,652

Lease liabilities, net of current

1,699,682

Total operating lease liabilities

$

2,393,334

Other Information:

Weighted average remaining lease term

3.36 years

Weighted average discount rate

5.36%

Schedule of operating lease cost

Three months ended March 31, 

2023

    

2022

Lease costs, unrelated parties

$

160,486

$

158,084

Lease costs, related parties

32,120

Lease payments, unrelated parties

166,938

85,352

Lease payments, related parties

32,120

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment, Gross $ 6,208,374 $ 5,769,655
Less accumulated depreciation (1,397,330) (1,181,625)
Property and equipment, net 4,811,044 4,588,030
Furniture and fixtures    
Property, Plant and Equipment, Gross 143,573 139,336
Laboratory equipment    
Property, Plant and Equipment, Gross 4,566,146 4,237,089
Leasehold improvements    
Property, Plant and Equipment, Gross $ 1,498,655 $ 1,393,230
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2021
Dec. 31, 2022
Dec. 31, 2020
Accounting Policies [Line Items]          
Cash, cash equivalents, and marketable securities $ 45,200,000     $ 41,400,000  
Milestone payment received 9,013,304 $ 30,000,000      
Revenue recognized under "ERC"     $ 191,199    
Receivables under "ERC" 547,580   $ 738,778   $ 738,778
Depreciation 230,101 92,490      
Research and development 7,661,519 5,115,699      
Comprehensive loss $ 7,778,524 $ 7,818,094      
Antidilutive securities 7,971,557 5,674,191      
Grant Income $ 0 $ 0      
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan          
Accounting Policies [Line Items]          
Milestone payment received $ 12,000,000.0        
Minimum          
Accounting Policies [Line Items]          
Estimated useful lives (in years) 5 years        
Maximum          
Accounting Policies [Line Items]          
Estimated useful lives (in years) 7 years        
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)
Mar. 31, 2023
USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Amortized Cost of Marketable Securities $ 34,471,356
Recurring  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable Securities 34,566,342
Level 1 | Recurring  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Marketable Securities $ 34,566,342
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDER'S EQUITY (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 18 Months Ended
Jun. 22, 2021
Mar. 31, 2023
Dec. 31, 2022
Class of Stock [Line Items]      
Commission rate on sale price per share   3.00%  
Common stock, shares issued   25,255,154 25,241,402
Common stock, shares outstanding   25,255,154 25,241,402
June 2021 ATM Program      
Class of Stock [Line Items]      
Maximum aggregate offering price $ 75.0    
Number of common stock shares issued     2,098,333
Average price     $ 5.93
Gross proceeds from sale of common stock     $ 12.4
Issuance costs     $ 0.4
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)
Mar. 31, 2023
$ / shares
shares
STOCK AWARDS, WARRANTS AND OPTIONS  
Warrants Outstanding at Beginning | shares 105,782
Warrants Outstanding at Ending | shares 105,782
Weighted Average Exercise Price Outstanding at Beginning | $ / shares $ 1.37
Weighted Average Exercise Price Outstanding at Ending | $ / shares $ 1.37
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) - $ / shares
3 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Class of Warrant or Right [Line Items]    
Warrants Outstanding 105,782 105,782
Common Warrants with Expiration on December 2024 One    
Class of Warrant or Right [Line Items]    
Grant Date Dec. 19, 2019  
Warrants Outstanding 40,782 40,782
Exercise Price per Share $ 1.10  
Expiration Date Dec. 19, 2024  
Common Stock Warrants With Expiration On December 2025 Two    
Class of Warrant or Right [Line Items]    
Grant Date Mar. 27, 2020  
Warrants Outstanding 65,000 65,000
Exercise Price per Share $ 1.5313  
Expiration Date Mar. 27, 2025  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected volatility, Maximum 121.00%  
Expected volatility, Minimum 115.00%  
Expected volatility   123.00%
Expected term   6 years
Dividend yield 0.00% 0.00%
Risk-free interest rates, Minimum 3.60% 1.50%
Risk-free interest rates, Maximum 3.90% 1.70%
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 5 years  
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 7 years  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation cost $ 2,194,784 $ 1,065,329
General and administrative    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation cost 1,754,223 857,583
Research and development    
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]    
Stock-based compensation cost $ 440,561 $ 207,746
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) - Stock Option
3 Months Ended
Mar. 31, 2023
USD ($)
$ / shares
shares
Number of Options  
Outstanding at Beginning of the period | shares 5,776,839
Granted | shares 2,220,979
Exercised | shares (19,688)
Expired/Cancelled | shares (112,355)
Outstanding at End of the period | shares 7,865,775
Exercisable | shares 3,091,952
Weighted Average Exercise Price  
Outstanding at Beginning of the period | $ / shares $ 2.97
Granted | $ / shares 3.91
Exercised | $ / shares 1.52
Expired/Cancelled | $ / shares 4.66
Outstanding at Ending of the period | $ / shares 3.22
Exercisable | $ / shares $ 2.69
Aggregate Intrinsic Value  
Exercised | $ $ 54,741
Outstanding | $ 8,303,587
Exercisable | $ $ 4,890,171
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.1
STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)
1 Months Ended 3 Months Ended
Jan. 01, 2023
shares
Jan. 01, 2022
shares
Jun. 11, 2021
shares
Jan. 01, 2021
shares
Jun. 30, 2021
shares
Mar. 31, 2023
USD ($)
item
$ / shares
shares
Mar. 31, 2022
$ / shares
Jun. 30, 2020
shares
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]                
Number of plans | item           5    
Percentage of outstanding shares         5.00%      
Number of shares available for issuance           1,756,664    
Minimum limit of fair market value to be treated as non-statutory stock | $           $ 100,000    
Terms of stock option plans           10 years    
Estimated weighted fair value of option granted (in per share) | $ / shares           $ 3.47 $ 2.87  
Total unrecognized fair value compensation cost | $           $ 15,200,000    
Weighted average period           1 year 6 months    
Stock Option | Stock Option Plan 2020                
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]                
Number of shares authorized for issuance               2,500,000
Number of additional shares authorized     0 823,084        
Stock Option | Stock Option Plan 2021                
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]                
Number of shares authorized for issuance         3,500,000      
Number of additional shares authorized 1,262,070 1,209,250            
Minimum                
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]                
Vesting period           1 year    
Maximum                
Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]                
Vesting period           4 years    
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.1
CONCENTRATIONS (Details)
Mar. 31, 2023
USD ($)
item
CONCENTRATIONS  
Number of financial institutions | item 2
Cash, FDIC insured amount $ 250,000
Cash, uninsured deposits $ 45,300,000
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.1
GOVERNMENT GRANT AWARDS (Details)
3 Months Ended
Jun. 16, 2016
USD ($)
item
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
CIRM liability   $ 3,376,259 $ 3,376,259
California Institute for Regenerative Medicine      
Minimum expected contribution $ 2,300,000    
Number of times, maximum royalty to be paid on total amount of award | item 9    
Term of award   10 years  
Debt term   5 years  
Grant award liability $ 3,400,000 $ 3,400,000  
California Institute for Regenerative Medicine | LIBOR      
Interest rate   1.00%  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
COMMITMENTS AND CONTINGENCIES    
2023 (remainder) $ 601,801  
2024 765,986  
2025 710,259  
2026 547,948  
Total minimum lease payments 2,625,994  
Less: imputed interest (232,660)  
Total operating lease liabilities 2,393,334  
Included in the condensed consolidated balance sheet:    
Current portion of lease liabilities 693,652 $ 682,039
Lease liabilities, net of current 1,699,682 $ 1,878,070
Total operating lease liabilities $ 2,393,334  
Weighted average remaining lease term 3 years 4 months 9 days  
Weighted average discount rate 5.36%  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended
Dec. 01, 2022
Jul. 01, 2022
Nov. 01, 2021
Oct. 01, 2021
Dec. 31, 2022
Jul. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
COMMITMENTS AND CONTINGENCIES                
Operating lease, ROU asset         $ 2,349,974   $ 2,189,651  
Operating lease, ROU liability             $ 2,393,334  
Number of months of base salary             6 months  
Restructuring reserve             $ 0  
Short-term offices lease                
COMMITMENTS AND CONTINGENCIES                
Base rent per month           $ 7,869    
Written Notice Period             90 days  
Operating lease expense             $ 23,607 $ 17,394
Facilities Lease                
COMMITMENTS AND CONTINGENCIES                
Lease renewal term           24 months    
Base rent per month           $ 10,707    
Property Located at 10865 Road to Cure in Diego                
COMMITMENTS AND CONTINGENCIES                
Lease term       5 years        
Lease renewal term       5 years        
Base rent per month $ 51,444              
Operating lease percentage       3.00%        
Monthly lease payment   $ 49,322            
Vivarium Space Lease [Member]                
COMMITMENTS AND CONTINGENCIES                
Lease renewal term     1 year          
Base rent per month     $ 4,021   $ 4,202      
Written Notice Period     60 days          
Monthly rent escalation, percentage         4.50%      
Vivarium Space Lease [Member] | Minimum                
COMMITMENTS AND CONTINGENCIES                
Lease term     1 year          
Vivarium Space Lease [Member] | Maximum                
COMMITMENTS AND CONTINGENCIES                
Lease term     5 years          
Unrelated Party                
COMMITMENTS AND CONTINGENCIES                
Operating lease expense             160,486 158,084
Operating lease payments             166,938 $ 85,352
Related party                
COMMITMENTS AND CONTINGENCIES                
Operating lease expense             32,120  
Operating lease payments             $ 32,120  
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.1
LICENSE AGREEMENTS (Details)
1 Months Ended 3 Months Ended
Apr. 28, 2021
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2023
EUR (€)
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Jan. 24, 2022
USD ($)
LICENSE AGREEMENTS              
Milestone payment received     $ 9,013,304   $ 30,000,000    
Revenue     2,986,696        
Deferred revenue, current     31,012,773     $ 17,980,599  
Deferred revenue, net of current     5,449,062     $ 9,467,932  
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States              
LICENSE AGREEMENTS              
Potential milestone payments             $ 705,000,000.0
Upfront Payment         30,000,000.0    
Deferred revenue liability   $ 30,000,000.0 24,500,000   30,000,000.0    
Revenue     3,000,000.0        
Deferred revenue, current     19,000,000.0        
Deferred revenue, net of current     $ 5,400,000        
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01              
LICENSE AGREEMENTS              
Revenue, Remaining Performance Obligation, Percentage     78.00%        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period     9 months        
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01              
LICENSE AGREEMENTS              
Revenue, Remaining Performance Obligation, Percentage     78.00%        
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period     12 months        
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan              
LICENSE AGREEMENTS              
Potential milestone payments     $ 89,000,000        
Upfront Payment     12,000,000.0        
Milestone payment received     12,000,000.0        
Deferred revenue liability     12,000,000.0        
Deferred revenue, current     $ 12,000,000.0        
Rome License Agreement              
LICENSE AGREEMENTS              
Notice period     90 days 90 days      
JHU License Agreement              
LICENSE AGREEMENTS              
Notice period     60 days 60 days      
Milestone payments to be made upon completion of certain phases   500,000     $ 500,000    
Threshold period to cure breach     30 days 30 days      
CSMC License Agreement              
LICENSE AGREEMENTS              
Notice period     90 days 90 days      
Exosomes License Agreement              
LICENSE AGREEMENTS              
Notice period 90 days   90 days 90 days      
Upfront Payment $ 10,000            
Minimum | Rome License Agreement              
LICENSE AGREEMENTS              
Minimum annual royalty payments | €       € 20,000      
Maximum | JHU License Agreement              
LICENSE AGREEMENTS              
Potential milestone payments     $ 1,850,000        
Completion Of Phase Two Due | JHU License Agreement              
LICENSE AGREEMENTS              
Milestones paid   $ 250,000          
Patent rights | JHU License Agreement              
LICENSE AGREEMENTS              
Agreement effective period     20 years 20 years      
Patent rights | Exosomes License Agreement              
LICENSE AGREEMENTS              
Agreement effective period 20 years            
Particular Patent or Application or Any Particular Licensed Product | Exosomes License Agreement              
LICENSE AGREEMENTS              
Notice period 60 days            
Non Payment of Royalties | CSMC License Agreement              
LICENSE AGREEMENTS              
Agreement termination period     30 days 30 days      
Non Payment of Royalties | Exosomes License Agreement              
LICENSE AGREEMENTS              
Threshold period to cure breach     30 days 30 days      
CSMC Agreement Compliance | CSMC License Agreement              
LICENSE AGREEMENTS              
Agreement termination period     90 days 90 days      
CSMC Agreement Compliance | Exosomes License Agreement              
LICENSE AGREEMENTS              
Threshold period to cure breach     90 days 90 days      
Material Breach Has Not Been Cured | CSMC License Agreement              
LICENSE AGREEMENTS              
Agreement termination period     90 days 90 days      
Material Breach Has Not Been Cured | Exosomes License Agreement              
LICENSE AGREEMENTS              
Threshold period to cure breach     90 days 90 days      
Fails To Cure Breach after Notice From CSMC | CSMC License Agreement              
LICENSE AGREEMENTS              
Agreement termination period     90 days 90 days      
Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement              
LICENSE AGREEMENTS              
Threshold period to cure breach 60 days   90 days 90 days      
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 31, 2022
Jul. 31, 2020
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
RELATED PARTY TRANSACTIONS          
Accounts payable and accrued expenses, related party     $ 18,716   $ 89,234
Board of Directors Chairman | Consulting Agreement [Member]          
RELATED PARTY TRANSACTIONS          
Monthly consulting fees     $ 10,000    
Notice period for termination of agreement     30 days    
Dr Eduardo Marban | Consulting Agreement [Member]          
RELATED PARTY TRANSACTIONS          
Granted option 50,000 50,000      
CSMC          
RELATED PARTY TRANSACTIONS          
Accounts payable and accrued expenses, related party     $ 8,716   $ 79,234
Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party     $ 111,400 $ 66,600  
XML 45 capr-20230331x10q_htm.xml IDEA: XBRL DOCUMENT 0001133869 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001133869 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001133869 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001133869 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001133869 us-gaap:RetainedEarningsMember 2023-03-31 0001133869 us-gaap:ComprehensiveIncomeMember 2023-03-31 0001133869 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001133869 us-gaap:RetainedEarningsMember 2022-12-31 0001133869 us-gaap:ComprehensiveIncomeMember 2022-12-31 0001133869 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001133869 us-gaap:RetainedEarningsMember 2022-03-31 0001133869 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001133869 us-gaap:RetainedEarningsMember 2021-12-31 0001133869 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001133869 us-gaap:CommonStockMember 2023-03-31 0001133869 us-gaap:CommonStockMember 2022-12-31 0001133869 us-gaap:CommonStockMember 2022-03-31 0001133869 us-gaap:CommonStockMember 2021-12-31 0001133869 capr:June2021AtMarketProgramMember 2022-12-31 0001133869 us-gaap:EmployeeStockOptionMember 2022-12-31 0001133869 capr:ConsultingAgreementMember capr:DrEduardoMarbanMember 2022-01-01 2022-01-31 0001133869 capr:ConsultingAgreementMember capr:DrEduardoMarbanMember 2020-07-01 2020-07-31 0001133869 us-gaap:EmployeeStockOptionMember 2023-03-31 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2021Member 2021-06-30 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2020Member 2020-06-30 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2021Member 2023-01-01 2023-01-01 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2021Member 2022-01-01 2022-01-01 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2020Member 2021-06-11 2021-06-11 0001133869 us-gaap:EmployeeStockOptionMember capr:StockOptionPlan2020Member 2021-01-01 2021-01-01 0001133869 2024-04-01 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2023-03-31 0001133869 2023-04-01 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2023-01-01 2023-03-31 0001133869 capr:CsmcMember 2023-01-01 2023-03-31 0001133869 capr:CsmcMember 2022-01-01 2022-03-31 0001133869 srt:MinimumMember 2023-01-01 2023-03-31 0001133869 srt:MaximumMember 2023-01-01 2023-03-31 0001133869 us-gaap:LeaseholdImprovementsMember 2023-03-31 0001133869 us-gaap:FurnitureAndFixturesMember 2023-03-31 0001133869 us-gaap:EquipmentMember 2023-03-31 0001133869 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001133869 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001133869 us-gaap:EquipmentMember 2022-12-31 0001133869 capr:June2021AtMarketProgramMember 2021-06-21 2022-12-31 0001133869 us-gaap:ComprehensiveIncomeMember 2023-01-01 2023-03-31 0001133869 capr:UnrelatedPartyMember 2023-01-01 2023-03-31 0001133869 capr:RelatedPartyMember 2023-01-01 2023-03-31 0001133869 capr:UnrelatedPartyMember 2022-01-01 2022-03-31 0001133869 capr:CorporateOfficesLeaseMember 2022-01-01 2022-03-31 0001133869 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001133869 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001133869 srt:MinimumMember capr:VivariumSpaceLeaseMember 2021-11-01 0001133869 srt:MaximumMember capr:VivariumSpaceLeaseMember 2021-11-01 0001133869 capr:FacilitiesLeaseMember 2022-07-31 0001133869 capr:VivariumSpaceLeaseMember 2021-11-01 0001133869 capr:PropertyLocatedAt10865RoadToCureInDiegoMember 2021-10-01 0001133869 capr:CsmcMember 2023-03-31 0001133869 capr:CsmcMember 2022-12-31 0001133869 capr:CaliforniaInstituteForRegenerativeMedicineMember us-gaap:LondonInterbankOfferedRateLIBORMember 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2022-03-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember 2022-12-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember 2022-12-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember 2023-03-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember 2023-03-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2025TwoMember 2023-01-01 2023-03-31 0001133869 capr:CommonStockWarrantsWithExpirationOnDecember2024OneMember 2023-01-01 2023-03-31 0001133869 2022-03-31 0001133869 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001133869 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001133869 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001133869 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001133869 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001133869 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001133869 2023-05-10 0001133869 capr:RomeLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:ExosomesLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:CsmcLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:CorporateOfficesLeaseMember 2023-01-01 2023-03-31 0001133869 capr:ParticularPatentOrApplicationOrAnyParticularLicensedProductMember capr:ExosomesLicenseAgreementMember 2021-04-28 2021-04-28 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember 2023-01-01 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2022-01-01 2022-03-31 0001133869 capr:ExosomesLicenseAgreementMember 2021-04-28 2021-04-28 0001133869 capr:NonPaymentOfRoyaltiesMember capr:ExosomesLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:MaterialBreachHasNotBeenCuredMember capr:ExosomesLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember capr:ExosomesLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:FailsToCureBreachAfterNoticeFromCsmcMember capr:ExosomesLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:JhuLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:FailsToCureBreachAfterNoticeFromCsmcMember capr:ExosomesLicenseAgreementMember 2021-04-28 2021-04-28 0001133869 capr:CaliforniaInstituteForRegenerativeMedicineMember 2023-01-01 2023-03-31 0001133869 2021-06-01 2021-06-30 0001133869 us-gaap:WarrantMember 2023-01-01 2023-03-31 0001133869 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001133869 srt:MaximumMember capr:JhuLicenseAgreementMember 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember 2023-03-31 0001133869 capr:CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember 2022-01-24 0001133869 capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember capr:JhuLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember capr:ExosomesLicenseAgreementMember 2021-04-28 2021-04-28 0001133869 capr:PropertyLocatedAt10865RoadToCureInDiegoMember 2021-10-01 2021-10-01 0001133869 capr:ConsultingAgreementMember srt:BoardOfDirectorsChairmanMember 2023-01-01 2023-03-31 0001133869 capr:CaliforniaInstituteForRegenerativeMedicineMember 2016-06-16 2016-06-16 0001133869 capr:JhuLicenseAgreementMember 2022-03-31 0001133869 capr:CompletionOfPhaseTwoDueMember capr:JhuLicenseAgreementMember 2022-03-01 2022-03-31 0001133869 capr:PropertyLocatedAt10865RoadToCureInDiegoMember 2022-07-01 2022-07-01 0001133869 capr:VivariumSpaceLeaseMember 2022-12-01 2022-12-31 0001133869 capr:PropertyLocatedAt10865RoadToCureInDiegoMember 2022-12-01 2022-12-01 0001133869 capr:FacilitiesLeaseMember 2022-07-01 2022-07-31 0001133869 capr:CorporateOfficesLeaseMember 2022-07-01 2022-07-31 0001133869 capr:VivariumSpaceLeaseMember 2021-11-01 2021-11-01 0001133869 2022-01-01 2022-03-31 0001133869 capr:CaliforniaInstituteForRegenerativeMedicineMember 2023-03-31 0001133869 capr:CaliforniaInstituteForRegenerativeMedicineMember 2016-06-16 0001133869 2021-01-01 2021-12-31 0001133869 2021-12-31 0001133869 2020-12-31 0001133869 capr:June2021AtMarketProgramMember 2021-06-22 2021-06-22 0001133869 2023-01-01 2023-03-31 0001133869 2022-12-31 0001133869 srt:MinimumMember capr:RomeLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 2023-03-31 0001133869 capr:NonPaymentOfRoyaltiesMember capr:CsmcLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:MaterialBreachHasNotBeenCuredMember capr:CsmcLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember capr:CsmcLicenseAgreementMember 2023-01-01 2023-03-31 0001133869 capr:FailsToCureBreachAfterNoticeFromCsmcMember capr:CsmcLicenseAgreementMember 2023-01-01 2023-03-31 iso4217:USD iso4217:EUR iso4217:USD shares pure capr:item shares -0.31 -0.32 25247354 24282743 2019-12-19 2024-12-19 2020-03-27 2025-03-27 0001133869 --12-31 2023 Q1 false P5Y 25255154 0 0 25241402 25255154 P60D P1Y P1Y P1Y P60D P5Y P24M 0.78 P9M 10-Q true 2023-03-31 false 001-34058 CAPRICOR THERAPEUTICS, INC. DE 88-0363465 10865 Road to the Cure, Suite 150, San Diego San Diego CA 92121 858 727-1755 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 per share CAPR NASDAQ 25269926 10605528 9603242 34566342 31818020 547580 547580 875092 919892 46594542 42888734 4811044 4588030 2189651 2349974 268172 268172 53863409 50094910 5407016 4834683 18716 89234 693652 682039 31012773 17980599 37132157 23586555 3376259 3376259 1699682 1878070 5449062 9467932 10525003 14722261 47657160 38308816 0.001 0.001 5000000 5000000 0 0 0.001 0.001 50000000 50000000 25255154 25241402 25255 25241 150934085 148735420 94986 105244 -144848077 -137079811 6206249 11786094 53863409 50094910 2986696 2986696 7661519 5115699 3509885 2715835 11171404 7831534 -8184708 -7831534 416442 13440 416442 13440 -7768266 -7818094 -10258 -7778524 -7818094 -0.31 -0.32 25247354 24282743 25241402 25241 148735420 105244 -137079811 11786094 2194784 2194784 13752 14 3881 3895 -10258 -10258 -7768266 -7768266 25255154 25255 150934085 94986 -144848077 6206249 24185001 24185 139404060 -108060279 31367966 1065329 1065329 139155 139 27326 27465 -7818094 -7818094 24324156 24324 140496715 -115878373 24642666 -7768266 -7818094 230101 92490 2194784 1065329 -6452 72734 -34753 -44800 -216691 572333 407203 -70518 -24540 9013304 30000000 4210086 24046566 34803580 0 32045000 0 347690 567616 105425 57744 -3211695 -625360 3895 27465 3895 27465 1002286 23448671 9603242 34885274 10605528 58333945 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.            ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple drug and vaccine candidates in various stages of development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023, from which the December 31, 2022 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basis of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities as of March 31, 2023 were approximately $45.2 million, compared to approximately $41.4 million as of December 31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a Japanese corporation, in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 – “License and Distribution Agreements”). Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity"). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with its research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase III clinical study of CAP-1002 in DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with potential commercialization of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of its research programs, including the expansion of our exosomes program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Uncertainty Related to the Coronavirus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees, and the impact may continue in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In light of past uncertainties due to COVID-19 and its economic and other impacts, the Company submitted for the Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021. As of March 31, 2023, the Company has recorded a receivable for $547,580 for the remainder of funds expected to be received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Marketable Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and are carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are presented as other comprehensive income (loss) as a separate component of stockholders’ equity. As of March 31, 2023, marketable securities consist primarily of short-term United States treasuries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from <span style="-sec-ix-hidden:Hidden_d9j0X8u4zEqgOj6dbZki7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $230,101 and $92,490 for the three months ended March 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,566,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,498,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,208,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,397,330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,811,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 842, <i style="font-style:italic;">Leases</i> (“ASC 842”), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases office and laboratory space, all of which are operating leases (see Note 6 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company adopted ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 – “License and Distribution Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and sharing of revenues are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or royalties achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exclusive Commercialization and Distribution Agreement for the U.S. (the “U.S. Distribution Agreement”) with Nippon Shinyaku the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the duration of the HOPE-3 clinical trial. Therefore, upon receipt of the upfront payment, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the “CIRM Award”) from the California Institute for Regenerative Medicine (“CIRM”) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized for the three months ended March 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, <i style="font-style:italic;">Research and Development</i>. Research and development (“R&amp;D”) costs amounted to approximately $7.7 million and $5.1 million for the three months ended March 31, 2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Comprehensive Income (Loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $7.8 million for the three months ended March 31, 2023 and 2022. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Trial Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basic and Diluted Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports earnings per share in accordance with FASB ASC 260-10, <i style="font-style:italic;">Earnings per Share.</i> Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023 and 2022, warrants and options to purchase 7,971,557 and 5,674,191 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three months ended March 31, 2023 and 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:82.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level Input:</p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;width:82.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Input Definition:</p></td></tr><tr><td style="vertical-align:bottom;width:15.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:15.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level I</p></td><td style="vertical-align:top;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:15.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level II</p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:15.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level III</p></td><td style="vertical-align:top;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes fair value measurements by level at March 31, 2023 for assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. The amortized cost for these marketable securities as of March 31, 2023 was $34,471,356.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Description of Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Capricor Therapeutics, Inc., a Delaware corporation (referred to herein as “Capricor Therapeutics” or the “Company” or “we”), is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. Capricor, Inc. (“Capricor”), a wholly-owned subsidiary of Capricor Therapeutics, was founded in 2005 as a Delaware corporation based on the innovative work of its founder, Eduardo Marbán, M.D., Ph.D. After completion of a merger between Capricor and a subsidiary of Nile Therapeutics, Inc., a Delaware corporation (“Nile”), on November 20, 2013, Capricor became a wholly-owned subsidiary of Nile and Nile formally changed its name to Capricor Therapeutics, Inc. Capricor Therapeutics, together with its subsidiary, Capricor, has multiple drug and vaccine candidates in various stages of development.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying unaudited interim condensed consolidated financial statements for Capricor Therapeutics and its wholly-owned subsidiary have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and with the instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations and cash flows in conformity with U.S. GAAP. In the Company’s opinion, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation have been included. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on March 17, 2023, from which the December 31, 2022 consolidated balance sheet has been derived. Interim results are not necessarily indicative of the results that may be expected for the year ending December 31, 2023.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basis of Consolidation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiary. All intercompany transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Liquidity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has historically financed its research and development activities as well as operational expenses primarily from equity financings, government grants, and payments from distribution agreements and collaboration partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents, and marketable securities as of March 31, 2023 were approximately $45.2 million, compared to approximately $41.4 million as of December 31, 2022. In the first quarter of 2023, the Company received an upfront payment of $12.0 million from Nippon Shinyaku Co., Ltd. (“Nippon Shinyaku”), a Japanese corporation, in accordance with its Japan Exclusive Commercialization and Distribution Agreement (see Note 7 – “License and Distribution Agreements”). Additionally, the Company has a Common Stock Sales Agreement in place with H.C. Wainwright &amp; Co. LLC ("Wainwright") to create at-the-market equity programs under which the Company, from time to time, sells shares of its common stock (see Note 2 - "Stockholders' Equity"). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s principal uses of cash are for research and development expenses, general and administrative expenses, capital expenditures and other working capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s future expenditures and capital requirements may be substantial and will depend on many factors, including, but not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with its research and development activities, clinical trials and preclinical studies, including the enrollment and progress of our ongoing HOPE-3 Phase III clinical study of CAP-1002 in DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with the manufacturing of our product candidates, including the expansion of our manufacturing capacity to support the potential commercialization of CAP-1002 for DMD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and costs associated with potential commercialization of its product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of its research programs, including the expansion of our exosomes program; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s options for raising additional capital include potentially seeking additional financing primarily from, but not limited to, the sale and issuance of equity or debt securities, the licensing or sale of its technology and other assets, potential distribution and other partnering opportunities, and from government grants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company will require substantial additional capital to fund its operations. The Company cannot provide assurances that financing will be available when and as needed or that, if available, financing will be available on favorable or acceptable terms. If the Company is unable to obtain additional financing when and if required, it would have a material adverse effect on the Company’s business and results of operations. The Company would likely need to delay, curtail or terminate portions of its clinical trial programs. To the extent the Company issues additional equity securities, its existing stockholders would experience substantial dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p> 45200000 41400000 12000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Uncertainty Related to the Coronavirus</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The COVID-19 pandemic presented substantial public health and economic challenges around the world. Our business operations and financial condition and results have been impacted to varying degrees, and the impact may continue in future periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In light of past uncertainties due to COVID-19 and its economic and other impacts, the Company submitted for the Employee Retention Credit (“ERC”), a credit against certain payroll taxes allowed to an eligible employer for qualifying wages, which was established by the CARES Act. The Company has submitted $738,778 in ERC for applicable 2020 and 2021 periods, receiving $191,199 in 2021. As of March 31, 2023, the Company has recorded a receivable for $547,580 for the remainder of funds expected to be received. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 738778 738778 191199 547580 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid investments with a maturity of less than 30 days at the date of purchase to be cash equivalents.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Marketable Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company determines the appropriate classification of its marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s marketable securities are considered as available-for-sale and are carried at estimated fair values. Realized gains and losses on the sale of debt and equity securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">are determined using the specific identification method. Unrealized gains and losses on available-for-sale securities are presented as other comprehensive income (loss) as a separate component of stockholders’ equity. As of March 31, 2023, marketable securities consist primarily of short-term United States treasuries. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Property and Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are stated at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation is computed using the straight-line method over the related estimated useful life of the asset, which such estimated useful lives range from <span style="-sec-ix-hidden:Hidden_d9j0X8u4zEqgOj6dbZki7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> to seven years. Leasehold improvements are depreciated on a straight-line basis over the shorter of the useful life of the asset or the lease term. Depreciation was $230,101 and $92,490 for the three months ended March 31, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,566,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,498,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,208,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,397,330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,811,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> P7Y 230101 92490 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment, net consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.92%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 143,573</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,336</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,566,146</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,237,089</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,498,655</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,393,230</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,208,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,769,655</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,397,330)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,181,625)</p></td></tr><tr><td style="vertical-align:bottom;width:67.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,811,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,588,030</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 143573 139336 4566146 4237089 1498655 1393230 6208374 5769655 1397330 1181625 4811044 4588030 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 842, <i style="font-style:italic;">Leases</i> (“ASC 842”), requires lessees to recognize most leases on the balance sheet with a corresponding right-to-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases office and laboratory space, all of which are operating leases (see Note 6 - “Commitments and Contingencies”). Most leases include the option to renew and the exercise of the renewal options is at the Company’s sole discretion. Options to renew a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will renew. In addition, the Company’s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and non-lease components together for existing classes of underlying assets and allocates the contract consideration to the lease component only. This practical expedient is not elected for manufacturing facilities and equipment embedded in product supply arrangements.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Revenue Recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company adopted ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>, which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries (see Note 7 – “License and Distribution Agreements).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when, or as, each performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s distribution agreements may entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, regulatory milestones and sales-based milestones. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income (loss) in the Company’s condensed consolidated statements of operation and comprehensive loss. Typically, milestone payments and sharing of revenues are achieved after the Company’s performance obligations associated with the distribution agreements have been completed and after the customer has assumed responsibility for the commercialization program. Milestones or royalties achieved after the Company’s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its distribution agreements. Typically, a significant financing component does not exist because the customer is paying for services in advance with an upfront payment. Additionally, future shared revenue payments are not substantially within the control of the Company or the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using either the proportional performance method or on a straight-line basis if efforts will be expended evenly over time. Percentage of completion of patient visits in clinical trials are used as the measure of performance. The Company feels this method of measurement to be the best depiction of the transfer of services and recognition of revenue. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Certain judgments affect the application of the Company’s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company’s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exclusive Commercialization and Distribution Agreement for the U.S. (the “U.S. Distribution Agreement”) with Nippon Shinyaku the transaction price consists of variable shared revenue payments and fixed components in the form of an upfront payment and milestones. The timing of the fixed component of the transaction price is upfront, however, the performance obligation is satisfied over a period of time, which is the duration of the HOPE-3 clinical trial. Therefore, upon receipt of the upfront payment, a contract liability is recorded which represents deferred revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Generally, government research grants that provide funding for research and development activities are recognized as income when the related expenses are incurred, as applicable. Because the terms of the grant award (the “CIRM Award”) from the California Institute for Regenerative Medicine (“CIRM”) allow Capricor to elect to convert the grant into a loan after the end of the project period, the CIRM Award is being classified as a liability rather than income (see Note 5 - “Government Grant Awards”). Grant income is due upon submission of a reimbursement request. The transaction price varies for grant income based on the expenses incurred under the awards. No grant income was recognized for the three months ended March 31, 2023 and 2022. </p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Research and Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Costs relating to the design and development of new products are expensed as research and development as incurred in accordance with Financial Accounting Standards Board (“FASB”) ASC 730-10, <i style="font-style:italic;">Research and Development</i>. Research and development (“R&amp;D”) costs amounted to approximately $7.7 million and $5.1 million for the three months ended March 31, 2023 and 2022, respectively. </p> 7700000 5100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Comprehensive Income (Loss)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) generally represents all changes in stockholders’ equity during the period except those resulting from investments by, or distributions to, stockholders. The Company’s comprehensive loss was approximately $7.8 million for the three months ended March 31, 2023 and 2022. The Company’s other comprehensive income (loss) is related to a net unrealized gain (loss) on marketable securities. </p> -7800000 -7800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Clinical Trial Expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As part of the process of preparing our condensed consolidated financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual process is designed to account for expenses resulting from our obligations under contracts with vendors, consultants, contract research organizations (“CROs”), and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such contracts. Our objective is to reflect the appropriate clinical trial expenses in our condensed consolidated financial statements by matching the appropriate expenses with the period in which services are provided and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates through financial models that take into account discussions with applicable personnel and outside service providers as to the progress or state of completion of trials, or the services completed. During the course of a clinical trial, we adjust our clinical expense </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recognition if actual results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or too low for any particular period.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for stock-based employee compensation arrangements in accordance with guidance issued by the FASB, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees, consultants, and directors based on estimated fair values.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company estimates the fair value of stock-based compensation awards on the date of grant using an option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company’s statements of operations and comprehensive loss. The Company estimates the fair value of stock-based compensation awards using the Black-Scholes model. This model requires the Company to estimate the expected volatility and value of its common stock and the expected term of the stock options, all of which are highly complex and subjective variables. The variables take into consideration, among other things, actual and projected stock option exercise behavior. For employees and directors, the expected life was calculated based on the simplified method as described by the SEC Staff Accounting Bulletin No. 110, Share-Based Payment. For other service providers, the expected life was calculated using the contractual term of the award. The Company's estimate of expected volatility was based on the historical stock price of the Company. The Company has selected a risk-free rate based on the implied yield available on U.S. Treasury securities with a maturity equivalent to the expected term of the options.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Basic and Diluted Loss per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reports earnings per share in accordance with FASB ASC 260-10, <i style="font-style:italic;">Earnings per Share.</i> Basic earnings (loss) per share is computed by dividing income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed similarly to basic earnings (loss) per share except that the denominator is increased to include the number of additional shares of common stock that would have been outstanding if the potential shares of common stock had been issued and if the additional shares of common stock were dilutive. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023 and 2022, warrants and options to purchase 7,971,557 and 5,674,191 shares of common stock, respectively, have been excluded from the computation of potentially dilutive securities. Potentially dilutive common shares, which primarily consist of stock options issued to employees, consultants, and directors as well as warrants issued, have been excluded from the diluted loss per share calculation because their effect is anti-dilutive. Because the impact of these items is anti-dilutive during periods of net loss, there was no difference between basic and diluted loss per share for the three months ended March 31, 2023 and 2022. </p> 7971557 5674191 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fair Value Measurements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Assets and liabilities recorded at fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.97%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:82.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level Input:</p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;width:82.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Input Definition:</p></td></tr><tr><td style="vertical-align:bottom;width:15.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:15.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level I</p></td><td style="vertical-align:top;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:15.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level II</p></td><td style="vertical-align:top;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.</p></td></tr><tr><td style="vertical-align:top;width:15.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Level III</p></td><td style="vertical-align:top;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:82.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes fair value measurements by level at March 31, 2023 for assets and liabilities measured at fair value on a recurring basis:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Carrying amounts reported in the balance sheet of cash and cash equivalents, receivables, accounts payable and accrued expenses approximate fair value due to their relatively short maturity. The carrying amounts of the Company’s marketable securities are based on market quotations from national exchanges at the balance sheet date. Interest and dividend income are recognized separately on the income statement based on classifications provided by the brokerage firm holding the investments. The fair value of borrowings is not considered to be significantly different from its carrying amount because the stated rates for such debt reflect current market rates and conditions. The amortized cost for these marketable securities as of March 31, 2023 was $34,471,356.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:43.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level I</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level II</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level III</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable Securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,566,342</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 34566342 34566342 34471356 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC, did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.            STOCKHOLDER’S EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ATM Program</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company established an “at-the-market” program (the “ATM Program”) on June 21, 2021, with an aggregate offering price of up to $75.0 million, pursuant to a Common Stock Sales Agreement with Wainwright by which Wainwright has sold and may continue to sell our common stock at the market prices prevailing at the time of sale. Wainwright is entitled to compensation for its services at a commission rate of 3.0% of the gross sales price per share of common stock sold plus reimbursement of certain expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From June 21, 2021 through December 31, 2022, the Company sold an aggregate of 2,098,333 shares of common stock under the ATM Program at an average price of approximately $5.93 per share for gross proceeds of approximately $12.4 million. The Company paid cash commissions on the gross proceeds, plus reimbursement of expenses to Wainwright, as well as legal and accounting fees in the aggregate amount of approximately $0.4 million. Subsequent to December 31, 2022 and through May 11, 2023, no shares were sold under the ATM Program. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Outstanding Shares</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">At March 31, 2023, the Company had 25,255,154 shares of common stock issued and <span style="-sec-ix-hidden:Hidden_ENogvh3HfECmyWpYM_wY3Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p> 75000000.0 0.030 2098333 5.93 12400000 400000 25255154 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.            STOCK AWARDS, WARRANTS AND OPTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all warrant activity for the three months ended March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:20.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_t3kODuRsmkSmqQNlgfPapQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12/19/2019</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_0ZE4tl2e5UCVYrYhBF1DWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12/19/2024</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_A-oLGghbc0CfXQvR_4rEcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3/27/2020</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kLKk6Njpv0aVZ-oEluEwXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3/27/2025</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Stock Options</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s Board of Directors (the “Board”) has approved five stock option plans: (i) the 2006 Stock Option Plan, (ii) the 2012 Restated Equity Incentive Plan (which superseded the 2006 Stock Option Plan) (the “2012 Plan”), (iii) the 2012 Non-Employee Director Stock Option Plan (the “2012 Non-Employee Director Plan”), (iv) the 2020 Equity Incentive Plan (the “2020 Plan”), and (v) the 2021 Equity Incentive Plan (the “2021 Plan”). At this time, the Company only issues options under the 2020 Plan and the 2021 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company’s stockholders approved the 2020 Equity Incentive Plan (the “2020 Plan”), which authorized 2,500,000 shares of common stock to be issued and allows for the grant of stock options as well as other forms of equity-based compensation.  Pursuant to the “evergreen” provision, on January 1, 2021, 823,084 shares were added under the 2020 Plan. Once the 2021 Plan was approved on June 11, 2021, no new shares were added to the share reserve under the 2020 Plan pursuant to its “evergreen” provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Company’s stockholders approved the 2021 Plan, which authorized 3,500,000 shares of common stock reserved under the 2021 Plan for the issuance of stock awards.  The number of shares available for issuance under the 2021 Plan shall be automatically increased on January 1 of each year, commencing with January 1, 2022, by an amount equal to the lesser of 5% of the outstanding shares of Common Stock as of the last day of the immediately preceding fiscal year or such number of shares determined by the compensation committee of the Board. On January 1, 2023 and 2022, 1,262,070 and 1,209,250 shares were added under the 2021 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, 1,756,664 options remain available for issuance under the respective stock option plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s stock option plans are administered by the Board, or the compensation committee of the Board, which determines the recipients and types of awards to be granted, as well as the number of shares subject to the awards, the exercise price and the vesting schedule. Each stock option granted will be designated in the award agreement as either an incentive stock option or a nonstatutory stock option. Notwithstanding such designation, however, to the extent that the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by the participant during any calendar year (under all plans of the Company and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Stock options are granted with an exercise price equal to the closing price of the Company’s common stock on the date of grant, and generally vest over a period of <span style="-sec-ix-hidden:Hidden_7YyEvXzmsUmNXzvy7IUftw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> to four years. The term of stock options granted under each of the plans cannot exceed ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated weighted average fair value of the options granted during the three months ended March 31, 2023 and 2022 were approximately $3.47 and $2.87 per share, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the three months ended March 31, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:77.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">115</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">123</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_gvZo-yTQh0Ccb0YJrh_nKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Risk-free interest rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">3.6</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">3.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">1.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">1.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Employee and non-employee stock-based compensation expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,754,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,194,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,065,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company does not recognize an income tax benefit as the Company believes that an actual income tax benefit may not be realized. For non-qualified stock options, the loss creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Common stock, stock options or other equity instruments issued to non-employees (including consultants) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. The fair value of stock options is determined using the Black-Scholes option-pricing model. The Company calculates the fair value for non-qualified options as of the date of grant and expenses over the applicable vesting periods. The Company accounts for forfeitures upon occurrence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of March 31, 2023, the total unrecognized fair value compensation cost related to non-vested stock options was approximately $15.2 million, which is expected to be recognized over a weighted average period of approximately 1.5 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a schedule summarizing employee and non-employee stock option activity for the three months ended March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,776,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,220,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,741</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,355)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,865,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,303,587</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,091,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,890,171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock for each of the respective periods.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all warrant activity for the three months ended March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.37</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 105782 1.37 105782 1.37 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes all outstanding warrants to purchase shares of the Company’s common stock:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;width:20.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Warrants Outstanding</b></p></td><td style="vertical-align:bottom;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">per Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_t3kODuRsmkSmqQNlgfPapQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12/19/2019</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 40,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_0ZE4tl2e5UCVYrYhBF1DWA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12/19/2024</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:42.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Common Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_A-oLGghbc0CfXQvR_4rEcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3/27/2020</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.5313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_kLKk6Njpv0aVZ-oEluEwXw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3/27/2025</span></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 40782 40782 1.10 65000 65000 1.5313 105782 105782 5 2500000 823084 0 3500000 0.05 1262070 1209250 1756664 100000 P4Y P10Y 3.47 2.87 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company estimates the fair value of each option award using the Black-Scholes option-pricing model. The Company used the following assumptions to estimate the fair value of stock options issued in the three months ended March 31, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:77.49%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:33.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">115</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">121</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">123</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_gvZo-yTQh0Ccb0YJrh_nKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5</span></span> - 7 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:62.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Risk-free interest rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">3.6</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">3.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:9.5pt;">1.5</span><span style="font-size:9.5pt;"> - </span><span style="font-size:9.5pt;">1.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1.15 1.21 1.23 P7Y P6Y 0 0 0 0 0.036 0.039 0.015 0.017 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Employee and non-employee stock-based compensation expense was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,754,223</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 857,583</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 440,561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,746</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,194,784</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,065,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1754223 857583 440561 207746 2194784 1065329 15200000 P1Y6M <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following is a schedule summarizing employee and non-employee stock option activity for the three months ended March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,776,839</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,220,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,688)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 54,741</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,355)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,865,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,303,587</p></td></tr><tr><td style="vertical-align:bottom;width:52.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at March 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,091,952</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,890,171</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 5776839 2.97 2220979 3.91 19688 1.52 54741 112355 4.66 7865775 3.22 8303587 3091952 2.69 4890171 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.            CONCENTRATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Concentration of Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash, cash equivalents, and marketable securities. The Company has historically maintained accounts at two financial institutions. These accounts are each insured by the Federal Deposit Insurance Corporation (the “FDIC”) for up to $250,000. The Company’s cash, cash equivalents, and marketable securities in excess of the FDIC insured limits as of March 31, 2023, were approximately $45.3 million. Historically, the Company has not experienced any significant losses in such accounts and does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. </p> 2 250000 45300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.            GOVERNMENT GRANT AWARDS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">CIRM Grant Award (HOPE)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June 16, 2016, Capricor entered into the CIRM Award with CIRM in the amount of approximately $3.4 million to fund, in part, Capricor’s Phase I/II HOPE-Duchenne clinical trial investigating CAP-1002 for the treatment of DMD-associated cardiomyopathy. Pursuant to terms of the CIRM Award, the disbursements were tied to the achievement of specified operational milestones. In addition, the terms of the CIRM Award included a co-funding requirement pursuant to which Capricor was required to spend approximately $2.3 million of its own capital to fund the CIRM funded research project. The CIRM Award is further subject to the conditions and requirements set forth in the CIRM Grants Administration Policy for Clinical Stage Projects. Such requirements include, without limitation, the filing of quarterly and annual reports with CIRM, the sharing of intellectual property pursuant to Title 17, California Code of Regulations (CCR) Sections 100600-100612, and the sharing with the State of California of a fraction of licensing revenue received from a CIRM funded research project and net commercial revenue from a commercialized product which resulted from the CIRM funded research as set forth in Title 17, CCR Section 100608. The maximum royalty on net commercial revenue that Capricor may be required to pay to CIRM is equal to nine times the total amount awarded and paid to Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 42pt 0pt;">After completing the CIRM funded research project and at any time after the award period end date (but no later than the ten-year anniversary of the date of the award), Capricor has the right to convert the CIRM Award into a loan, the terms of which will be determined based on various factors, including the stage of the research and development of the program at the time the election is made. On June 20, 2016, Capricor entered into a Loan Election Agreement with CIRM whereby, among other things, CIRM and Capricor agreed that if Capricor elects to convert the grant into a loan, the term</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">of the loan could be up to five years from the date of execution of the applicable loan agreement; provided that the maturity date of the loan will not surpass the ten-year anniversary of the grant date of the CIRM Award. Beginning on the date of the loan, the loan shall bear interest on the unpaid principal balance, plus the interest that has accrued prior to the election point according to the terms set forth in CIRM’s Loan Policy (the “New Loan Balance”), at a per annum rate equal to the LIBOR rate for a three-month deposit in U.S. dollars, as published by the Wall Street Journal on the loan date, plus one percent. Interest shall be compounded annually on the outstanding New Loan Balance commencing with the loan date and the interest shall be payable, together with the New Loan Balance, upon the due date of the loan. If Capricor elects to convert the CIRM Award into a loan, certain requirements of the CIRM Award will no longer be applicable, including the revenue sharing requirements. Capricor has not yet made its decision as to whether it will elect to convert the CIRM Award into a loan. If we elect to do so, Capricor would be required to repay some or all of the amounts awarded by CIRM; therefore, the Company accounts for this award as a liability rather than income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In 2019, Capricor completed all milestones and close-out activities associated with the CIRM Award and expended all funds received. As of March 31, 2023, Capricor’s liability balance for the CIRM Award was approximately $3.4 million.</p> 3400000 2300000 9 P10Y P5Y P10Y 0.01 3400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.            COMMITMENTS AND CONTINGENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Short-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases office space in Beverly Hills, California from The Bubble Real Estate Company, LLC ("Bubble Real Estate") pursuant to a lease beginning in 2013. Capricor subsequently entered into several amendments modifying certain terms of the lease. Effective January 1, 2021, we entered into a month-to-month lease amendment with Bubble Real Estate, which is terminable by either party upon 90 days’ written notice to the other party. Commencing in July 2022, the monthly lease payment was $7,869 per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred under short-term operating leases for the three months ended March 31, 2023 and 2022 were $23,607 and $17,394, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Long-Term Operating Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor leases facilities in Los Angeles, California from Cedars-Sinai Medical Center (“CSMC”), a related party (see Note 8 – “Related Party Transactions”), pursuant to a lease (the “Facilities Lease”) entered into in 2014. Capricor has subsequently entered into several amendments modifying certain terms of the lease. In July 2022, we entered into an amendment for an additional <span style="-sec-ix-hidden:Hidden_JfQB9herXU67sv2uCG-lgQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">24-month</span></span> period extending the term through July 31, 2024 with a monthly lease payment of $10,707. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a lease agreement commencing October 1, 2021 with Altman Investment Co, LLC (“Altman”) for office and laboratory space located at 10865 Road to the Cure, Suite 150, in San Diego, California (the “San Diego Lease”). The rent is subject to a 3.0% annual rent increase during the initial lease term of five years, plus certain operating expenses and taxes. The San Diego Lease contains an option for Capricor to renew it for an additional term of five years.  The Company has subsequently entered into several amendments to the San Diego Lease increasing the square footage of the premises and effective July 1, 2022 the monthly lease payment was increased to $49,322 per month. Effective December 1, 2022, the monthly lease payment was increased to $51,444 per month. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective November 1, 2021, the Company entered into a vivarium agreement with Explora BioLabs, Inc. (“Explora”), a Charles River Company, for vivarium space and services. Under the terms of the agreement, the Company is obligated to pay a base rent of $4,021 per month for an exclusive large vivarium room located in San Diego, California. The lease term is for <span style="-sec-ix-hidden:Hidden_iRawhORv9ECgs5RWwyh7Jg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></span> and will automatically renew for additional successive <span style="-sec-ix-hidden:Hidden_VhEJTa84WEmURbJoIoS_aA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-year</span></span> renewal terms unless either party provides the other party with <span style="-sec-ix-hidden:Hidden_s0KLSuthtUiA1y2TCWHUJQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span> written notice of its election not to renew prior to the end of the then-current term. In December 2022, we were notified by Explora of a monthly rent escalation of 4.5% bringing the base rent to approximately $4,202 per month effective January 1, 2023. For ASC 842 purposes, we applied a lease term of five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The long-term real estate operating leases are included in “lease right-of-use assets, net” on the Company’s condensed consolidated balance sheet and represent the Company’s right-to-use the underlying assets for the lease term. The Company’s obligation to make lease payments are included in “lease liabilities, current” and “lease liabilities, net of current” on the Company’s condensed consolidated balance sheet. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The table below excludes short-term operating leases. The following table summarizes maturities of lease liabilities and the reconciliation of lease liabilities as of March 31, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.96%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023 (remainder)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 601,801</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 765,986</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710,259</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 547,948</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,625,994</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232,660)</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,393,334</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Included in the condensed consolidated balance sheet:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693,652</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,699,682</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,393,334</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.36 years</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.36%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023, ROU assets for operating leases were approximately $2.2 million and operating lease liabilities were approximately $2.4 million. The following table contains a summary of the lease costs recognized and lease payments pertaining to the Company’s operating leases under ASC 842 for the period indicated: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,084</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,352</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Legal Contingencies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is not a party to any material legal proceedings at this time. From time to time, the Company may become involved in various legal proceedings that arise in the ordinary course of its business or otherwise. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Accounts Payable</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the normal course of business, disputes with vendors may arise. If a vendor disputed payment is probable and able to be estimated, we will record an estimated liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Other Funding Commitments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a party to various agreements, principally relating to licensed technology, that require future payments relating to milestones that may be met in subsequent periods or royalties on future sales of specific products (see Note 7 – “License and Distribution Agreements”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the Company is a party to various agreements with contract research, manufacturing and other organizations that generally provide for termination upon notice, with the exact amounts owed in the event of termination to be based on the timing of termination and the terms of the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Employee Severances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Board of Directors approves severance packages for specific full-time employees based on their length of service and position ranging up to six months of their base salaries, in the event of termination of their employment, subject to certain conditions. No liability under these severance packages has been recorded as of March 31, 2023.</p> P90D 7869 23607 17394 10707 0.030 P5Y P5Y 49322 51444 4021 0.045 4202 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.96%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023 (remainder)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 601,801</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 765,986</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 710,259</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 547,948</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,625,994</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (232,660)</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,393,334</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Included in the condensed consolidated balance sheet:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Current portion of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693,652</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities, net of current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,699,682</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,393,334</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other Information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted average remaining lease term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3.36 years</p></td></tr><tr><td style="vertical-align:bottom;width:80.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.36%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 601801 765986 710259 547948 2625994 232660 2393334 693652 1699682 2393334 P3Y4M9D 0.0536 2200000 2400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended March 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 160,486</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 158,084</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease costs, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, unrelated parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 166,938</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85,352</p></td></tr><tr><td style="vertical-align:bottom;width:68.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lease payments, related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 160486 158084 32120 166938 85352 32120 P6M 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.            LICENSE AND DISTRIBUTION AGREEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Intellectual Property Rights for Capricor’s Technology - CAP 1002 and Exosomes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor has entered into exclusive license agreements for intellectual property rights related to certain cardiac-derived cells with Università Degli Studi Di Roma La Sapienza (the “University of Rome”), Johns Hopkins University (“JHU”) and CSMC. Capricor has also entered into an exclusive license agreement for intellectual property rights related to exosomes with CSMC and JHU. In addition, Capricor has filed patent applications related to the technology developed by its own scientists. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">University of Rome License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and the University of Rome entered into a License Agreement, dated June 21, 2006 (the “Rome License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by the University of Rome to Capricor (with the right to sublicense) to develop and commercialize licensed products under the licensed patent rights in all fields. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Rome License Agreement, Capricor paid the University of Rome a license issue fee, is currently paying minimum annual royalties in the amount of 20,000 Euros per year, and is obligated to pay a lower-end of a mid-range double-digit percentage on all royalties received as a result of sublicenses granted, which are net of any royalties paid to third parties under a license agreement from such third party to Capricor. The minimum annual royalties are creditable against future royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Rome License Agreement will, unless extended or sooner terminated, remain in effect until the later of the last claim of any patent or until any patent application comprising licensed patent rights has expired or been abandoned. Under the terms of the Rome License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy. Either party may terminate the agreement upon the other party’s material breach, provided that the breaching party will have up to 90 days to cure its material breach. Capricor may also terminate for any reason upon 90 days’ written notice to the University of Rome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">The Johns Hopkins University License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;">License Agreement for CDCs</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and JHU entered into an Exclusive License Agreement, effective June 22, 2006 (the “JHU License Agreement”), which provides for the grant of an exclusive, world-wide, royalty-bearing license by JHU to Capricor (with the right to sublicense) to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how. Various amendments were entered into to revise certain provisions of the JHU License Agreement. Under the JHU License Agreement, Capricor is required to exercise commercially reasonable and diligent efforts to develop and commercialize licensed products covered by the licenses from JHU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the JHU License Agreement, JHU was paid an initial license fee and, thereafter, Capricor is required to pay minimum annual royalties on the anniversary dates of the JHU License Agreement. The minimum annual royalties are creditable against a low single-digit running royalty on net sales of products and net service revenues, which Capricor is also required to pay under the JHU License Agreement, which running royalty may be subject to further reduction in the event that Capricor is required to pay royalties on any patent rights to third parties in order to make or sell a licensed product. In addition, Capricor is required to pay a low double-digit percentage of the consideration received by it from sublicenses granted and is required to pay JHU certain defined development milestone payments upon the successful completion of certain phases of its clinical studies and upon receiving approval from the U.S. Food and Drug Administration (the “FDA”). The maximum aggregate amount of milestone payments payable under the JHU License Agreement, as amended, is $1,850,000. In March 2022, Capricor paid the $250,000 development milestone related to the Phase 2 study pursuant to the terms of the JHU License Agreement. The next milestone is triggered upon successful completion of a full Phase III study for which a payment of $500,000 will be due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The JHU License Agreement will, unless sooner terminated, continue in effect in each applicable country until the date of expiration of the last to expire patent within the patent rights, or, if no patents are issued, then for twenty years from the effective date. Under the terms of the JHU License Agreement, either party may terminate the agreement should the other party become insolvent or file a petition in bankruptcy, or fail to cure a material breach within 30 days after notice. In addition, Capricor may terminate for any reason upon 60 days’ written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><i style="font-style:italic;text-decoration-line:none;">License Agreement for Exosome-based Vaccines and Therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Capricor and JHU entered into an Exclusive License Agreement (the “JHU Exosome License Agreement”) effective April 28, 2021 for its co-owned interest in certain intellectual property rights related to exosome-mRNA vaccines and therapeutics. The JHU Exosome License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license of JHU’s co-owned rights by JHU to Capricor, with the right to sublicense, in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the JHU Exosome License Agreement, JHU was paid an upfront license fee of $10,000 and Capricor has agreed to reimburse JHU for certain fees and costs incurred in connection with the prosecution of certain patent rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, Capricor is required to meet certain development milestones for which a milestone payment fee shall be due and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a double-digit percentage of any non-royalty consideration received from any sublicenses, subject to certain exclusions. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to pay royalties on one or more third party patents as a requirement to make or sell a licensed product. In addition, Capricor will, beginning with the third year of the JHU Exosome License Agreement, be obligated to pay JHU a minimum annual royalty which is non-refundable but will be credited against royalties incurred by Capricor for the year in which the minimum annual royalty becomes due.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The JHU Exosome License Agreement will, unless sooner terminated, continue in each country until the date of expiration of the last to expire patent included within the patent rights in that country, or if no patents issue, then for 20 years. The JHU Exosome License Agreement may be terminated by Capricor upon 90 days’ written notice in its discretion and with 60 days’ notice with respect to any particular patent or application or as to any particular licensed product. The JHU Exosome License Agreement may also be terminated by either party if the other party fails to perform or otherwise breaches any of its obligations and fails to cure such breach within a <span style="-sec-ix-hidden:Hidden_VZFeaYJ5nEirFsP5V5ArDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">60-day</span></span> cure period commencing upon notice. A material breach by Capricor may include (a) a delinquency with respect to payment or reporting; (b) the failure by Capricor to timely achieve a specified milestone or otherwise failing to diligently develop, commercialize, and sell licensed products throughout the term of the JHU Exosome License Agreement; (c) non-compliance with record keeping or audit obligations; (d) voluntary bankruptcy or insolvency of Capricor; and (e) non-compliance with Capricor’s insurance obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 36pt;">Cedars-Sinai Medical Center License Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">License Agreement for CDCs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the “Original CSMC License Agreement”), for certain intellectual property related to its cardiosphere-derived cell (“CDC”) technology. In 2013, the Original CSMC License Agreement was amended twice resulting in, among other things, a reduction in the percentage of sublicense fees which would have been payable to CSMC. Effective December 30, 2013, Capricor entered into an Amended and Restated Exclusive License Agreement with CSMC (the “Amended CSMC License Agreement”), which amended, restated, and superseded the Original CSMC License Agreement, pursuant to which, among other things, certain definitions were added or amended, the timing of certain obligations was revised and other obligations of the parties were clarified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) to conduct research using the patent rights and know-how and develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license for any future rights, Capricor will have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Original CSMC License Agreement, CSMC was paid a license fee and Capricor was obligated to reimburse CSMC for certain fees and costs incurred in connection with the prosecution of certain patent rights. Additionally, Capricor is required to meet certain spending and development milestones. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended CSMC License Agreement, Capricor remains obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a low double-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty-bearing product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Amended CSMC License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Amended CSMC License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days’ notice from CSMC if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights, and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 20, 2015, August 5, 2016, December 26, 2017, June 20, 2018, and July 27, 2021, Capricor and CSMC entered into a number of amendments to the Amended CSMC License Agreement, pursuant to which the parties agreed to add and delete certain patent applications from the list of scheduled patents, among other things. Capricor reimbursed CSMC for certain attorneys’ fees and filing fees incurred in connection with the additional patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-indent:36pt;margin:0pt 0pt 12pt 36pt;">License Agreement for Exosomes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the “Exosomes License Agreement”), for certain intellectual property rights related to CDC-derived exosomes technology. The Exosomes License Agreement provides for the grant of an exclusive, world-wide, royalty-bearing license by CSMC to Capricor (with the right to sublicense) in order to conduct research using the patent rights and know-how and to develop and commercialize products in the field using the patent rights and know-how. In addition, Capricor has the exclusive right to negotiate for an exclusive license to any future rights arising from related work conducted by or under the direction of Dr. Eduardo Marbán on behalf of CSMC. In the event the parties fail to agree upon the terms of an exclusive license, Capricor shall have a non-exclusive license to such future rights, subject to royalty obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Exosomes License Agreement, CSMC was paid a license fee and Capricor reimbursed CSMC for certain fees and costs incurred in connection with the preparation and prosecution of certain patent applications. Additionally, Capricor is required to meet certain non-monetary development milestones and is obligated to pay low single-digit royalties on sales of royalty-bearing products as well as a single-digit percentage of the consideration received from any sublicenses or other grant of rights. The above-mentioned royalties are subject to reduction in the event Capricor becomes obligated to obtain a license from a third party for patent rights in connection with the royalty bearing product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exosomes License Agreement will, unless sooner terminated, continue in effect on a country by country basis until the last to expire of the patents covering the patent rights or future patent rights. Under the terms of the Exosomes License Agreement, unless waived by CSMC, the agreement shall automatically terminate: (i) if Capricor ceases, dissolves or winds up its business operations; (ii) in the event of the insolvency or bankruptcy of Capricor or if Capricor makes an assignment for the benefit of its creditors; (iii) if performance by either party jeopardizes the licensure, accreditation or tax exempt status of CSMC or the agreement is deemed illegal by a governmental body; (iv) within 30 days for non-payment of royalties; (v) after 90 days if Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights; (vi) if a material breach has not been cured within 90 days; or (vii) if Capricor challenges any of the CSMC patent rights. If Capricor fails to undertake commercially reasonable efforts to exploit the patent rights or future patent rights and fails to cure that breach after 90 days’ notice from CSMC, instead of terminating the license, CSMC has the option to convert any exclusive license to Capricor to a non-exclusive or co-exclusive license. Capricor may terminate the agreement if CSMC fails to cure any material breach within 90 days after notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 27, 2015, June 10, 2015, August 5, 2016, December 26, 2017, June 20, 2018, September 25, 2018, August 19, 2020, August 28, 2020, and March 19, 2021, Capricor and CSMC entered into a number of amendments to the Exosomes License Agreement. Collectively, these amendments added additional patent applications and patent families to the Exosomes License Agreement, added certain defined product development milestone payments, modified certain milestone deadlines, and added certain performance milestones with respect to product candidates covered by certain future patent rights in order to maintain an exclusive license to those future patent rights; failure to meet those milestones would cause CSMC to have the right to convert the license from exclusive to non-exclusive or co-exclusive, or to terminate the license, subject to Capricor’s right to license such patent rights for internal research purposes on a non-exclusive basis.  These amendments also obligated Capricor to reimburse CSMC for certain attorneys’ fees and filing fees in connection with the additional patent applications and patent families. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cell Line License Agreement with Life Technologies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On March 7, 2022, Capricor entered into a non-exclusive cell line license agreement with Life Technologies Corporation, a subsidiary of Thermo Fisher Scientific, Inc., for the supply of certain cells which we will use in connection with the development of our exosomes platform. An initial license fee payment was made in the first quarter of 2022 and additional milestone fees may become due on the progress of our development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: United States)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">On January 24, 2022, Capricor entered into the U.S. Distribution Agreement with Nippon Shinyaku, a Japanese corporation. Under the terms of the U.S. Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in the United States of CAP-1002, for the treatment of DMD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the U.S. Distribution Agreement, Capricor will be responsible for the conduct of the HOPE-3 trial as well as the manufacturing of CAP-1002. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in the United States. Pursuant to the U.S. Distribution Agreement, Capricor has the obligation to sell commercial product to Nippon Shinyaku, subject to regulatory approval, and in addition Capricor will have the right to receive a meaningful, double-digit share of product revenue and additional development and sales-based milestone payments, if achieved. In the first quarter of 2022, Capricor received an upfront payment of $30.0 million. Pursuant to the terms of the U.S. Distribution Agreement, there are potential additional sales and development milestone payments of up to $705.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the U.S. Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. At the inception, the Company identified one distinct performance obligation. The Company determined that the performance obligation is the conduct of the HOPE-3, Phase III clinical study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company determined the initial transaction price totaled $30.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. The Company has allocated the total $30.0 million initial transaction price to its one distinct performance obligation. Revenue will be recognized using a proportional performance method in relation to the completion of the HOPE-3 clinical study to determine the extent of progress towards completion. Under this method, the transaction price is recognized over the contract’s entire performance period using a cost percentage per patient visit relative to the total estimated cost of patient visits. For the three months ended March 31, 2023, the Company recognized approximately $3.0 million as revenue. In relation to the U.S. Distribution Agreement, as of March 31, 2023, the Company recorded approximately $19.0 million as current deferred revenue and approximately $5.4 million as deferred revenue, net of current portion, on the Company’s condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company had no opening or closing contract asset balances recognized.  The difference between the opening and closing balances of the Company’s contract liability results from the Company performance of services in connection to its performance obligation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized. As of March 31, 2023, remaining performance obligations related to the U.S. Distribution Agreement were approximately $24.5 million. 78% of the remaining performance obligations are expected to be recognized over the next 12 months, with the <span style="-sec-ix-hidden:Hidden_Mv-MwVRzbk6EdFnReBOb8g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">remainder</span></span> recognized <span style="-sec-ix-hidden:Hidden_1AhNpnfUTEe_tb88744Z_g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">thereafter</span></span>. Remaining performance obligations estimates are subject to change.   </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Distribution Agreement with Nippon Shinyaku (Territory: Japan)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 10, 2023, Capricor entered into an Exclusive Commercialization and Distribution Agreement (the “Japan Distribution Agreement”) with Nippon Shinyaku. Under the terms of the Japan Distribution Agreement, Capricor appointed Nippon Shinyaku as its exclusive distributor in Japan of CAP-1002 for the treatment of DMD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Japan Distribution Agreement, Capricor received an upfront payment of $12.0 million in the first quarter of 2023, and in addition, Capricor will potentially receive additional development and sales-based milestone payments of up to approximately $89 million, subject to foreign currency exchange rates, and a meaningful double-digit share of product revenue. Nippon Shinyaku will be responsible for the distribution of CAP-1002 in Japan. Capricor will be responsible for the conduct of clinical development in Japan, as may be required, as well as the manufacturing of CAP-1002. Capricor will sell commercial product to Nippon Shinyaku. In addition, Capricor or its designee will hold the Marketing Authorization in Japan if the product is approved in that territory.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has evaluated the Japan Distribution Agreement in accordance with ASU 606, <i style="font-style:italic;">Revenue for Contracts from Customers</i>. The Company determined the initial transaction price totaled $12.0 million, which was the upfront payment fee. The Company has excluded any future milestone or shared revenue payments from this transaction price to date based on probability. At this time, the Company is evaluating the regulatory pathway to achieve potential product approval in this territory. Until such time, the Company cannot identify any distinct performance obligation. As such, the Company has recorded the entire upfront payment fee of $12.0 million as current deferred revenue on the Company’s condensed consolidated balance sheets as of March 31, 2023. </p> 20000 P90D P90D 1850000 250000 500000 P20Y P30D P60D 10000 P20Y P90D P60D P30D P90D P90D P90D P90D P30D P90D P90D P90D P90D 30000000.0 705000000.0 30000000.0 30000000.0 3000000.0 19000000.0 5400000 24500000 0.78 P12M 12000000.0 89000000 12000000.0 12000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.            RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Lease and Sub-Lease Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As noted above, Capricor is a party to lease agreements with CSMC (see Note 6 – “Commitments and Contingencies”), and CSMC has served as an investigative site in Capricor’s clinical trials. Additionally, Dr. Eduardo Marbán, who is a stockholder of Capricor Therapeutics and has participated from time to time as an observer at the Company’s meetings of the Board of Directors, is the Director of the Cedars-Sinai Smidt Heart Institute, and co-founder of Capricor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Consulting Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2013, Capricor entered into a Consulting Agreement with Dr. Frank Litvack, the Company’s Executive Chairman and a member of its Board of Directors, whereby Capricor agreed to pay Dr. Litvack $10,000 per month for consulting services. The agreement is terminable upon 30 days’ notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2020, Capricor entered into an Advisory Services Agreement with Dr. Eduardo Marbán whereby he was granted an option to purchase 50,000 shares of the Company's common stock. Additionally, in January 2022, Dr. Eduardo Marbán was granted an additional option grant to purchase 50,000 shares of the Company’s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Payables to Related Party</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2023 and December 31, 2022, the Company had accounts payable and accrued expenses to related parties totaling $18,716 and $89,234, respectively. CSMC accounts for $8,716 and $79,234 of the total accounts payable and accrued expense to related parties as of March 31, 2023 and December 31, 2022, respectively. CSMC expenses relate to research and development costs, clinical trial costs, license and patent fees, and facilities rent. During the three months ended March 31, 2023 and 2022, the Company paid CSMC approximately $111,400 and $66,600, respectively, for such costs.</p> 10000 P30D 50000 50000 18716 89234 8716 79234 111400 66600 EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 123 235 1 false 47 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://capricor.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 10201 - Disclosure - STOCKHOLDER'S EQUITY Sheet http://capricor.com/role/DisclosureStockholderSEquity STOCKHOLDER'S EQUITY Notes 8 false false R9.htm 10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions STOCK AWARDS, WARRANTS AND OPTIONS Notes 9 false false R10.htm 10401 - Disclosure - CONCENTRATIONS Sheet http://capricor.com/role/DisclosureConcentrations CONCENTRATIONS Notes 10 false false R11.htm 10501 - Disclosure - GOVERNMENT GRANT AWARDS Sheet http://capricor.com/role/DisclosureGovernmentGrantAwards GOVERNMENT GRANT AWARDS Notes 11 false false R12.htm 10601 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://capricor.com/role/DisclosureCommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 12 false false R13.htm 10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS Sheet http://capricor.com/role/DisclosureLicenseAndDistributionAgreements LICENSE AND DISTRIBUTION AGREEMENTS Notes 13 false false R14.htm 10801 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://capricor.com/role/DisclosureRelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 14 false false R15.htm 20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 15 false false R16.htm 30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies 16 false false R17.htm 30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables STOCK AWARDS, WARRANTS AND OPTIONS (Tables) Tables http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions 17 false false R18.htm 30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://capricor.com/role/DisclosureCommitmentsAndContingencies 18 false false R19.htm 40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details) Details 19 false false R20.htm 40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 20 false false R21.htm 40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details) Sheet http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details) Details 21 false false R22.htm 40201 - Disclosure - STOCKHOLDER'S EQUITY (Details) Sheet http://capricor.com/role/DisclosureStockholderSEquityDetails STOCKHOLDER'S EQUITY (Details) Details http://capricor.com/role/DisclosureStockholderSEquity 22 false false R23.htm 40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details) Details 23 false false R24.htm 40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details) Details 24 false false R25.htm 40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details) Details 25 false false R26.htm 40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details) Details 26 false false R27.htm 40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details) Details 27 false false R28.htm 40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details) Sheet http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details) Details 28 false false R29.htm 40401 - Disclosure - CONCENTRATIONS (Details) Sheet http://capricor.com/role/DisclosureConcentrationsDetails CONCENTRATIONS (Details) Details http://capricor.com/role/DisclosureConcentrations 29 false false R30.htm 40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details) Sheet http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails GOVERNMENT GRANT AWARDS (Details) Details http://capricor.com/role/DisclosureGovernmentGrantAwards 30 false false R31.htm 40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details) Sheet http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details) Details 31 false false R32.htm 40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Sheet http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails COMMITMENTS AND CONTINGENCIES - Additional Information (Details) Details 32 false false R33.htm 40701 - Disclosure - LICENSE AGREEMENTS (Details) Sheet http://capricor.com/role/DisclosureLicenseAgreementsDetails LICENSE AGREEMENTS (Details) Details 33 false false R34.htm 40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details) Sheet http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails RELATED PARTY TRANSACTIONS (Details) Details http://capricor.com/role/DisclosureRelatedPartyTransactions 34 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept DueToRelatedPartiesCurrent in us-gaap/2022 used in 6 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. capr-20230331x10q.htm 13, 34 [dq-0542-Deprecated-Concept] Concept LondonInterbankOfferedRateLIBORMember in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. capr-20230331x10q.htm 27 [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 23 fact(s) appearing in ix:hidden were eligible for transformation: capr:ThresholdPeriodToCureBreach, capr:WrittenNoticePeriod, us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:LesseeOperatingLeaseRenewalTerm, us-gaap:LessorOperatingLeaseTermOfContract, us-gaap:PreferredStockSharesOutstanding, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1, us-gaap:RevenueRemainingPerformanceObligationPercentage, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding - capr-20230331x10q.htm 9 [ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies - capr-20230331x10q.htm 9 capr-20230331x10q.htm capr-20230331.xsd capr-20230331_cal.xml capr-20230331_def.xml capr-20230331_lab.xml capr-20230331_pre.xml capr-20230331xex31d1.htm capr-20230331xex31d2.htm capr-20230331xex32d1.htm capr-20230331xex32d2.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "capr-20230331x10q.htm": { "axisCustom": 2, "axisStandard": 18, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 350, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 123, "dts": { "calculationLink": { "local": [ "capr-20230331_cal.xml" ] }, "definitionLink": { "local": [ "capr-20230331_def.xml" ] }, "inline": { "local": [ "capr-20230331x10q.htm" ] }, "labelLink": { "local": [ "capr-20230331_lab.xml" ] }, "presentationLink": { "local": [ "capr-20230331_pre.xml" ] }, "schema": { "local": [ "capr-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 378, "entityCount": 1, "hidden": { "http://capricor.com/20230331": 2, "http://fasb.org/us-gaap/2022": 25, "http://xbrl.sec.gov/dei/2022": 5, "total": 32 }, "keyCustom": 41, "keyStandard": 194, "memberCustom": 28, "memberStandard": 18, "nsprefix": "capr", "nsuri": "http://capricor.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://capricor.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - CONCENTRATIONS", "menuCat": "Notes", "order": "10", "role": "http://capricor.com/role/DisclosureConcentrations", "shortName": "CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "capr:GovernmentGrantAwardsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - GOVERNMENT GRANT AWARDS", "menuCat": "Notes", "order": "11", "role": "http://capricor.com/role/DisclosureGovernmentGrantAwards", "shortName": "GOVERNMENT GRANT AWARDS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "capr:GovernmentGrantAwardsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10601 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "12", "role": "http://capricor.com/role/DisclosureCommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "capr:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10701 - Disclosure - LICENSE AND DISTRIBUTION AGREEMENTS", "menuCat": "Notes", "order": "13", "role": "http://capricor.com/role/DisclosureLicenseAndDistributionAgreements", "shortName": "LICENSE AND DISTRIBUTION AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "capr:LicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10801 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "14", "role": "http://capricor.com/role/DisclosureRelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "20102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "15", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "16", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_B0Jtm6XilkSiXaoHxkGyPA", "decimals": null, "first": true, "lang": "en-US", "name": "capr:ScheduleOfWarrantActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS (Tables)", "menuCat": "Tables", "order": "17", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_us-gaap_WarrantMember_B0Jtm6XilkSiXaoHxkGyPA", "decimals": null, "first": true, "lang": "en-US", "name": "capr:ScheduleOfWarrantActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30603 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "menuCat": "Tables", "order": "18", "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "menuCat": "Details", "order": "19", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "capr:LiquidityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40102 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "menuCat": "Details", "order": "20", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "capr:LiquidityPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "capr:AmortizedCostOfMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40103 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)", "menuCat": "Details", "order": "21", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Fair value measurements by Levels (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "capr:AmortizedCostOfMarketableSecurities", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "3", "first": true, "lang": null, "name": "capr:CommissionRateOnSalePricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_oclvqFi5-U6AkPDQ5GOU7w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40201 - Disclosure - STOCKHOLDER'S EQUITY (Details)", "menuCat": "Details", "order": "22", "role": "http://capricor.com/role/DisclosureStockholderSEquityDetails", "shortName": "STOCKHOLDER'S EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "3", "first": true, "lang": null, "name": "capr:CommissionRateOnSalePricePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_oclvqFi5-U6AkPDQ5GOU7w", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_agCUfXk4jEeO_gNeZ9N1-Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_7wfsxwTs7UOHyHIWXjBgtQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)", "menuCat": "Details", "order": "23", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "capr:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_agCUfXk4jEeO_gNeZ9N1-Q", "decimals": "2", "lang": null, "name": "capr:ClassOfWarrantOrRightWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HhUsbUgLBkumkiPp_FwKpQ", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Unit_Standard_shares_7wfsxwTs7UOHyHIWXjBgtQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40302 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)", "menuCat": "Details", "order": "24", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Outstanding Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_us-gaap_ClassOfWarrantOrRightAxis_capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember_sgFvtnHyNUGGve-nyWMsnw", "decimals": "0", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_7wfsxwTs7UOHyHIWXjBgtQ", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_oclvqFi5-U6AkPDQ5GOU7w", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40303 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)", "menuCat": "Details", "order": "25", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_oclvqFi5-U6AkPDQ5GOU7w", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40304 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "26", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "capr:ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_3I1KHfwL5EyCBFE5YX-Jyw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_7wfsxwTs7UOHyHIWXjBgtQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40306 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)", "menuCat": "Details", "order": "27", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_us-gaap_OptionIndexedToIssuersEquityEquityAxis_us-gaap_EmployeeStockOptionMember_3I1KHfwL5EyCBFE5YX-Jyw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_7wfsxwTs7UOHyHIWXjBgtQ", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "INF", "first": true, "lang": null, "name": "capr:ShareBasedCompensationNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_j3UHMiaGS0Kf0_3sFVhjAA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40307 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)", "menuCat": "Details", "order": "28", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "INF", "first": true, "lang": null, "name": "capr:ShareBasedCompensationNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_j3UHMiaGS0Kf0_3sFVhjAA", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "INF", "first": true, "lang": null, "name": "capr:NumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_j3UHMiaGS0Kf0_3sFVhjAA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - CONCENTRATIONS (Details)", "menuCat": "Details", "order": "29", "role": "http://capricor.com/role/DisclosureConcentrationsDetails", "shortName": "CONCENTRATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "INF", "first": true, "lang": null, "name": "capr:NumberOfFinancialInstitutions", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_j3UHMiaGS0Kf0_3sFVhjAA", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HhUsbUgLBkumkiPp_FwKpQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_HhUsbUgLBkumkiPp_FwKpQ", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLongTermDebtNoncurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - GOVERNMENT GRANT AWARDS (Details)", "menuCat": "Details", "order": "30", "role": "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "shortName": "GOVERNMENT GRANT AWARDS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "capr:GovernmentGrantAwardsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_6_16_2016_To_6_16_2016_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_capr_CaliforniaInstituteForRegenerativeMedicineMember_zH1JwnIbLU6DXraWSSlTkg", "decimals": "-5", "lang": null, "name": "capr:MinimumExpectedContribution", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40601 - Disclosure - COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)", "menuCat": "Details", "order": "31", "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Future Minimum Rental Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2022_agCUfXk4jEeO_gNeZ9N1-Q", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40602 - Disclosure - COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "menuCat": "Details", "order": "32", "role": "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "COMMITMENTS AND CONTINGENCIES - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "lang": "en-US", "name": "capr:SeverancePackageToBePaidForPeriodOfBaseSalary", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncreaseDecreaseInContractWithCustomerLiability", "reportCount": 1, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40701 - Disclosure - LICENSE AGREEMENTS (Details)", "menuCat": "Details", "order": "33", "role": "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "shortName": "LICENSE AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_1_24_2022_us-gaap_TypeOfArrangementAxis_capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember_iHPpZWjZUUSTOveViBNs5A", "decimals": "-5", "lang": null, "name": "capr:PotentialMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_3_31_2023_-RUclWFb-ECAP6VQaYQGzQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40801 - Disclosure - RELATED PARTY TRANSACTIONS (Details)", "menuCat": "Details", "order": "34", "role": "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails", "shortName": "RELATED PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_us-gaap_RelatedPartyTransactionAxis_capr_ConsultingAgreementMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_BoardOfDirectorsChairmanMember_W1npDioMF0Szlp2FwYQR5Q", "decimals": "0", "lang": null, "name": "capr:MonthlyConsultingFeesToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nKusMADeAU6DQloTLx_eQg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_nKusMADeAU6DQloTLx_eQg", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_hegYUOlYhkiLvaMw_HUNMw", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - STOCKHOLDER'S EQUITY", "menuCat": "Notes", "order": "8", "role": "http://capricor.com/role/DisclosureStockholderSEquity", "shortName": "STOCKHOLDER'S EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - STOCK AWARDS, WARRANTS AND OPTIONS", "menuCat": "Notes", "order": "9", "role": "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions", "shortName": "STOCK AWARDS, WARRANTS AND OPTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "capr-20230331x10q.htm", "contextRef": "Duration_1_1_2023_To_3_31_2023_Sn2f0B8ufE2TFe7SSqeOfw", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "capr_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_AgreementTerminationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the agreement termination period.", "label": "Agreement Termination Period", "terseLabel": "Agreement termination period" } } }, "localname": "AgreementTerminationPeriod", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "durationItemType" }, "capr_AmortizedCostOfMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of marketable security, classified as current.", "label": "Amortized Cost of Marketable Securities" } } }, "localname": "AmortizedCostOfMarketableSecurities", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "monetaryItemType" }, "capr_AnnualPaymentsForRoyalties": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount paid for royalties on an annual basis.", "label": "Annual Payments For Royalties", "terseLabel": "Minimum annual royalty payments" } } }, "localname": "AnnualPaymentsForRoyalties", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "capr_AwardAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOVERNMENT GRANT AWARDS" } } }, "localname": "AwardAbstract", "nsuri": "http://capricor.com/20230331", "xbrltype": "stringItemType" }, "capr_CaliforniaInstituteForRegenerativeMedicineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "California Institute for Regenerative Medicine" } } }, "localname": "CaliforniaInstituteForRegenerativeMedicineMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "domainItemType" }, "capr_ClassOfWarrantOrRightWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price Outstanding at Ending", "periodStartLabel": "Weighted Average Exercise Price Outstanding at Beginning" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageExercisePrice", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" ], "xbrltype": "perShareItemType" }, "capr_ClinicalTrialExpensePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for clinical trail expense.", "label": "Clinical Trial Expense, Policy [Policy Text Block]", "terseLabel": "Clinical Trial Expense" } } }, "localname": "ClinicalTrialExpensePolicyPolicyTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., Japan.", "label": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan" } } }, "localname": "CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Commercialization and Distribution Agreement with Nippon Shinyaku, Co., Ltd., United States.", "label": "Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States" } } }, "localname": "CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_CommissionRateOnSalePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of commission on sale price per common shares sold to be paid by the entity.", "label": "Commission Rate On Sale Price Per Share", "terseLabel": "Commission rate on sale price per share" } } }, "localname": "CommissionRateOnSalePricePerShare", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "percentItemType" }, "capr_CommitmentsAndContingenciesDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "Commitments and Contingencies Disclosure [Line Items]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureLineItems", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_CommitmentsAndContingenciesDisclosureTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Table]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_CommonStockSharesAuthorizedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The maximum value of share authorized.", "label": "Common Stock, Shares Authorized, Value", "terseLabel": "Maximum aggregate offering price" } } }, "localname": "CommonStockSharesAuthorizedValue", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "monetaryItemType" }, "capr_CommonStockWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants.", "label": "Common Warrants" } } }, "localname": "CommonStockWarrantsMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "capr_CommonStockWarrantsWithExpirationOnDecember2024OneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants with expiration on December 2024 one.", "label": "Common Warrants with Expiration on December 2024 One" } } }, "localname": "CommonStockWarrantsWithExpirationOnDecember2024OneMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "capr_CommonStockWarrantsWithExpirationOnDecember2025TwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to common stock warrants with expiration on December 2025 two.", "label": "Common Stock Warrants With Expiration On December 2025 Two" } } }, "localname": "CommonStockWarrantsWithExpirationOnDecember2025TwoMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "domainItemType" }, "capr_CompletionOfPhaseTwoDueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to completion of phase two.", "label": "Completion Of Phase Two Due" } } }, "localname": "CompletionOfPhaseTwoDueMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to agreements for consulting and advisory services.", "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "capr_CorporateOfficesLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to corporate offices under operating lease.", "label": "Corporate Offices Lease [Member]", "terseLabel": "Short-term offices lease" } } }, "localname": "CorporateOfficesLeaseMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_CsmcLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "CSMC License Agreement" } } }, "localname": "CsmcLicenseAgreementMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_CsmcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CSMC" } } }, "localname": "CsmcMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]", "verboseLabel": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Line Items]" } } }, "localname": "DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationLineItems", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Stockholders Equity, stock Options And Warrants Additional Information [Table]" } } }, "localname": "DisclosureStockholdersEquityStockOptionsAndWarrantsAdditionalInformationTable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_DrEduardoMarbanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Dr Eduardo Marban" } } }, "localname": "DrEduardoMarbanMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "capr_EmployeeRetentionCreditCaresActReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of receivables under Employee Retention Credit, CARES Act.", "label": "Employee Retention Credit, CARES Act, Receivable", "terseLabel": "Receivables under \"ERC\"" } } }, "localname": "EmployeeRetentionCreditCaresActReceivable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_EmployeeRetentionCreditCaresActRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of revenue recognized under Employee Retention Credit, CARES Act.", "label": "Employee Retention Credit, CARES Act, Revenue", "terseLabel": "Revenue recognized under \"ERC\"" } } }, "localname": "EmployeeRetentionCreditCaresActRevenue", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_ExosomesLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exosomes License Agreement" } } }, "localname": "ExosomesLicenseAgreementMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_FacilitiesLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to facilities lease.", "label": "Facilities Lease" } } }, "localname": "FacilitiesLeaseMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_FailsToCureBreachAfterNoticeFromCsmcMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fails to cure that breach after notice from CSMC.", "label": "Fails To Cure Breach after Notice From CSMC" } } }, "localname": "FailsToCureBreachAfterNoticeFromCsmcMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to failure to undertake commercially reasonable efforts to exploit the patent rights or future patent rights", "label": "CSMC Agreement Compliance" } } }, "localname": "FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_GovernmentGrantAwardsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure about government grant awards.", "label": "Government Grant Awards Disclosure [Text Block]", "terseLabel": "GOVERNMENT GRANT AWARDS" } } }, "localname": "GovernmentGrantAwardsDisclosureTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwards" ], "xbrltype": "textBlockItemType" }, "capr_GrantAwardLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of grant liability.", "label": "Grant Award Liability", "terseLabel": "Grant award liability" } } }, "localname": "GrantAwardLiability", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "monetaryItemType" }, "capr_GrantIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as grant income.", "label": "Grant Income" } } }, "localname": "GrantIncome", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_IncreaseDecreaseFromGrantsReceivable": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in grants receivable (or one business cycle).", "label": "Increase Decrease from Grants Receivable", "negatedLabel": "Receivables" } } }, "localname": "IncreaseDecreaseFromGrantsReceivable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "capr_JhuLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JHU License Agreement" } } }, "localname": "JhuLicenseAgreementMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_June2021AtMarketProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to At the Market (ATM) program.", "label": "June 2021 ATM Program" } } }, "localname": "June2021AtMarketProgramMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "domainItemType" }, "capr_LesseeOperatingLeaseBaseLeaseRentPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of base lease rent per month under the operating lease.", "label": "Lessee Operating Lease, Base Lease Rent Per Month", "terseLabel": "Base rent per month" } } }, "localname": "LesseeOperatingLeaseBaseLeaseRentPerMonth", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_LesseeOperatingLeaseLeaseRentPerMonth": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount operating lease rent per month.", "label": "Lessee Operating Lease Lease Rent Per Month", "terseLabel": "Monthly lease payment" } } }, "localname": "LesseeOperatingLeaseLeaseRentPerMonth", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_LesseeOperatingLeaseMonthlyRentEscalationPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of escalation of monthly base rent of lessee's operating lease.", "label": "Lessee, Operating Lease, Monthly Rent Escalation, Percent", "terseLabel": "Monthly rent escalation, percentage" } } }, "localname": "LesseeOperatingLeaseMonthlyRentEscalationPercent", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "capr_LicenseAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AND DISTRIBUTION AGREEMENTS" } } }, "localname": "LicenseAgreementsAbstract", "nsuri": "http://capricor.com/20230331", "xbrltype": "stringItemType" }, "capr_LicenseAgreementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NA", "label": "LICENSE AGREEMENTS [Line Items]", "terseLabel": "LICENSE AGREEMENTS" } } }, "localname": "LicenseAgreementsLineItems", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "capr_LicenseAgreementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSE AGREEMENTS [Table]" } } }, "localname": "LicenseAgreementsTable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "capr_LicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure relating to licensing agreements entered into for acquiring intellectual property rights, for the grant of an exclusive, world-wide, royalty-bearing license to develop and commercialize licensed products under the licensed patent rights in all fields and a nonexclusive right to the know-how, Collaboration Agreement and Exclusive License Option, and funding and equipment necessary for conducting clinical trial.", "label": "License Agreements [Text Block]", "verboseLabel": "LICENSE AND DISTRIBUTION AGREEMENTS" } } }, "localname": "LicenseAgreementsTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAndDistributionAgreements" ], "xbrltype": "textBlockItemType" }, "capr_LiquidityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity position during the period.", "label": "Liquidity [Policy Text Block]", "terseLabel": "Liquidity" } } }, "localname": "LiquidityPolicyTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "capr_LongTermOperatingLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to long term operating leases.", "label": "Long Term Operating Leases [Member]" } } }, "localname": "LongTermOperatingLeasesMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_MaterialBreachHasNotBeenCuredMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Material breach has not been cured.", "label": "Material Breach Has Not Been Cured" } } }, "localname": "MaterialBreachHasNotBeenCuredMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments during the period.", "label": "Milestone Payments", "terseLabel": "Milestones paid" } } }, "localname": "MilestonePayments", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "capr_MilestonePaymentsInPhasesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Milestone Payments in Phases [Axis]" } } }, "localname": "MilestonePaymentsInPhasesAxis", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "capr_MilestonePaymentsInPhasesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Milestone Payments in Phases [Domain]" } } }, "localname": "MilestonePaymentsInPhasesDomain", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone payments to be made upon successful completion of certain phases as per License agreement.", "label": "Milestone Payments To Be Made Upon Successful Completion Of Certain Phases", "terseLabel": "Milestone payments to be made upon completion of certain phases" } } }, "localname": "MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "capr_MinimumExpectedContribution": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount of contribution to be made.", "label": "Minimum Expected Contribution", "terseLabel": "Minimum expected contribution" } } }, "localname": "MinimumExpectedContribution", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "monetaryItemType" }, "capr_MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The minimum limit of aggregate fair market value will be treated as non-statutory stock options.", "label": "Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock", "verboseLabel": "Minimum limit of fair market value to be treated as non-statutory stock" } } }, "localname": "MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "capr_MonthlyConsultingFeesToRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly consulting fees as per consulting agreement entered into with related party.", "label": "Monthly Consulting Fees to Related Party", "terseLabel": "Monthly consulting fees" } } }, "localname": "MonthlyConsultingFeesToRelatedParty", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "capr_NonPaymentOfRoyaltiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-payment of royalties.", "label": "Non Payment of Royalties" } } }, "localname": "NonPaymentOfRoyaltiesMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_NoncashLeaseExpenses": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings related to noncash lease , which is added back to net income when calculating cash provided by (used in) operations using the indirect method.", "label": "Noncash Lease Expenses", "terseLabel": "Changes in lease liabilities" } } }, "localname": "NoncashLeaseExpenses", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "capr_NumberOfFinancialInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of financial institutions", "label": "Number of Financial Institutions", "terseLabel": "Number of financial institutions" } } }, "localname": "NumberOfFinancialInstitutions", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "integerItemType" }, "capr_NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of times on total award amount which is the maximum amount of royalty to be payable on commercial revenue.", "label": "Number of Times on Total Award Amount, Maximum Royalty on Commercial revenue To be Payable", "terseLabel": "Number of times, maximum royalty to be paid on total amount of award" } } }, "localname": "NumberOfTimesOnTotalAwardAmountMaximumRoyaltyOnCommercialRevenueToBePayable", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "integerItemType" }, "capr_OperatingLeasePercentageOfIncreaseInAnnualLeaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of increase in annual lease rent in an operating lease.", "label": "Operating Lease Percentage of Increase in Annual Lease Rent", "terseLabel": "Operating lease percentage" } } }, "localname": "OperatingLeasePercentageOfIncreaseInAnnualLeaseRent", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "capr_ParticularPatentOrApplicationOrAnyParticularLicensedProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Respect to any particular patent or application or as to any particular licensed product.", "label": "Particular Patent or Application or Any Particular Licensed Product" } } }, "localname": "ParticularPatentOrApplicationOrAnyParticularLicensedProductMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_PaymentsToAcquireLeaseholdImprovements": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of leasehold improvements during the period.", "label": "Payments to Acquire Leasehold Improvements", "negatedLabel": "Payments for leasehold improvements" } } }, "localname": "PaymentsToAcquireLeaseholdImprovements", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "capr_PeriodOfAgreementWillBeInEffective": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period for which agreement will be effective.", "label": "Period of Agreement Will be in Effective", "terseLabel": "Agreement effective period" } } }, "localname": "PeriodOfAgreementWillBeInEffective", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "durationItemType" }, "capr_PotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of milestone payments payable under the JHU License Agreement.", "label": "Potential Milestone Payments", "terseLabel": "Potential milestone payments" } } }, "localname": "PotentialMilestonePayments", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "capr_PropertyLocatedAt10865RoadToCureInDiegoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Property Located at 10865 Road to Cure in Diego.", "label": "Property Located at 10865 Road to Cure in Diego" } } }, "localname": "PropertyLocatedAt10865RoadToCureInDiegoMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party" } } }, "localname": "RelatedPartyMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_RomeLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Rome license agreement.", "label": "Rome License Agreement" } } }, "localname": "RomeLicenseAgreementMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.", "label": "Schedule Of Employee And Nonemployee Service Share-Based Compensation Allocation Of Recognized Period Costs Table Text Block", "terseLabel": "Schedule of employee and non-employee stock based compensation expense" } } }, "localname": "ScheduleOfEmployeeAndNonemployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "textBlockItemType" }, "capr_ScheduleOfWarrantActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all warrant activity during the period.", "label": "Schedule Of Warrant Activity [Table Text Block]", "terseLabel": "Summary of warrant activity" } } }, "localname": "ScheduleOfWarrantActivityTableTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "textBlockItemType" }, "capr_SeverancePackageToBePaidForPeriodOfBaseSalary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum number of months of base salaries used for severance packages for specific full-time employees.", "label": "Severance Package To Be Paid For Period Of Base Salary", "terseLabel": "Number of months of base salary" } } }, "localname": "SeverancePackageToBePaidForPeriodOfBaseSalary", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "capr_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of annual increase for each year to authorized shares under any stock compensation plan.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized", "terseLabel": "Percentage of outstanding shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "capr_ShareBasedCompensationNumberOfPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share based compensation plans .", "label": "Share Based Compensation, Number of Plans", "terseLabel": "Number of plans" } } }, "localname": "ShareBasedCompensationNumberOfPlans", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "capr_StockAwardsWarrantsAndOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK AWARDS, WARRANTS AND OPTIONS" } } }, "localname": "StockAwardsWarrantsAndOptionsAbstract", "nsuri": "http://capricor.com/20230331", "xbrltype": "stringItemType" }, "capr_StockOptionPlan2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Stock Option Plan 2020 [Member]", "terseLabel": "Stock Option Plan 2020" } } }, "localname": "StockOptionPlan2020Member", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_StockOptionPlan2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Stock Option Plan 2021" } } }, "localname": "StockOptionPlan2021Member", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_TermOfAward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of award.", "label": "Term of Award", "terseLabel": "Term of award" } } }, "localname": "TermOfAward", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "durationItemType" }, "capr_TerminableNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terminable notice period.", "label": "Terminable Notice Period", "terseLabel": "Notice period for termination of agreement" } } }, "localname": "TerminableNoticePeriod", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "durationItemType" }, "capr_ThresholdPeriodToCureBreach": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Threshold period to cure breach.", "label": "Threshold Period to Cure Breach", "terseLabel": "Threshold period to cure breach" } } }, "localname": "ThresholdPeriodToCureBreach", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "durationItemType" }, "capr_UnrelatedPartyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Unrelated Party [Axis]" } } }, "localname": "UnrelatedPartyAxis", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "capr_UnrelatedPartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Unrelated Party [Domain]" } } }, "localname": "UnrelatedPartyDomain", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_UnrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Unrelated Party" } } }, "localname": "UnrelatedPartyMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Until the date of expiration of the last to expire patent within the parent rights.", "label": "Patent rights" } } }, "localname": "UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "capr_UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy as it relates to unusual or infrequent items related to the Covid-19 pandemic.", "label": "Unusual Or Infrequent Items Or Both Covid 19 Policy Policy Text Block", "terseLabel": "Business Uncertainty Related to the Coronavirus" } } }, "localname": "UnusualOrInfrequentItemsOrBothCovid19PolicyPolicyTextBlock", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "capr_UpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront Payment made during the period", "label": "Upfront Payment" } } }, "localname": "UpfrontPayment", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "capr_VivariumSpaceLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to leases vivarium space.", "label": "Vivarium Space Lease [Member]" } } }, "localname": "VivariumSpaceLeaseMember", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "capr_WrittenNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "These lines are represents that notice period.", "label": "Written Notice Period", "terseLabel": "Notice period" } } }, "localname": "WrittenNoticePeriod", "nsuri": "http://capricor.com/20230331", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "durationItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r397" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://capricor.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r368", "r421", "r457", "r458", "r459" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_BoardOfDirectorsChairmanMember": { "auth_ref": [ "r413" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman" } } }, "localname": "BoardOfDirectorsChairmanMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r193", "r194", "r195", "r196", "r250", "r336", "r358", "r370", "r371", "r380", "r384", "r392", "r419", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r193", "r194", "r195", "r196", "r250", "r336", "r358", "r370", "r371", "r380", "r384", "r392", "r419", "r462", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r193", "r194", "r195", "r196", "r242", "r250", "r277", "r278", "r279", "r335", "r336", "r358", "r370", "r371", "r380", "r384", "r392", "r415", "r419", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r193", "r194", "r195", "r196", "r242", "r250", "r277", "r278", "r279", "r335", "r336", "r358", "r370", "r371", "r380", "r384", "r392", "r415", "r419", "r463", "r464", "r465", "r466", "r467" ], "lang": { "en-us": { "role": { "label": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r369", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r369", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r154", "r251", "r400", "r412" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r154", "r251", "r400", "r401", "r412" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r13" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r113" ], "calculation": { "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r20", "r21", "r119", "r355", "r363", "r364" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r286", "r287", "r288", "r409", "r410", "r411", "r450" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "ADDITIONAL PAID-IN CAPITAL [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation cost" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Antidilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r93", "r99", "r115", "r140", "r173", "r176", "r180", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r293", "r297", "r310", "r391", "r417", "r418", "r460" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r109", "r120", "r140", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r293", "r297", "r310", "r391", "r417", "r418", "r460" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Marketable Securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r40", "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r36", "r111", "r372" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r37" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and marketable securities" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r31", "r36", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents balance at end of period", "periodStartLabel": "Cash and cash equivalents balance at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r31", "r89" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash, FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash, Uninsured Amount", "terseLabel": "Cash, uninsured deposits" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.", "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "verboseLabel": "Grant Date" } } }, "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r225" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise Price per Share" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants Outstanding at Ending", "periodStartLabel": "Warrants Outstanding at Beginning", "verboseLabel": "Warrants Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r95", "r103" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies.", "verboseLabel": "COMMITMENTS AND CONTINGENCIES (NOTE 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r53", "r191", "r192", "r365", "r416" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r409", "r410", "r450" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "COMMON STOCK [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Common Stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r58" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r391" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value, 50,000,000 shares authorized, 25,255,154 and 25,241,402 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r69" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.", "label": "OTHER COMPREHENSIVE INCOME [Member]" } } }, "localname": "ComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r22", "r124", "r126", "r131", "r351", "r356" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "negatedLabel": "Comprehensive loss", "totalLabel": "COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "CONCENTRATIONS" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r80", "r373" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r227", "r228", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r227", "r228", "r240" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r227", "r228", "r240" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "verboseLabel": "Debt term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r34", "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r34", "r172" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "verboseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Derivative, Variable Interest Rate", "verboseLabel": "Interest rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r254", "r282", "r283", "r285", "r289", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK AWARDS, WARRANTS AND OPTIONS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptions" ], "xbrltype": "textBlockItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r12", "r199", "r200", "r201", "r205", "r206", "r207", "r329", "r408" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Accounts payable and accrued expenses, related party" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r132", "r146", "r147", "r148", "r149", "r150", "r155", "r157", "r159", "r160", "r161", "r163", "r301", "r302", "r352", "r357", "r375" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "verboseLabel": "Net loss per share, basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r132", "r146", "r147", "r148", "r149", "r150", "r157", "r159", "r160", "r161", "r163", "r301", "r302", "r352", "r357", "r375" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "verboseLabel": "Net loss per share, diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Basic and Diluted Loss per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r448" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Total unrecognized fair value compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Option [Member]", "terseLabel": "Stock Option" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Laboratory equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r58", "r107", "r127", "r128", "r129", "r141", "r142", "r143", "r145", "r151", "r153", "r164", "r186", "r226", "r286", "r287", "r288", "r290", "r291", "r300", "r311", "r312", "r313", "r314", "r315", "r316", "r325", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r303", "r304", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r84", "r85", "r86", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Schedule of fair value measurements" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r208", "r243", "r244", "r245", "r246", "r247", "r248", "r304", "r332", "r333", "r334", "r378", "r379", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value, Hierarchy [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r303", "r304", "r305", "r306", "r309" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r208", "r243", "r248", "r304", "r332", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r208", "r243", "r244", "r245", "r246", "r247", "r248", "r332", "r333", "r334", "r378", "r379", "r381", "r382", "r383" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r307", "r309" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesFairValueMeasurementsByLevelsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r25" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrantsReceivableCurrent": { "auth_ref": [ "r402" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Grants Receivable, Current", "verboseLabel": "Receivables" } } }, "localname": "GrantsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid in cash" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r337", "r405" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "verboseLabel": "Milestone payment received" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.", "label": "Increase (Decrease) in Due to Related Parties, Current", "terseLabel": "Accounts payable and accrued expenses, related party" } } }, "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r33" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r33" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r133", "r136", "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Net", "terseLabel": "Interest paid in cash" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r26" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r454" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of operating lease cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r455" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]", "terseLabel": "Schedule of Future Minimum Rental Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r324" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Operating Leases, Future Minimum Payments Due", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r324" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r324" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r324" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r455" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Operating Leases, Future Minimum Payments, Remainder of Fiscal Year", "verboseLabel": "2023 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r324" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r453" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LessorOperatingLeaseTermOfContract": { "auth_ref": [ "r456" ], "lang": { "en-us": { "role": { "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessor, Operating Lease, Term of Contract", "verboseLabel": "Lease term" } } }, "localname": "LessorOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r14", "r140", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r294", "r297", "r298", "r310", "r376", "r417", "r460", "r461" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r94", "r101", "r391", "r407", "r414", "r451" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r110", "r140", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r294", "r297", "r298", "r310", "r391", "r417", "r460", "r461" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r140", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r294", "r297", "r298", "r310", "r417", "r460", "r461" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "TOTAL LONG-TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "verboseLabel": "LONG-TERM LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "LIBOR" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r97" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r135" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r135" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r31", "r32", "r35" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r23", "r35", "r96", "r104", "r108", "r123", "r125", "r129", "r140", "r144", "r146", "r147", "r148", "r149", "r152", "r153", "r158", "r173", "r175", "r179", "r181", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r302", "r310", "r377", "r417" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "NET LOSS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r27" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "TOTAL OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "TOTAL OPERATING EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r173", "r175", "r179", "r181", "r377" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Leases, Rent Expense, Net", "verboseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r318" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc2Details": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease, ROU liability", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Included in the condensed consolidated balance sheet:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r318" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Lease liabilities, current", "verboseLabel": "Current portion of lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r318" ], "calculation": { "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsCalc3Details": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease liabilities, net of current", "verboseLabel": "Lease liabilities, net of current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r319", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r317" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease, ROU asset", "verboseLabel": "Lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r323", "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r322", "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityEquityAxis": { "auth_ref": [ "r54", "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Information by type of options indexed to an issuer's equity.", "label": "Option Indexed to Issuer's Equity [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityEquityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r54", "r81", "r82", "r83" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r92", "r98", "r114" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "verboseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]", "verboseLabel": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "verboseLabel": "OTHER COMPREHENSIVE INCOME (LOSS)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r121", "r122" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax", "terseLabel": "Net unrealized loss on marketable securities", "verboseLabel": "Unrealized gain on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r16" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-term Debt, Noncurrent", "terseLabel": "CIRM liability" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r30" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "verboseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r48" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r28" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r209" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r209" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "verboseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r391" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized, none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r403" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r29" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from sale of common stock", "verboseLabel": "Gross proceeds from sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Proceeds from sales and maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r29", "r77" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r108", "r123", "r125", "r134", "r140", "r144", "r152", "r153", "r173", "r175", "r179", "r181", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r292", "r295", "r296", "r302", "r310", "r353", "r377", "r388", "r389", "r404", "r417" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r50", "r112" ], "calculation": { "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "verboseLabel": "Property, Plant and Equipment, Gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r52", "r102", "r354", "r391" ], "calculation": { "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property and equipment, net", "verboseLabel": "PROPERTY AND EQUIPMENT, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r52", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives (in years)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r249", "r328", "r329" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r106", "r328", "r329", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Purchases from Related Party", "terseLabel": "Payment for reimbursement for research and development, license and patent fees and facilities rent expenses incurred by related party" } } }, "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r249", "r328", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r459" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r326", "r327", "r329", "r330", "r331" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r79", "r105", "r468" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r79" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r188", "r190" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "terseLabel": "Restructuring reserve" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r65", "r100", "r362", "r364", "r391" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r107", "r141", "r142", "r143", "r145", "r151", "r153", "r186", "r286", "r287", "r288", "r290", "r291", "r300", "r359", "r361" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "ACCUMULATED DEFICIT [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r170", "r171", "r174", "r177", "r178", "r182", "r183", "r184", "r238", "r239", "r338" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue from Contract with Customer, Including Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r241", "r374" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r229" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r130", "r140", "r170", "r171", "r174", "r177", "r178", "r182", "r183", "r184", "r185", "r197", "r198", "r200", "r201", "r202", "r203", "r204", "r206", "r207", "r310", "r353", "r417" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "TOTAL REVENUE" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "verboseLabel": "REVENUE" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATIONS" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r75", "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r252", "r253", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r70", "r71", "r73" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Schedule of employee and non-employee stock option" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of fair value of option using Black-Scholes option" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r55", "r56", "r57", "r59", "r60", "r61", "r62", "r63", "r64", "r65", "r116", "r117", "r118", "r165", "r209", "r210", "r211", "r213", "r217", "r222", "r224", "r380", "r399", "r406" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r66", "r68" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of outstanding warrants" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r33" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date", "verboseLabel": "Expiration Date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsOutstandingWarrantsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "verboseLabel": "Expected volatility, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "verboseLabel": "Expected volatility, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "verboseLabel": "Risk-free interest rates, Maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "verboseLabel": "Risk-free interest rates, Minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r387" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "verboseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Granted option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureRelatedPartyTransactionsDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Estimated weighted fair value of option granted (in per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of stock options outstanding", "verboseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at End of the period", "periodStartLabel": "Outstanding at Beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at Ending of the period", "periodStartLabel": "Outstanding at Beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired/Cancelled" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Average price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r386" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Terms of stock option plans" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable", "verboseLabel": "Aggregate intrinsic value of exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsAdditionalInformationDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r40", "r138" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r58", "r107", "r127", "r128", "r129", "r141", "r142", "r143", "r145", "r151", "r153", "r164", "r186", "r226", "r286", "r287", "r288", "r290", "r291", "r300", "r311", "r312", "r313", "r314", "r315", "r316", "r325", "r359", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r141", "r142", "r143", "r164", "r338" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails", "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r6", "r58", "r65" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of common stock shares issued", "verboseLabel": "Issuance of common stock, net of fees (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r58", "r65", "r263" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "verboseLabel": "Stock options exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsStockOptionActivityDetails", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r5", "r6", "r65", "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures", "verboseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r58", "r65" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock options exercised" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r47", "r391", "r407", "r414", "r451" ], "calculation": { "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets", "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDER'S EQUITY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r67", "r139", "r210", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r223", "r226", "r299" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDER'S EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockholderSEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Text Block [Abstract]" } } }, "localname": "TextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureLicenseAgreementsDetails", "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r43", "r44", "r45", "r166", "r167", "r168", "r169" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureGovernmentGrantAwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/DisclosureStockAwardsWarrantsAndOptionsTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r156", "r161" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Weighted-average number of shares of common stock outstanding diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r155", "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Weighted-average number of shares of common stock outstanding basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://capricor.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r393": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r394": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r395": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r396": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r397": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r398": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=126970277&loc=d3e23176-110880", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90193-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90198-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 53 0001558370-23-009521-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-009521-xbrl.zip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end